{"meta":{"query_hash":"598cba118836","filters":{"venue":"Antiviral Therapy"},"cohort_total":150,"direct_labels_cover":1,"predictions_cover":150,"exported":150,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/598cba118836","api":"https://metacan.xera.ac/api/v1/cohort?venue=Antiviral+Therapy"},"results":[{"id":"W101727076","doi":"10.1177/135965350701200709","title":"Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Receiver operating characteristic; Support vector machine; Univariate; Covariate; Population; Artificial intelligence; Sensitivity (control systems); Biology; Computational biology; Statistics; Medicine; Internal medicine; Mathematics; Multivariate statistics; Computer science","score_opus":0.0380916285824094,"score_gpt":0.3250282618337816,"score_spread":0.2869366332513722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W101727076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894685,0.00055716414,0.009320103,0.00009700083,0.0000083714685,0.000023214661,0.00028838054,0.000051149687,0.00018615129],"genre_scores_gemma":[0.9953275,0.00007272905,0.0041885506,0.000023444549,0.000010878602,0.00001264319,0.00031597874,0.0000034192112,0.000044813565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907637,0.0004789473,0.000087654145,0.0001608918,0.00014299263,0.000053089287],"domain_scores_gemma":[0.9913155,0.0068782414,0.0008983927,0.00022312296,0.00044888523,0.00023587549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004812844,0.00059369596,0.0004996765,0.0011131231,0.00013006965,0.0005613169,0.00035849767,0.00044448607,0.0005069475],"category_scores_gemma":[0.007205656,0.000111172776,0.00042124648,0.00047252933,0.00024709126,0.00028525756,0.00025092755,0.0006358572,0.00014953339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011752981,0.00013213628,0.91822773,0.00007164761,0.00040285397,0.00006995827,0.000036101042,0.0288681,0.0030034522,0.000082176986,0.0002968918,0.047633648],"study_design_scores_gemma":[0.00009304553,0.0009992401,0.41413683,0.000053853906,0.0002604909,0.0005221923,0.00005946129,0.5765694,0.0060657775,0.0007674277,0.00043923254,0.000033147153],"about_ca_topic_score_codex":0.0012691681,"about_ca_topic_score_gemma":0.0015304012,"teacher_disagreement_score":0.004812844,"about_ca_system_score_codex":0.00027799333,"about_ca_system_score_gemma":0.00042975237,"threshold_uncertainty_score":0.02545309},"labels":[],"label_agreement":null},{"id":"W105581188","doi":"10.1177/135965350400900314","title":"Psychosocial Determinants of Adherence to Highly Active Antiretroviral Therapy among Injection Drug Users in Vancouver","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria; Centre for Advancing Health Outcomes; University of British Columbia; HIV Legal Network; St. Paul's Hospital","funders":"","keywords":"Medicine; Psychosocial; Psychological intervention; Logistic regression; Internal medicine; Social support; Family medicine; Psychiatry; Psychology","score_opus":0.02763876814259041,"score_gpt":0.3531195655408389,"score_spread":0.3254807973982485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W105581188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992071,0.0001790884,0.000011733938,0.00005919461,0.0000016929928,0.0000146588645,0.00008495798,8.506093e-7,0.0004406673],"genre_scores_gemma":[0.99938226,0.00023769132,0.000031969837,0.000022770006,0.0000012813791,0.0000071668483,0.00008092702,6.726338e-7,0.00023513347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999622,0.00007869022,0.00002598142,0.000032321077,0.00012804942,0.00011285126],"domain_scores_gemma":[0.99910116,0.00014877718,0.0001878773,0.000022987013,0.00023043567,0.00030881402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004716752,0.00022143265,0.0003618037,0.0007694942,0.0015777234,0.0011979886,0.00044367035,0.00030892214,0.001535461],"category_scores_gemma":[0.0017041853,0.0003532604,0.00017538063,0.0012136342,0.00043611982,0.00016295984,0.0007326325,0.00067542854,0.00013601428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003240299,0.000051359777,0.9932929,0.000020874028,0.000018097728,0.000064242224,0.0011132333,0.000025268128,0.00012906121,0.000017017268,0.000118823205,0.005116784],"study_design_scores_gemma":[0.000004849215,0.000028602859,0.9979944,0.00002014006,0.000009520499,0.000043975255,0.0016365979,0.0000820804,0.000021861682,0.000009064903,0.00014551658,0.000003454175],"about_ca_topic_score_codex":0.8047631,"about_ca_topic_score_gemma":0.84812784,"teacher_disagreement_score":0.8047631,"about_ca_system_score_codex":0.003256499,"about_ca_system_score_gemma":0.0033002272,"threshold_uncertainty_score":0.3927734},"labels":[],"label_agreement":null},{"id":"W121874703","doi":"10.1177/135965350701200701","title":"The association of bone mineral density with HIV infection and antiretroviral treatment in women","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention","keywords":"Medicine; Lopinavir; Bone mineral; Confidence interval; Odds ratio; Confounding; Internal medicine; Femoral neck; Osteoporosis; Human immunodeficiency virus (HIV); Antiretroviral therapy; Gastroenterology; Viral load; Immunology","score_opus":0.011322236836392503,"score_gpt":0.28635020929502053,"score_spread":0.27502797245862803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W121874703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758494,0.001652361,0.000051931507,0.00009906298,0.000010854502,0.0000031526645,0.00018001226,0.0000023532023,0.0004153681],"genre_scores_gemma":[0.9995208,0.00023456803,0.000034457487,0.000027436558,0.000012682755,0.000004017246,0.000089053545,7.1485596e-7,0.00007626851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961346,0.00015719557,0.000038194,0.00006374686,0.00007416376,0.00005319914],"domain_scores_gemma":[0.9986615,0.0005160953,0.0005048612,0.00005132996,0.00009781413,0.00016833447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006607988,0.00017901926,0.00027629826,0.0006126988,0.00032220944,0.00045403212,0.00030185503,0.00051682815,0.0013064289],"category_scores_gemma":[0.003030571,0.00021232785,0.00024216447,0.0008556548,0.0003695958,0.0002213824,0.00027242122,0.00042543237,0.00017354629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005549346,0.0000068836885,0.99933124,0.0000049303762,0.000030052895,0.000027738117,0.000021413844,0.00000915007,0.00004393106,0.0000055268433,0.000026113723,0.00043755095],"study_design_scores_gemma":[0.0000052156765,0.000052847594,0.99938464,0.000007287048,0.000029518373,0.0002635263,0.000057099005,0.00006286014,0.000021653124,0.000016088703,0.00009778475,0.000001525547],"about_ca_topic_score_codex":0.004200456,"about_ca_topic_score_gemma":0.0036374019,"teacher_disagreement_score":0.004200456,"about_ca_system_score_codex":0.00018985529,"about_ca_system_score_gemma":0.00020976245,"threshold_uncertainty_score":0.008352041},"labels":[],"label_agreement":null},{"id":"W133318803","doi":"10.1177/135965350400900522","title":"Management of Antiviral Resistance in Patients with Chronic Hepatitis B","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"","keywords":"Medicine; Hepatitis B virus; Drug resistance; Antiviral drug; Context (archaeology); Hepatitis B; Immunology; Antiviral therapy; Viral load; Internal medicine; Virology; Virus; Chronic hepatitis; Biology","score_opus":0.011217361470056192,"score_gpt":0.2543613498727539,"score_spread":0.24314398840269769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W133318803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.101199724,0.8329085,0.004779705,0.03481098,0.002000122,0.00027371367,0.000072505114,0.00015571405,0.023799045],"genre_scores_gemma":[0.6170862,0.34721088,0.008508823,0.017662538,0.0044923667,0.0005164783,0.00021431259,0.00003698396,0.0042714966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996257,0.00020689839,0.000045113145,0.000026570471,0.000058867932,0.000036750254],"domain_scores_gemma":[0.9996178,0.00013968343,0.00010486758,0.0000074318828,0.000058842157,0.00007136571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082965725,0.00023008953,0.00064645003,0.00030583722,0.00059254555,0.0005589403,0.00027609445,0.00081277237,0.0011974751],"category_scores_gemma":[0.0020786321,0.00007209481,0.0002507324,0.000249373,0.00023372474,0.0004450258,0.00041780953,0.0009425077,0.00031611454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009233179,0.0002625375,0.029038606,0.0026723184,0.00010318934,0.005523033,0.0011707563,0.00040286416,0.003119487,0.0015671635,0.031699106,0.92351764],"study_design_scores_gemma":[0.0017217707,0.009606409,0.21186224,0.014246117,0.0007567578,0.10258846,0.0054520816,0.0044991043,0.0053637247,0.018130735,0.6256181,0.00015445462],"about_ca_topic_score_codex":0.00039897568,"about_ca_topic_score_gemma":0.0005639231,"teacher_disagreement_score":0.0011974751,"about_ca_system_score_codex":0.00030047653,"about_ca_system_score_gemma":0.00058263366,"threshold_uncertainty_score":0.0043876767},"labels":[],"label_agreement":null},{"id":"W1343435","doi":"10.1177/135965350501000608","title":"A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Toronto General Hospital; St. Thomas Hospital; University Health Network; Ottawa Hospital","funders":"Malmö Högskola; Sahlgrenska Universitetssjukhuset; Temple University; University of Miami","keywords":"Ritonavir; Lopinavir; Discontinuation; Lopinavir/ritonavir; Medicine; Saquinavir; Internal medicine; Adverse effect; Randomized controlled trial; Gastroenterology; Intention-to-treat analysis; Population; Viral load; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.03754823925892261,"score_gpt":0.33972346927245534,"score_spread":0.30217523001353275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1343435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98395234,0.0057043205,0.0006953747,0.001346639,0.00063560635,0.004013602,0.0012864985,0.00012760103,0.002238031],"genre_scores_gemma":[0.98248935,0.002109027,0.002645908,0.0017868942,0.0007545225,0.0056807394,0.0016282942,0.00003437854,0.0028709145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978849,0.0016772663,0.00006779086,0.0001983823,0.00007569833,0.00009592245],"domain_scores_gemma":[0.9983814,0.0005660642,0.00049617386,0.0001219217,0.00005569965,0.00037872256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045947772,0.0017976159,0.002778399,0.00035563757,0.00035482767,0.0010459054,0.0009960931,0.0017022202,0.0077202213],"category_scores_gemma":[0.0037035279,0.0006265401,0.0014993093,0.0002787614,0.0010103249,0.0010691509,0.0005091031,0.0020532669,0.0007877197],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.991824,0.0012268706,0.000381578,0.00027635737,0.0002806071,0.00001767295,0.00002005815,0.00014309365,0.00059030106,0.00006829843,0.00035450337,0.004816682],"study_design_scores_gemma":[0.97968674,0.018419176,0.00078770565,0.000029697903,0.00019773818,0.000025237428,0.000007575973,0.00032081784,0.00012774025,0.00009553917,0.00029491546,0.0000070440424],"about_ca_topic_score_codex":0.0003729138,"about_ca_topic_score_gemma":0.0008224255,"teacher_disagreement_score":0.0077202213,"about_ca_system_score_codex":0.0005864693,"about_ca_system_score_gemma":0.0009805938,"threshold_uncertainty_score":0.025826752},"labels":[],"label_agreement":null},{"id":"W136034343","doi":"10.1177/135965350400900218","title":"Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Hazard ratio; Population; Drug; Immunology; Confidence interval; Pharmacology","score_opus":0.031223057954219847,"score_gpt":0.3249935126038499,"score_spread":0.29377045464963003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W136034343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999608,0.00014637953,0.000033671142,0.000021666332,0.0000016624347,0.0000038130013,0.000043123007,0.0000020616458,0.00013971444],"genre_scores_gemma":[0.9997316,0.000049755403,0.000037396334,0.000016577771,0.000005151452,0.0000039738343,0.00006515876,7.536543e-7,0.00008960133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995461,0.00021081188,0.000042064137,0.000044269214,0.00008746408,0.0000692525],"domain_scores_gemma":[0.9964831,0.0013390658,0.0015239255,0.00010431843,0.00018662933,0.00036289947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072259636,0.00016956606,0.00025234235,0.0003615347,0.00016617167,0.0003792372,0.00019176489,0.00045645577,0.0011507806],"category_scores_gemma":[0.005923843,0.00016531306,0.00018647275,0.00032305188,0.00015585568,0.00024925152,0.00018640806,0.00050931645,0.0001970931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021721583,0.00006558508,0.99736553,0.0000065790714,0.0000326739,0.000022383256,0.00004589051,0.000052952044,0.00010751702,0.000006298777,0.00004082645,0.0020365636],"study_design_scores_gemma":[0.000009140074,0.00020530536,0.99899584,0.0000049355745,0.000016803237,0.00013856869,0.000042470958,0.00048302425,0.0000528479,0.000010061987,0.00003880768,0.000002036352],"about_ca_topic_score_codex":0.0019097349,"about_ca_topic_score_gemma":0.0014437772,"teacher_disagreement_score":0.0019097349,"about_ca_system_score_codex":0.0001554892,"about_ca_system_score_gemma":0.00013968628,"threshold_uncertainty_score":0.0038497448},"labels":[],"label_agreement":null},{"id":"W139360933","doi":"10.1177/135965350400900613","title":"Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Didanosine; Stavudine; Ribavirin; Pegylated interferon; Gastroenterology; Internal medicine; Medicine; Asymptomatic; Immunology; Hepatitis C virus; Concomitant; Biology; Virology; Zidovudine; Viral disease; Virus","score_opus":0.018135878339821943,"score_gpt":0.31147816091440433,"score_spread":0.2933422825745824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W139360933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99965394,0.00024494706,0.0000134745815,0.0000121891035,0.000004642944,0.0000071949603,0.0000097224965,0.0000014010005,0.00005247788],"genre_scores_gemma":[0.9996389,0.00010996278,0.000063504674,0.00002454439,0.000014260406,0.000011710607,0.000054152395,5.907506e-7,0.00008232808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998615,0.000055863464,0.0000114165905,0.000021413907,0.0000163342,0.000033458626],"domain_scores_gemma":[0.99953735,0.00007869901,0.00011361139,0.000019523,0.00003099624,0.00021989305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027054545,0.00030342667,0.00056282413,0.00015305221,0.000282585,0.00021207656,0.00014789245,0.00030518012,0.00075998914],"category_scores_gemma":[0.0007768036,0.00012352066,0.00027293467,0.00011796171,0.00018429417,0.0001635835,0.00020377777,0.00037278087,0.00009747446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3156182,0.015143027,0.44481105,0.00057107804,0.0006648913,0.0031021303,0.0009704291,0.0010644345,0.10265857,0.00006392389,0.0006445549,0.11468776],"study_design_scores_gemma":[0.0062172203,0.19744638,0.7840449,0.000053783668,0.00037209073,0.0021238124,0.0005200372,0.0012947996,0.006894076,0.000044344222,0.00095787033,0.000030708587],"about_ca_topic_score_codex":0.0007085,"about_ca_topic_score_gemma":0.0012053049,"teacher_disagreement_score":0.00075998914,"about_ca_system_score_codex":0.0002788518,"about_ca_system_score_gemma":0.00019453008,"threshold_uncertainty_score":0.0025424361},"labels":[],"label_agreement":null},{"id":"W1483464410","doi":"10.1177/135965350701200405","title":"Plasma Concentrations of the HIV-Protease Inhibitor Lopinavir are Suboptimal in Children Aged 2 Years and Below","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Cmin; Lopinavir; Pharmacokinetics; Cmax; Lopinavir/ritonavir; Medicine; Regimen; Ritonavir; Human immunodeficiency virus (HIV); Area under the curve; Pharmacology; Internal medicine; Viral load; Immunology; Antiretroviral therapy","score_opus":0.011341620185126057,"score_gpt":0.25182638738981433,"score_spread":0.24048476720468828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1483464410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981476,0.0008285977,0.00007746944,0.000046741734,0.000005501472,0.000007490333,0.00025083803,0.000008719835,0.0006271092],"genre_scores_gemma":[0.9989918,0.0004272473,0.00015239604,0.00004453049,0.000008644557,0.000009379669,0.0002520097,0.000004453454,0.00010946713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993882,0.00010120503,0.000065856366,0.00014505275,0.00012197206,0.00017757919],"domain_scores_gemma":[0.9990044,0.00019525076,0.0004964546,0.000024054978,0.00013268676,0.00014709808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005030696,0.00035914793,0.00074878003,0.0005490321,0.0004103064,0.00074802723,0.00025800813,0.0005543932,0.001342275],"category_scores_gemma":[0.0025297478,0.0002554028,0.0003540441,0.0005134617,0.00045677632,0.0004477128,0.00033205966,0.00039220587,0.00033311392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024319925,0.000033613243,0.992132,0.000041979987,0.0000312666,0.00085811014,0.00023271416,0.00009317647,0.0021588383,0.000031021715,0.00028440956,0.003859563],"study_design_scores_gemma":[0.000010276135,0.00029597164,0.9951605,0.000019148394,0.000042997894,0.0029591434,0.00031781962,0.00006442068,0.0005390514,0.000025786547,0.00056022976,0.00000473609],"about_ca_topic_score_codex":0.006039654,"about_ca_topic_score_gemma":0.0060368287,"teacher_disagreement_score":0.006039654,"about_ca_system_score_codex":0.00048087377,"about_ca_system_score_gemma":0.00041878052,"threshold_uncertainty_score":0.012008965},"labels":[],"label_agreement":null},{"id":"W1528578169","doi":"10.1177/135965350701200810","title":"Amphipathic DNA Polymers are Candidate Vaginal Microbicides and Block Herpes Simplex Virus Binding, Entry and Viral Gene Expression","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; National Institute of Allergy and Infectious Diseases","keywords":"Herpes simplex virus; Biology; Virology; Microbicides for sexually transmitted diseases; HeLa; Viral entry; Virus; Viral shedding; DNA; Avidity; Molecular biology; Viral replication; Immunology; Cell; Biochemistry; Antibody; Medicine; Population","score_opus":0.015303283359318784,"score_gpt":0.2860751315980268,"score_spread":0.270771848238708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1528578169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604523,0.025351139,0.008393157,0.00022801154,0.00006169139,0.00019689614,0.00044786095,0.00011490723,0.004753982],"genre_scores_gemma":[0.9728784,0.0101535255,0.013219426,0.00011305017,0.000031522737,0.00015574136,0.00040394752,0.000015355692,0.0030291008],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998853,0.000023681683,0.0000068766694,0.000021361875,0.00004315645,0.00001952978],"domain_scores_gemma":[0.99987423,0.000029689223,0.000052367344,0.000008027041,0.000015717831,0.0000199716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002551465,0.00035184523,0.00018705703,0.00024019451,0.000116251984,0.00027264573,0.00021722438,0.0003844183,0.0018807657],"category_scores_gemma":[0.00019690846,0.00012894563,0.00016899176,0.00016276201,0.00023075739,0.0001872301,0.0001780644,0.00047092605,0.00046895255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014141566,0.00006720475,0.0002999548,0.00022264743,0.000006984081,0.000112886584,0.0000115316625,0.00027778692,0.9853895,0.0002492991,0.000070934795,0.013149856],"study_design_scores_gemma":[0.00004335807,0.0018732707,0.001578766,0.000038583225,0.00001795079,0.00063094683,0.000015838721,0.00045486676,0.9878814,0.00007086397,0.0073863748,0.000007837148],"about_ca_topic_score_codex":0.00008770625,"about_ca_topic_score_gemma":0.00015791392,"teacher_disagreement_score":0.0018807657,"about_ca_system_score_codex":0.0001722385,"about_ca_system_score_gemma":0.00016389297,"threshold_uncertainty_score":0.0062918067},"labels":[],"label_agreement":null},{"id":"W1560982094","doi":"10.1177/135965350601100509","title":"Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic","funders":"","keywords":"Lamivudine; HBsAg; Medicine; Cohort; Internal medicine; Human immunodeficiency virus (HIV); Cohort study; Hepatitis B; Virology; Hepatitis B virus; Virus","score_opus":0.021099107068077202,"score_gpt":0.30463682028091765,"score_spread":0.28353771321284044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1560982094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990765,0.00021161138,0.000102722326,0.0000151727545,0.0000033663239,0.00000869588,0.00048426108,0.0000022699055,0.0000953849],"genre_scores_gemma":[0.99900323,0.000114427516,0.00009005535,0.000012077895,0.0000045383895,0.000009155994,0.0006424185,0.0000029131968,0.00012107978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855405,0.0005101021,0.00011139099,0.0003840119,0.00021944137,0.00022104607],"domain_scores_gemma":[0.9968516,0.0009009127,0.000934272,0.0005266976,0.00029194052,0.00049455115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031060777,0.0006342385,0.00060391915,0.0009479861,0.00057042605,0.0010848705,0.000754858,0.0005564184,0.0011240644],"category_scores_gemma":[0.0033242821,0.0004920266,0.0019378527,0.00094654976,0.00035253642,0.00048340627,0.0008729014,0.00085616333,0.00020660736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006113997,0.000042329055,0.9976712,0.000008693508,0.00044090417,0.00007924205,0.00007004526,0.0001425851,0.00010396877,0.000008762344,0.00004971104,0.0007712169],"study_design_scores_gemma":[0.000029472372,0.00021964665,0.99857354,0.000005920254,0.0001685889,0.0001360092,0.000113426526,0.00056485995,0.000069975555,0.000009939534,0.00010061596,0.000007985901],"about_ca_topic_score_codex":0.017255256,"about_ca_topic_score_gemma":0.013179893,"teacher_disagreement_score":0.017255256,"about_ca_system_score_codex":0.0007416667,"about_ca_system_score_gemma":0.0006207435,"threshold_uncertainty_score":0.034309626},"labels":[],"label_agreement":null},{"id":"W1576163479","doi":"10.1177/135965350801300802","title":"Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of Calgary","funders":"National Institute on Alcohol Abuse and Alcoholism","keywords":"Medicine; Internal medicine; Hazard ratio; Confidence interval; Prospective cohort study; Gastroenterology; Cohort; Anemia; Antiretroviral therapy; Proportional hazards model; Human immunodeficiency virus (HIV); Viral load; Immunology","score_opus":0.027629529567991664,"score_gpt":0.3344858308340465,"score_spread":0.30685630126605484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1576163479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193716,0.005421913,0.00089668535,0.00012644668,0.00003599135,0.000055936947,0.0012770048,0.000017102973,0.00023190929],"genre_scores_gemma":[0.9967276,0.0010608595,0.0007830528,0.00002675073,0.000028420032,0.000047392634,0.0012565753,0.000008098002,0.00006116299],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99068755,0.0054975683,0.0010945802,0.0016367784,0.0007612118,0.00032235458],"domain_scores_gemma":[0.957939,0.016756581,0.014051788,0.006407739,0.0026556477,0.0021891815],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01573174,0.0008885949,0.0015776551,0.0028332705,0.000995616,0.0022598202,0.001141842,0.00086931157,0.0006778755],"category_scores_gemma":[0.028637955,0.00083066575,0.00372292,0.003365336,0.00045679134,0.00078459416,0.001870789,0.0009977781,0.00008796565],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004969422,0.000011798173,0.99418795,0.00005040841,0.0035770182,0.00004917767,0.00007365095,0.00020801355,0.00005660369,0.000022769069,0.0001104605,0.0011552501],"study_design_scores_gemma":[0.00008418195,0.00019295719,0.99436474,0.00006621193,0.0030632496,0.00028840968,0.00017135325,0.0013712693,0.00005298919,0.00007919505,0.0002393042,0.00002609059],"about_ca_topic_score_codex":0.0099701695,"about_ca_topic_score_gemma":0.00879954,"teacher_disagreement_score":0.9984223,"about_ca_system_score_codex":0.0004581982,"about_ca_system_score_gemma":0.0010608506,"threshold_uncertainty_score":0.08319837},"labels":[],"label_agreement":null},{"id":"W15969640","doi":"10.1177/135965350000500112","title":"The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan","year":2000,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Regimen; Internal medicine; Medicine; Drug resistance; Genotyping; Confounding; Viral load; HIV drug resistance; Observational study; Odds ratio; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genotype; Biology","score_opus":0.052429182704700567,"score_gpt":0.34540640566846403,"score_spread":0.2929772229637635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W15969640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79825896,0.08856063,0.08772865,0.00086020184,0.00090577843,0.0075372094,0.0111727705,0.00059716473,0.0043786927],"genre_scores_gemma":[0.9413899,0.006129299,0.03705412,0.00045905472,0.0003035628,0.004574378,0.009175304,0.00030449906,0.00060984865],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.73201066,0.1506945,0.07729479,0.01301912,0.025001023,0.0019798554],"domain_scores_gemma":[0.46502355,0.26537618,0.068387955,0.14991398,0.050022997,0.0012753587],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.23619124,0.0023277292,0.006826993,0.015287063,0.0007759409,0.005019018,0.002644212,0.001293214,0.00089134794],"category_scores_gemma":[0.27735436,0.001776263,0.010476365,0.013339631,0.0015176415,0.0025781733,0.0025038694,0.0019262516,0.00037863085],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010843469,0.00023134891,0.8263757,0.008326334,0.05995205,0.00056231703,0.0012811495,0.0029192844,0.005551842,0.0009149212,0.0016177034,0.08142387],"study_design_scores_gemma":[0.0015717722,0.0044665355,0.90499514,0.0024936232,0.050776515,0.001557499,0.0009948638,0.004384874,0.009112387,0.00084344065,0.018476393,0.00032692394],"about_ca_topic_score_codex":0.0028290437,"about_ca_topic_score_gemma":0.0027819553,"teacher_disagreement_score":0.23619124,"about_ca_system_score_codex":0.0016212079,"about_ca_system_score_gemma":0.0026921174,"threshold_uncertainty_score":0.9419122},"labels":[],"label_agreement":null},{"id":"W168560548","doi":"10.3851/imp2572","title":"Safety and Efficacy of Chop for Treatment of Diffuse Large B-Cell Lymphoma with Different Combination Antiretroviral Therapy Regimens: Sculpt Study","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Université de Montréal; McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Diffuse large B-cell lymphoma; Antiretroviral therapy; Lymphoma; CHOP; Internal medicine; Oncology; Human immunodeficiency virus (HIV); Virology; Viral load","score_opus":0.01528697986025719,"score_gpt":0.2682580903614997,"score_spread":0.25297111050124255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W168560548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949301,0.003075459,0.00022278115,0.0001025394,0.000021805827,0.0003244499,0.00059139176,0.000020135805,0.00071124174],"genre_scores_gemma":[0.99590105,0.0015540493,0.00036188267,0.0003204544,0.00011577114,0.00024384532,0.0012138245,0.000008238465,0.00028087257],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999044,0.00049411773,0.00009033643,0.00013431058,0.00017204095,0.00006507415],"domain_scores_gemma":[0.9970842,0.0007242908,0.00096347375,0.00026974594,0.00021494887,0.0007434129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021381513,0.0005103029,0.001294068,0.00046808418,0.00027786958,0.0006614648,0.0006375803,0.00080982264,0.0014580354],"category_scores_gemma":[0.002003337,0.00019383983,0.0012497517,0.00070784095,0.0005419917,0.00046515028,0.00034429753,0.0013146995,0.00026779744],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6475134,0.014288846,0.14357051,0.0010330732,0.0052376497,0.00057215424,0.00030773133,0.0017298954,0.014900903,0.00012957586,0.0013989694,0.16931726],"study_design_scores_gemma":[0.22253564,0.401821,0.36020932,0.0001752358,0.003392258,0.001527234,0.000123417,0.0029743146,0.0029120971,0.00018192877,0.0040897042,0.0000578611],"about_ca_topic_score_codex":0.0005636576,"about_ca_topic_score_gemma":0.0008422843,"teacher_disagreement_score":0.0021381513,"about_ca_system_score_codex":0.0008298351,"about_ca_system_score_gemma":0.000855442,"threshold_uncertainty_score":0.011307776},"labels":[],"label_agreement":null},{"id":"W1687303282","doi":"10.1177/135965350601100208","title":"Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4 <sup>+</sup> T-Cell Count and HIV-1 Rna Load","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic","funders":"","keywords":"Biology; Reverse transcriptase; Drug resistance; Virology; Seroconversion; Mutation; Interquartile range; Population; Wild type; Virus; Viral load; Genetics; Gene; Medicine; Internal medicine; RNA; Mutant","score_opus":0.006189843537791374,"score_gpt":0.2233159166469177,"score_spread":0.21712607310912632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1687303282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99972695,0.0000856526,0.00001868643,0.0000065996373,6.8652304e-7,0.0000021690132,0.000021785068,0.0000019468084,0.000135444],"genre_scores_gemma":[0.99972624,0.00003940898,0.00005638189,0.000009180912,0.000004236218,0.000001820151,0.000071409726,0.0000016865574,0.000089678295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99967945,0.000120282384,0.000019014002,0.00005141851,0.00006416547,0.00006567759],"domain_scores_gemma":[0.99879885,0.00046482572,0.00033217363,0.00006928406,0.00007340908,0.00026138357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045018728,0.00023453396,0.0002645131,0.0002727778,0.00020307988,0.00032464348,0.00014608416,0.00022637953,0.00097149424],"category_scores_gemma":[0.0023896701,0.00015501711,0.00016391109,0.00020539705,0.00021859986,0.00021675476,0.00018678808,0.00030339544,0.00012425131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009252802,0.0007026473,0.85914445,0.00009155736,0.0001830516,0.0018794979,0.00040100046,0.0014804227,0.09120164,0.0001212007,0.00023498375,0.035306856],"study_design_scores_gemma":[0.00010691107,0.0052935164,0.98274565,0.000011943973,0.00008752556,0.003187109,0.000073514086,0.0018332292,0.0062747067,0.000058466227,0.00031104425,0.000016344231],"about_ca_topic_score_codex":0.0014025945,"about_ca_topic_score_gemma":0.0017869379,"teacher_disagreement_score":0.0014025945,"about_ca_system_score_codex":0.00039080033,"about_ca_system_score_gemma":0.00017804961,"threshold_uncertainty_score":0.0032500029},"labels":[],"label_agreement":null},{"id":"W1703585126","doi":"10.1177/135965350200700407","title":"Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Viral load; Discontinuation; Antiretroviral therapy; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Virology; Intensive care medicine; Immunology","score_opus":0.10938389424447433,"score_gpt":0.35304386302550805,"score_spread":0.24365996878103374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1703585126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5923309,0.1307746,0.24041861,0.0055565415,0.0038045563,0.014288153,0.0041986844,0.0003653252,0.008262757],"genre_scores_gemma":[0.9509948,0.0030646387,0.032837033,0.001782684,0.0011585795,0.008456693,0.0011287499,0.0001376512,0.00043923708],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.1128017,0.8229671,0.03581284,0.008926366,0.018717498,0.0007744165],"domain_scores_gemma":[0.097611435,0.83045936,0.042126708,0.023306904,0.0056658923,0.0008296657],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5579955,0.0027437585,0.00939409,0.005348078,0.0012092924,0.0040665073,0.0025216055,0.004241676,0.001967195],"category_scores_gemma":[0.6239101,0.0013919385,0.015970875,0.005920421,0.005502984,0.00564724,0.004095337,0.0046776957,0.000322035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21398969,0.00091832294,0.25550374,0.03567009,0.3058267,0.00062417466,0.0026648664,0.017432729,0.0020615382,0.007689762,0.0028067522,0.15481159],"study_design_scores_gemma":[0.07003209,0.12382895,0.48219308,0.014074734,0.11496953,0.0024254373,0.0020323894,0.09275134,0.007683489,0.06260448,0.02639933,0.0010051903],"about_ca_topic_score_codex":0.0003200806,"about_ca_topic_score_gemma":0.0004352325,"teacher_disagreement_score":0.4420045,"about_ca_system_score_codex":0.001259999,"about_ca_system_score_gemma":0.0018978728,"threshold_uncertainty_score":0.5450703},"labels":[],"label_agreement":null},{"id":"W172708961","doi":"10.1177/135965350601100108","title":"Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; AIDS Vancouver; University of British Columbia; Providence Health Care","funders":"","keywords":"Nephrotoxicity; Antiretroviral therapy; Medicine; Mitochondrial toxicity; Human immunodeficiency virus (HIV); Lentivirus; Mechanism (biology); Kidney; Virology; Immunology; Internal medicine; Pharmacology; Viral load; Viral disease","score_opus":0.020830012184985775,"score_gpt":0.2323322019368617,"score_spread":0.2115021897518759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W172708961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992669,0.0005177458,0.000055491848,0.000014358576,0.000001478104,0.0000054981524,0.00002034921,9.592044e-7,0.000117171],"genre_scores_gemma":[0.9996487,0.00015347975,0.000108116845,0.000010849235,0.000005883109,0.0000040777077,0.0000311386,2.8484163e-7,0.00003739184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978644,0.00008760459,0.000023191464,0.00003086125,0.000040880688,0.000031010797],"domain_scores_gemma":[0.99939144,0.00018835839,0.0002426406,0.000021040196,0.00006468691,0.000091787166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060697,0.00016130245,0.00021378214,0.00056657696,0.00030071352,0.00047224294,0.00020806651,0.00024109252,0.0008199446],"category_scores_gemma":[0.00095422694,0.00009158242,0.00015497483,0.0004867532,0.00020885102,0.00030219738,0.00029178287,0.00022727555,0.000057629226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004861903,0.00006085679,0.99341786,0.00003192479,0.000032224092,0.00014218182,0.0000913864,0.000026994505,0.0014118854,0.00001702293,0.000020607158,0.004260791],"study_design_scores_gemma":[0.000019189727,0.0011313636,0.99591726,0.00001535956,0.000071201386,0.001136763,0.00039536474,0.00035835188,0.00070303853,0.00005177794,0.00019649212,0.0000038363355],"about_ca_topic_score_codex":0.0005788672,"about_ca_topic_score_gemma":0.0008889075,"teacher_disagreement_score":0.0008199446,"about_ca_system_score_codex":0.0001744668,"about_ca_system_score_gemma":0.00021366579,"threshold_uncertainty_score":0.0032100081},"labels":[],"label_agreement":null},{"id":"W176944265","doi":"10.1177/135965350100600206","title":"Avanti 3: A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Lamivudine plus Zidovudine versus Lamivudine plus Zidovudine plus Nelfinavir in HIV-1-Infected Antiretroviral-Naive Patients","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; St. Paul's Hospital","funders":"","keywords":"Lamivudine; Nelfinavir; Zidovudine; Medicine; Tolerability; Placebo; Gastroenterology; Internal medicine; Adverse effect; Pharmacology; Randomized controlled trial; Indinavir; Virology; Sida; Viral load; Human immunodeficiency virus (HIV); Viral disease; Antiretroviral therapy; Virus","score_opus":0.04664450726182794,"score_gpt":0.318903719057104,"score_spread":0.27225921179527607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176944265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836367,0.006727403,0.0013368854,0.000812331,0.000978869,0.0035147928,0.0010880707,0.0002977327,0.001607316],"genre_scores_gemma":[0.9846681,0.002654027,0.003124096,0.0012667875,0.0010827283,0.004676746,0.0008208321,0.00003486414,0.0016717832],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984193,0.0010935793,0.00010011307,0.00019934274,0.000075537384,0.00011217533],"domain_scores_gemma":[0.99807894,0.0007439208,0.0004702818,0.00013280527,0.00008209424,0.00049190584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002569862,0.0017112382,0.003914948,0.00057867414,0.0005554961,0.0010032672,0.0012255394,0.0022179764,0.006313808],"category_scores_gemma":[0.0028787297,0.0008899023,0.0019642417,0.0005001909,0.0015167869,0.0010333015,0.00046118273,0.0025607783,0.0009492456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9906143,0.001844944,0.00015753403,0.00021557066,0.00030449659,0.000014233527,0.000013075588,0.00009262599,0.0010958477,0.00003951326,0.00017052391,0.0054372046],"study_design_scores_gemma":[0.9673605,0.03146684,0.00042485562,0.000011246082,0.00015026313,0.000018982371,0.000005444415,0.00022745816,0.00015095745,0.000059544673,0.000117328214,0.000006546726],"about_ca_topic_score_codex":0.00062050245,"about_ca_topic_score_gemma":0.0011476481,"teacher_disagreement_score":0.006313808,"about_ca_system_score_codex":0.0005908264,"about_ca_system_score_gemma":0.000979885,"threshold_uncertainty_score":0.02112174},"labels":[],"label_agreement":null},{"id":"W1828979694","doi":"10.3851/imp2768","title":"Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medical Research Council; European Commission; Stichting HIV Monitoring; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Institut National de la Santé et de la Recherche Médicale; Styrelsen för Internationellt Utvecklingssamarbete; Michael Smith Health Research BC; GlaxoSmithKline; National Science Foundation; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs; Office of Research and Development","keywords":"Medicine; Cart; Hazard ratio; Demography; Cohort; Antiretroviral therapy; Proportional hazards model; Mortality rate; Cohort study; Human immunodeficiency virus (HIV); Men who have sex with men; Cause of death; Viral load; Internal medicine; Immunology; Confidence interval; Disease; Syphilis","score_opus":0.022517346372524966,"score_gpt":0.26678252525695517,"score_spread":0.2442651788844302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1828979694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911767,0.003286111,0.00007355543,0.00022428356,0.000013876322,0.000016505875,0.0033638014,0.0000067874157,0.0018383992],"genre_scores_gemma":[0.9967092,0.0011339026,0.000078993085,0.000088537694,0.000009964766,0.000007136536,0.0016674752,0.0000030091117,0.00030172901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994543,0.00006441684,0.00003840941,0.0000924515,0.00016825055,0.0001822308],"domain_scores_gemma":[0.99909854,0.00007600797,0.00024109209,0.00003379247,0.00035523783,0.00019539097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006824281,0.00030083596,0.00035279055,0.0012187505,0.0008120493,0.0008100862,0.00051143824,0.00029985694,0.0011696612],"category_scores_gemma":[0.0016273538,0.00012851441,0.0005609767,0.0022213515,0.00036207697,0.00022275826,0.00052075397,0.0003100537,0.00009676838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078091165,0.000005540961,0.9971787,0.000014197188,0.00011774491,0.000031145308,0.00010278448,0.00007347307,0.00003558728,0.00005024017,0.00028522912,0.002027269],"study_design_scores_gemma":[0.00000454814,0.000009837831,0.9990646,0.000016051741,0.000049304173,0.00006596929,0.00023934332,0.00008423812,0.000022627451,0.00002161259,0.00041808948,0.0000037460109],"about_ca_topic_score_codex":0.8885028,"about_ca_topic_score_gemma":0.91505104,"teacher_disagreement_score":0.8885028,"about_ca_system_score_codex":0.0043453416,"about_ca_system_score_gemma":0.005852421,"threshold_uncertainty_score":0.22430766},"labels":[],"label_agreement":null},{"id":"W184261913","doi":"10.1177/135965350801300109","title":"Prospective Cohort Study of HIV Post-Exposure Prophylaxis for Sexual Assault Survivors","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Sexual Assault and Victimization Studies","field":"Social Sciences","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Ontario HIV Treatment Network; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Prospective cohort study; Odds ratio; Cohort; Confidence interval; Logistic regression; Cohort study; Risk assessment; Internal medicine","score_opus":0.03995670463885869,"score_gpt":0.32735074145387444,"score_spread":0.28739403681501574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W184261913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973525,0.00020285073,0.00009843274,0.00004672388,0.000011901091,0.00009687628,0.0017465508,0.0000046401606,0.00043949528],"genre_scores_gemma":[0.9978782,0.00018724921,0.00017352257,0.000070291826,0.000013598573,0.000112664384,0.0011102315,0.000002995303,0.00045137884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992943,0.00016432139,0.000069214715,0.00016172508,0.00017286585,0.00013753233],"domain_scores_gemma":[0.9983511,0.00016300312,0.0005205529,0.00017562858,0.0002864799,0.00050323736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010425881,0.00036342704,0.00046183844,0.0006686156,0.0010009678,0.00075497845,0.000499322,0.0004754648,0.0022653092],"category_scores_gemma":[0.0022518153,0.00049660983,0.00046003636,0.0010846494,0.00020256257,0.00049020373,0.0004410233,0.0008639782,0.00042727895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091113114,0.000051510633,0.9991248,0.000007589346,0.00003390392,0.00005303548,0.00008113628,0.000006465803,0.00006383289,0.000007672863,0.00010941063,0.00036946835],"study_design_scores_gemma":[0.000020088715,0.00028335422,0.9988049,0.000010449096,0.000037295245,0.0002034608,0.00025665923,0.00006412328,0.000023200711,0.0000103125285,0.0002820453,0.00000402673],"about_ca_topic_score_codex":0.022171272,"about_ca_topic_score_gemma":0.025565492,"teacher_disagreement_score":0.022171272,"about_ca_system_score_codex":0.00042048,"about_ca_system_score_gemma":0.0007682128,"threshold_uncertainty_score":0.04408443},"labels":[],"label_agreement":null},{"id":"W1845536215","doi":"10.1177/135965350300800406","title":"Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Amprenavir; Regimen; Drug resistance; Protease inhibitor (pharmacology); Internal medicine; Medicine; Viral load; Pharmacology; Virology; Immunology; Biology; Protease; Virus; HIV-1 protease; Antiretroviral therapy; Microbiology","score_opus":0.009401912719932652,"score_gpt":0.25375400540812737,"score_spread":0.24435209268819472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1845536215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996277,0.00010862242,0.000032486256,0.000020675847,0.0000028325032,0.0000062714907,0.000046271194,0.0000013528094,0.00015373273],"genre_scores_gemma":[0.99965465,0.00003993391,0.00006319689,0.00003142569,0.000009166151,0.00000488218,0.00009134288,0.0000011129342,0.00010429894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958414,0.00016459163,0.000049850834,0.000050971048,0.000057115412,0.00009343752],"domain_scores_gemma":[0.9982722,0.0005674345,0.000616787,0.00007936725,0.00010921233,0.00035493114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005128591,0.00027779702,0.00036120036,0.00033389413,0.00037719644,0.00049505744,0.00018294083,0.0004766817,0.0012696498],"category_scores_gemma":[0.0033191296,0.00027060063,0.00025205212,0.0003329955,0.00020817667,0.00039976148,0.00020878215,0.0005598126,0.00032810375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007874189,0.0001122689,0.9948724,0.000009540909,0.00003434496,0.00022342565,0.00012596192,0.00013507079,0.0006125519,0.0000116757055,0.00009680113,0.002978577],"study_design_scores_gemma":[0.00006068358,0.001056952,0.9966274,0.0000070763535,0.000030780728,0.00097227574,0.00019530178,0.00048682702,0.0002502044,0.000028935705,0.00027401382,0.000009587025],"about_ca_topic_score_codex":0.0012059647,"about_ca_topic_score_gemma":0.0014100396,"teacher_disagreement_score":0.0012696498,"about_ca_system_score_codex":0.000173768,"about_ca_system_score_gemma":0.00014765053,"threshold_uncertainty_score":0.0042473674},"labels":[],"label_agreement":null},{"id":"W1881862380","doi":"10.1177/135965350501002s02","title":"Possible Ways Nucleoside Analogues Can Affect Mitochondrial Dna Content and Gene Expression during HIV Therapy","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Mitochondrial toxicity; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Mitochondrial DNA; Toxicity; Biology; Nucleoside analogue; Mitochondrion; Reverse-transcriptase inhibitor; Nucleoside; Mitochondrial respiratory chain; Virology; Affect (linguistics); Pharmacology; Gene; Human immunodeficiency virus (HIV); Polymerase chain reaction; Medicine; Genetics; Internal medicine; Psychology","score_opus":0.03792874157312286,"score_gpt":0.2623311100440043,"score_spread":0.2244023684708814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1881862380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8784342,0.10121755,0.008547642,0.0008526364,0.0002912495,0.0001361285,0.00027795223,0.00013258481,0.0101101445],"genre_scores_gemma":[0.977487,0.017538708,0.0023249965,0.00018709656,0.000103087536,0.000062597945,0.00014480566,0.000017162325,0.0021344984],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997658,0.000112595604,0.000018007635,0.000028924747,0.000044457716,0.000030163212],"domain_scores_gemma":[0.9998348,0.00008990349,0.00003553164,0.000010884959,0.00001602314,0.000012913149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040701634,0.00015468326,0.00037193304,0.00017089788,0.00017311642,0.000519783,0.0002520913,0.00045905073,0.0017749615],"category_scores_gemma":[0.0005591281,0.00012838139,0.00026038123,0.00015573164,0.0002734994,0.00032519858,0.00014711524,0.00040181624,0.00020179861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023565236,0.0001723676,0.0053465455,0.0006604539,0.00007393026,0.0010455172,0.0002883879,0.00067360577,0.9132872,0.0024213952,0.0003029349,0.07337113],"study_design_scores_gemma":[0.00024321546,0.010987165,0.05495655,0.00020275495,0.00029641422,0.004796512,0.00047488933,0.0022991926,0.8782318,0.0030528156,0.044413466,0.000045233537],"about_ca_topic_score_codex":0.00016821446,"about_ca_topic_score_gemma":0.00033404763,"teacher_disagreement_score":0.0017749615,"about_ca_system_score_codex":0.00027769664,"about_ca_system_score_gemma":0.00010561451,"threshold_uncertainty_score":0.0059378743},"labels":[],"label_agreement":null},{"id":"W1962555342","doi":"10.1177/135965350501002s01","title":"Mitochondria, HIV Infection and Its Treatment: Where Do We Go from Here?","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Mitochondrion; Medicine; Virology; Internal medicine; Immunology; Biology; Genetics","score_opus":0.02467248099761497,"score_gpt":0.3138175768285701,"score_spread":0.2891450958309551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1962555342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022203868,0.73846835,0.00024345375,0.24839613,0.011268047,0.000012184545,0.00003522596,0.000032506192,0.0013221564],"genre_scores_gemma":[0.00471432,0.9105073,0.0006292615,0.05789612,0.021258064,0.00005620615,0.000076404576,0.00003684845,0.0048254007],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99607867,0.0019389765,0.00033463794,0.00037228403,0.0007769599,0.0004985739],"domain_scores_gemma":[0.98816,0.004664043,0.0010150137,0.00046671086,0.002879554,0.0028146175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00984755,0.0011329429,0.0032589813,0.0021268488,0.0030676997,0.0115847755,0.002270056,0.012112349,0.018091012],"category_scores_gemma":[0.0129307,0.00058488426,0.0009448279,0.0024079678,0.0060873143,0.025702506,0.003784183,0.015364981,0.0066997814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006243383,0.00022047799,0.0011751651,0.00863748,0.00014441012,0.00039432984,0.0012827606,0.00015668815,0.0008822669,0.015779799,0.45767435,0.513028],"study_design_scores_gemma":[0.00008037458,0.00032888085,0.0018727898,0.007625833,0.0001052909,0.00056032353,0.0041311863,0.000118713004,0.00031206693,0.030594919,0.9541662,0.00010338742],"about_ca_topic_score_codex":0.0043025245,"about_ca_topic_score_gemma":0.009962558,"teacher_disagreement_score":0.018091012,"about_ca_system_score_codex":0.0036303287,"about_ca_system_score_gemma":0.008488304,"threshold_uncertainty_score":0.06052053},"labels":[],"label_agreement":null},{"id":"W1970848393","doi":"10.3851/imp1646","title":"Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis <i>in vivo</i>","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Provincial Laboratory of Public Health; University of Calgary","funders":"","keywords":"Oncolytic virus; In vivo; Viral replication; Biology; Virology; Protease inhibitor (pharmacology); In vitro; Virus; Protease; Viral load; Enzyme; Biochemistry","score_opus":0.014293093578494034,"score_gpt":0.29012677507396284,"score_spread":0.27583368149546883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970848393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96404594,0.012756985,0.015401243,0.00023238122,0.00009067728,0.00016897148,0.0006645853,0.00035698368,0.0062822294],"genre_scores_gemma":[0.9842821,0.003450678,0.008118043,0.00007710871,0.000018516203,0.000061176324,0.0007192574,0.000032757325,0.0032405097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999515,0.000005936242,0.0000033431988,0.000010484313,0.000010228364,0.000018543762],"domain_scores_gemma":[0.99996793,0.000006789755,0.00000962193,0.0000030395881,0.000004994082,0.000007563237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010666641,0.0005316875,0.00019003569,0.00019261077,0.00011594665,0.00016882234,0.00027379527,0.0002753269,0.0008332422],"category_scores_gemma":[0.000050038776,0.00009587961,0.00021968929,0.00008311299,0.00014887893,0.00016407481,0.00007587162,0.00036820033,0.0003293492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020501977,0.00004586723,0.0000588068,0.000055570108,0.000005845384,0.00004159251,0.0000045954334,0.00020369295,0.99662197,0.00011924111,0.000079052035,0.0025587287],"study_design_scores_gemma":[0.000032433916,0.00048250917,0.0005029556,0.000004022112,0.000012845436,0.00023993137,0.0000019706029,0.0005569098,0.9960347,0.000017445882,0.0021116605,0.0000026727732],"about_ca_topic_score_codex":0.00068215106,"about_ca_topic_score_gemma":0.0007790498,"teacher_disagreement_score":0.0008332422,"about_ca_system_score_codex":0.00036990226,"about_ca_system_score_gemma":0.00020749931,"threshold_uncertainty_score":0.0027874708},"labels":[],"label_agreement":null},{"id":"W1970961290","doi":"10.3851/imp2750","title":"Pharmacokinetics of Raltegravir in the Semen of HIV-Infectedmen","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Women's College Hospital; University of Toronto; Maple Leaf Medical Clinic; St. Michael's Hospital","funders":"Johnson and Johnson; Merck Canada; Abbott Canada; Gilead Sciences; Ontario HIV Treatment Network; Pfizer; ViiV Healthcare; Eli Lilly and Company","keywords":"Raltegravir; Pharmacokinetics; Semen; Medicine; Blood sampling; Blood plasma; Internal medicine; Venous blood; Pharmacology; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Andrology; Immunology; Antiretroviral therapy","score_opus":0.01959320124081224,"score_gpt":0.29079744455224044,"score_spread":0.2712042433114282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970961290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246573,0.0055541345,0.0010333515,0.00010693475,0.000014137043,0.000050082424,0.0002881783,0.000027773647,0.00045978182],"genre_scores_gemma":[0.9965713,0.000997161,0.0014680427,0.000112702626,0.000020152254,0.000023108023,0.000281689,0.000006366663,0.00051952386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968433,0.000115911986,0.000016252376,0.0000742628,0.00008506813,0.000024264262],"domain_scores_gemma":[0.99966395,0.00009518211,0.00011081489,0.000019038784,0.000075814045,0.000035247056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007957671,0.00022882543,0.0003710724,0.0003364078,0.00021312763,0.00079003384,0.00026602705,0.00033968937,0.0018950963],"category_scores_gemma":[0.001577121,0.0002479848,0.00025386337,0.00027559084,0.00028112935,0.0003925807,0.00020246467,0.00036749232,0.0002708753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009495685,0.00073735125,0.50541383,0.0011061366,0.0007550728,0.0008823083,0.0020336343,0.0023607472,0.37481683,0.0006483025,0.0011939526,0.10055604],"study_design_scores_gemma":[0.0005739534,0.022493964,0.7888979,0.0003097389,0.00074101705,0.007904574,0.0019128587,0.015003658,0.14897472,0.0005883451,0.012499496,0.00009984097],"about_ca_topic_score_codex":0.0015232146,"about_ca_topic_score_gemma":0.0010768586,"teacher_disagreement_score":0.0018950963,"about_ca_system_score_codex":0.00038037013,"about_ca_system_score_gemma":0.0003930205,"threshold_uncertainty_score":0.006339729},"labels":[],"label_agreement":null},{"id":"W1973346526","doi":"10.3851/imp1558","title":"Use of Newer Antiretroviral Agents, Darunavir and Etravirine with or without Raltegravir, in Pregnancy: A Report of two Cases","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; St. Michael's Hospital; Hospital for Sick Children; University of Ottawa; Women's College Hospital; University of Toronto","funders":"","keywords":"Etravirine; Raltegravir; Darunavir; Medicine; Pregnancy; Regimen; Obstetrics; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Biology","score_opus":0.06270585587226628,"score_gpt":0.33928624158068993,"score_spread":0.27658038570842364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973346526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97752964,0.005421759,0.0037958405,0.0027737666,0.0003607257,0.00020830189,0.00014869538,0.0001079389,0.009653291],"genre_scores_gemma":[0.9940744,0.0024269046,0.0011592648,0.00065318967,0.00034184745,0.00005429475,0.00008472155,0.000018909233,0.0011864607],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99808574,0.00040507675,0.00033212645,0.00035233438,0.00029738818,0.00052744726],"domain_scores_gemma":[0.99460816,0.0016610721,0.0021271985,0.0004885954,0.00023507449,0.00087986345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010353398,0.0024648835,0.0007122013,0.0027055421,0.0029450157,0.0015131609,0.0018929086,0.004823281,0.0014340387],"category_scores_gemma":[0.009343051,0.0017144971,0.0013067643,0.0017136217,0.0028535246,0.0014923647,0.0018548287,0.0033263746,0.00059075514],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006443046,0.00014798366,0.035280515,0.000049449427,0.000027377017,0.95920044,0.0010728082,0.000111328925,0.00052673975,0.000378284,0.0004531816,0.0026874167],"study_design_scores_gemma":[0.0000101437045,0.000099334335,0.0054684323,0.00002343134,0.00002169081,0.99289376,0.00033028095,0.00011445466,0.000386529,0.000075681804,0.0005633424,0.000012889565],"about_ca_topic_score_codex":0.005975292,"about_ca_topic_score_gemma":0.0040908623,"teacher_disagreement_score":0.005975292,"about_ca_system_score_codex":0.0013665096,"about_ca_system_score_gemma":0.0012895598,"threshold_uncertainty_score":0.011881053},"labels":[],"label_agreement":null},{"id":"W1982724696","doi":"10.3851/imp1936","title":"Pleconaril Revisited: Clinical Course of Chronic Enteroviral Meningoencephalitis after Treatment Correlates with <i>In Vitro</i> Susceptibility","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral Infections and Immunology Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leids Universitair Medisch Centrum; ZonMw; Egg Farmers of Canada","keywords":"Medicine; Antibody; Enterovirus; Immunology; Case fatality rate; Echovirus; Meningoencephalitis; Virology; Virus; Internal medicine; Epidemiology","score_opus":0.05374512684499121,"score_gpt":0.34881838741023474,"score_spread":0.2950732605652435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982724696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798196,0.008717874,0.0007747577,0.001344875,0.000094973235,0.00013933056,0.0001751222,0.00006205025,0.008871458],"genre_scores_gemma":[0.9978453,0.0009471553,0.00017053145,0.0004433947,0.00013737784,0.000018228258,0.000142701,0.0000054929073,0.0002898733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963105,0.0000915722,0.000058984915,0.000073648145,0.00006781551,0.00007694176],"domain_scores_gemma":[0.998451,0.0003786926,0.0006457057,0.000099428886,0.00012593226,0.00029924954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051262445,0.00073725637,0.0007702561,0.00058324623,0.00068007293,0.00081606937,0.0005346597,0.0015070108,0.001480391],"category_scores_gemma":[0.0021172846,0.00019484007,0.00031511046,0.0006277412,0.00085013505,0.0008937982,0.0003915711,0.0014538331,0.00035746087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040260334,0.00041839416,0.6349484,0.00044841343,0.00013593845,0.30965853,0.0010399662,0.00029753736,0.01949028,0.00041578067,0.0022563916,0.026864398],"study_design_scores_gemma":[0.00026311592,0.0028197102,0.46839508,0.0002185843,0.0001888823,0.51691663,0.0006681876,0.0010458101,0.0043579643,0.00026772008,0.00481066,0.00004765193],"about_ca_topic_score_codex":0.001175195,"about_ca_topic_score_gemma":0.001515992,"teacher_disagreement_score":0.0015070108,"about_ca_system_score_codex":0.00056553487,"about_ca_system_score_gemma":0.000504043,"threshold_uncertainty_score":0.0049524307},"labels":[],"label_agreement":null},{"id":"W1987541968","doi":"10.3851/imp1752","title":"Antiviral Effects of Interferon-β are Enhanced in the Absence of the Translational Suppressor 4E-BP1 in Myocarditis Induced by Coxsackievirus B3","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral Infections and Immunology Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Myocarditis; Immune system; Interferon; Viral Myocarditis; Immunology; Context (archaeology); Virology; Coxsackievirus; Biology; Virus; Medicine; Enterovirus; Internal medicine","score_opus":0.018834269006448936,"score_gpt":0.31064841703811297,"score_spread":0.29181414803166406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987541968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969362,0.0014932428,0.00071298203,0.000048580572,0.00003096713,0.00001555785,0.00021532504,0.00003443026,0.00051272515],"genre_scores_gemma":[0.9962475,0.00079573895,0.0012659681,0.000049491107,0.000021145343,0.000039559254,0.0006292161,0.000024841871,0.0009266106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983275,0.000035554716,0.000022907454,0.000027450254,0.000043863874,0.00003743534],"domain_scores_gemma":[0.99978095,0.000041266296,0.000082820414,0.000021181786,0.000015935055,0.0000577666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022884461,0.0005281785,0.0003348246,0.00028331098,0.00014709952,0.00022818403,0.00017077278,0.00032983875,0.0012283892],"category_scores_gemma":[0.00013381691,0.00015925623,0.00028882775,0.00011850807,0.0003146062,0.00015647127,0.00016437986,0.00067597395,0.00036493136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001600225,0.000021972926,0.00010390204,0.000018566376,0.0000022682175,0.00002353523,0.0000036211047,0.000011641821,0.9994461,0.000010194736,0.0000061328783,0.00019201853],"study_design_scores_gemma":[0.000042766114,0.0007127482,0.0071044294,0.000008162694,0.00002523338,0.0002979314,0.000017911858,0.00029992356,0.99064696,0.000026874808,0.00081339735,0.0000036932058],"about_ca_topic_score_codex":0.00021680437,"about_ca_topic_score_gemma":0.00023396489,"teacher_disagreement_score":0.0012283892,"about_ca_system_score_codex":0.00018214992,"about_ca_system_score_gemma":0.00011840404,"threshold_uncertainty_score":0.0041093826},"labels":[],"label_agreement":null},{"id":"W1990570958","doi":"10.3851/imp2076","title":"Pill Burden in HIV Infection: 20 Years of Experience","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Medicine; Pill; Medical prescription; Cohort; Pharmacy; Dosing; Human immunodeficiency virus (HIV); Cohort study; Internal medicine; Pediatrics; Immunology; Pharmacology; Family medicine","score_opus":0.026215799350104187,"score_gpt":0.3016907207139864,"score_spread":0.2754749213638822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990570958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97253823,0.014877683,0.00017800988,0.0028726328,0.000069555215,0.000041833606,0.0008011454,0.000025025387,0.008595839],"genre_scores_gemma":[0.9857328,0.01127081,0.00024856726,0.0007381392,0.00010218423,0.000017075428,0.00065625104,0.000005260327,0.0012288864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942964,0.00011848049,0.00004698441,0.000052219162,0.00023269674,0.00012002455],"domain_scores_gemma":[0.9988154,0.0001776964,0.0003729818,0.000038025024,0.00018501181,0.0004107776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009553718,0.00021933601,0.00026758076,0.00067863823,0.00053581473,0.00087453896,0.00043725834,0.00039500787,0.0016051312],"category_scores_gemma":[0.0028006511,0.00015840375,0.00020674216,0.0015905587,0.00048625423,0.00078220194,0.0008815591,0.00053841295,0.00021649328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008290469,0.00011797132,0.90138143,0.00012726797,0.0000536806,0.000499176,0.003179256,0.00017347078,0.00015096001,0.00023612572,0.003144468,0.09085326],"study_design_scores_gemma":[0.000013924342,0.00020215553,0.9830867,0.00015905684,0.000041652867,0.0019054486,0.0027062185,0.0003793103,0.00008094388,0.00016243127,0.01124634,0.000015847718],"about_ca_topic_score_codex":0.07867899,"about_ca_topic_score_gemma":0.08411885,"teacher_disagreement_score":0.07867899,"about_ca_system_score_codex":0.0016568383,"about_ca_system_score_gemma":0.0016622595,"threshold_uncertainty_score":0.15644205},"labels":[],"label_agreement":null},{"id":"W19918097","doi":"10.3851/imp1418","title":"Psycho-social Resilience and Risky HIV Behaviors among Black Males who have Sex with Males","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Homelessness and Social Issues","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Psychosocial; Men who have sex with men; Psychological resilience; Demography; Psychology; Human immunodeficiency virus (HIV); Gerontology; Social psychology; Medicine; Psychiatry; Sociology; Family medicine","score_opus":0.06380651931898393,"score_gpt":0.4061485044869769,"score_spread":0.34234198516799297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W19918097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992938,0.00012837634,0.0000071139866,0.00013714276,0.000003956288,0.0000026478756,0.0000282564,5.7534027e-7,0.00039815984],"genre_scores_gemma":[0.9996805,0.00009238436,0.000008068938,0.000028525714,0.0000069895736,0.0000018343079,0.000016329514,3.848304e-7,0.000164882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998894,0.000033663473,0.0000055335545,0.000010279527,0.000016866567,0.000044300046],"domain_scores_gemma":[0.99948645,0.00006983037,0.00023484378,0.000015930025,0.000021264223,0.00017172022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023941095,0.00012755541,0.00012509107,0.0004810879,0.0005791721,0.00041247852,0.00016281276,0.00030964753,0.003925474],"category_scores_gemma":[0.001121872,0.00016087022,0.00027463346,0.00023961601,0.0002599774,0.00031081252,0.00043028672,0.00041722908,0.00016240451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006508528,0.00013156129,0.9961332,0.000006596044,0.000028360995,0.00005828407,0.00033833057,0.000015470187,0.00011648674,0.000054160515,0.000097659504,0.002954903],"study_design_scores_gemma":[0.0000040892965,0.000061721075,0.9987042,0.000016811971,0.0000148401905,0.00008396131,0.0008739988,0.00006284203,0.0000278967,0.000037815393,0.00010988595,0.0000019256381],"about_ca_topic_score_codex":0.00880553,"about_ca_topic_score_gemma":0.0145786805,"teacher_disagreement_score":0.00880553,"about_ca_system_score_codex":0.00020354532,"about_ca_system_score_gemma":0.000285325,"threshold_uncertainty_score":0.017508566},"labels":[],"label_agreement":null},{"id":"W2000115405","doi":"10.3851/imp2957","title":"Viral Shedding and Susceptibility to Oseltamivir in Hospitalized Immunocompromised Patients with Influenza in the Influenza Resistance Information Study (IRIS)","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Oseltamivir; Medicine; Viral shedding; Virus; Internal medicine; Influenza A virus; Neuraminidase inhibitor; Drug resistance; Virology; Resistance mutation; Immunology; Polymerase chain reaction; Biology; Coronavirus disease 2019 (COVID-19); Reverse transcriptase; Microbiology; Disease","score_opus":0.027255917356657555,"score_gpt":0.3361962305247872,"score_spread":0.30894031316812964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000115405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995634,0.00007856196,0.0000188279,0.000012171494,0.000002029755,0.000009635811,0.00020797648,0.0000010788957,0.00010644558],"genre_scores_gemma":[0.9994407,0.000046291934,0.00004098708,0.000022786873,0.0000061432766,0.000013343918,0.00036943404,9.300692e-7,0.000059175713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952507,0.00017008296,0.00007660817,0.00009451171,0.00006176821,0.00007197495],"domain_scores_gemma":[0.99892884,0.00020137985,0.00049816235,0.00009408296,0.000067083194,0.00021047884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008649262,0.0002624149,0.00042167256,0.00034189378,0.00037217792,0.00057079917,0.0001857094,0.00034268966,0.0011630933],"category_scores_gemma":[0.0019701498,0.0002427593,0.0003920629,0.0004308601,0.0001847171,0.00032226133,0.0004161018,0.00056290196,0.00021423452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009052906,0.00010553671,0.9974832,0.000015794729,0.0000451705,0.00006633975,0.00008964826,0.000019034282,0.0004980447,0.000005042693,0.00006746822,0.0006994666],"study_design_scores_gemma":[0.00008259179,0.000636646,0.9983797,0.000009772393,0.000039263603,0.00036643786,0.00013922599,0.00009976694,0.000116551535,0.000007061038,0.00011967547,0.0000031947013],"about_ca_topic_score_codex":0.0013240246,"about_ca_topic_score_gemma":0.0018381148,"teacher_disagreement_score":0.0013240246,"about_ca_system_score_codex":0.0001948408,"about_ca_system_score_gemma":0.0001924683,"threshold_uncertainty_score":0.0045741796},"labels":[],"label_agreement":null},{"id":"W2001797772","doi":"10.3851/imp1614","title":"Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"National Institute on Drug Abuse; F. Hoffmann-La Roche; Canadian Institutes of Health Research; Abbott Laboratories","keywords":"Medicine; Odds ratio; Abstinence; Confidence interval; Logistic regression; Drug; Internal medicine; Cohort; Cohort study; Psychiatry","score_opus":0.018337812836971144,"score_gpt":0.3015202938073326,"score_spread":0.2831824809703614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001797772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383837,0.0015599539,0.00008073215,0.00040210586,0.000011985022,0.000047710986,0.0021539242,0.00000595618,0.0018992369],"genre_scores_gemma":[0.9982942,0.00063074025,0.00010036933,0.00006143294,0.0000053571544,0.000010610919,0.00066349853,0.000002321809,0.00023144408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986387,0.00013831678,0.00008716695,0.0001622277,0.0005389488,0.00043474173],"domain_scores_gemma":[0.9967084,0.00023314368,0.00093886635,0.00009478032,0.0011218349,0.0009028452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011901542,0.0003859361,0.00042136377,0.0012476115,0.002595823,0.0015727624,0.0015711839,0.0005658495,0.002228746],"category_scores_gemma":[0.0043765027,0.00032016062,0.00087605097,0.003515425,0.0006362534,0.00036547746,0.0010427024,0.0010895557,0.00015614039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005896629,0.00002770796,0.9973551,0.000036453082,0.00004740203,0.00004735816,0.00027362822,0.000055395343,0.00003983035,0.000045264474,0.00023863614,0.0017742594],"study_design_scores_gemma":[0.000007433499,0.00003219089,0.99872786,0.000049661237,0.000049457394,0.000057593323,0.0005318931,0.00017478122,0.000023295517,0.000022105532,0.00031390044,0.000009682257],"about_ca_topic_score_codex":0.98726636,"about_ca_topic_score_gemma":0.9894454,"teacher_disagreement_score":0.98726636,"about_ca_system_score_codex":0.02113533,"about_ca_system_score_gemma":0.030783799,"threshold_uncertainty_score":0.15334827},"labels":[],"label_agreement":null},{"id":"W2005994369","doi":"10.3851/imp1416","title":"Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"International Development Research Centre; Wellcome Trust","keywords":"Drug resistance; Medicine; Population; Cohort; Internal medicine; Cohort study; Epidemiology; Virology; Immunology; Biology; Genetics; Environmental health","score_opus":0.01668746901360428,"score_gpt":0.26401004703574676,"score_spread":0.24732257802214247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005994369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996983,0.00006756752,0.000012472467,0.000021570086,0.000001184799,0.0000049275377,0.000087595276,8.447777e-7,0.00010554536],"genre_scores_gemma":[0.99977463,0.000060141214,0.000026207232,0.000018191085,0.0000024569117,0.000005774572,0.000057895842,6.5754847e-7,0.000053939082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996995,0.00006368271,0.000027080821,0.000060852297,0.00004758515,0.00010147037],"domain_scores_gemma":[0.99952114,0.00007696442,0.00020059157,0.000018749412,0.0000559754,0.00012667259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023771776,0.00029060102,0.00022634694,0.000981298,0.00075737626,0.00063904765,0.0002714816,0.00041786153,0.0029367607],"category_scores_gemma":[0.0013833875,0.00026342663,0.00018905489,0.00076278404,0.0005339979,0.00046751762,0.00036051768,0.00031400778,0.0002044139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047541504,0.000026281316,0.99642783,0.000018375647,0.0000128139645,0.00025857793,0.00082205125,0.000018834537,0.0007404779,0.000022704231,0.00008927253,0.0015151519],"study_design_scores_gemma":[0.000008842584,0.00010535509,0.99739754,0.000018252793,0.000012226773,0.00090569945,0.0010890694,0.00006671159,0.00011638525,0.00002503699,0.00024980382,0.0000049948635],"about_ca_topic_score_codex":0.017090973,"about_ca_topic_score_gemma":0.019683538,"teacher_disagreement_score":0.017090973,"about_ca_system_score_codex":0.0005330375,"about_ca_system_score_gemma":0.00054858404,"threshold_uncertainty_score":0.033982992},"labels":[],"label_agreement":null},{"id":"W2006670989","doi":"10.3851/imp2680","title":"Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health","funders":"BioCryst","keywords":"Medicine; Tolerability; Neuraminidase inhibitor; Internal medicine; Oseltamivir; Neuraminidase; Viral shedding; Influenza A virus; Clinical endpoint; Randomized controlled trial; Adverse effect; Viral load; Dosing; Clinical trial; Virus; Virology; Coronavirus disease 2019 (COVID-19); Disease; Infectious disease (medical specialty)","score_opus":0.07120528762117101,"score_gpt":0.37553817732536693,"score_spread":0.3043328897041959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006670989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732367,0.019022796,0.0005681721,0.00090217293,0.00021299953,0.0014180967,0.0008113681,0.00006038504,0.0037672776],"genre_scores_gemma":[0.99177176,0.0038067158,0.0013378897,0.00082648144,0.00018207754,0.001022197,0.0005989773,0.000004724659,0.00044922077],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99963975,0.00021568834,0.00003240882,0.000032499694,0.000035352885,0.000044277713],"domain_scores_gemma":[0.99961394,0.00009814169,0.00012922805,0.00001390194,0.00002506187,0.000119856224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064864894,0.00031067684,0.00060285785,0.00016152764,0.00018067872,0.00030571537,0.00034778402,0.0004955766,0.0033725554],"category_scores_gemma":[0.00078264554,0.000111233014,0.00038180716,0.00018134304,0.00021899455,0.0002023649,0.00024041055,0.0008649972,0.00031790862],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3311612,0.012180943,0.025455827,0.005125605,0.001253543,0.0005876095,0.00021506472,0.0013478342,0.02385878,0.0006616722,0.008829206,0.5893227],"study_design_scores_gemma":[0.54442793,0.30986938,0.09632251,0.0017952974,0.0015477443,0.0028410337,0.00027176205,0.004467753,0.009808752,0.0012225503,0.02735339,0.00007190931],"about_ca_topic_score_codex":0.0002672139,"about_ca_topic_score_gemma":0.00071051903,"teacher_disagreement_score":0.0033725554,"about_ca_system_score_codex":0.00043054312,"about_ca_system_score_gemma":0.0006507722,"threshold_uncertainty_score":0.011282325},"labels":[],"label_agreement":null},{"id":"W200761781","doi":"10.1177/135965350400900404","title":"A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Zanamivir; Neuraminidase; Oseltamivir; Mutant; Virology; Virus; Neuraminidase inhibitor; Biology; Influenza A virus; Reverse genetics; Wild type; Viral replication; Resistance mutation; Orthomyxoviridae; Molecular biology; Gene; Reverse transcriptase; Genetics; Polymerase chain reaction; Medicine","score_opus":0.11300006086556541,"score_gpt":0.4166530347001304,"score_spread":0.30365297383456497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W200761781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991497,0.00072165916,0.005435864,0.00012189665,0.000045581084,0.00017887102,0.00036085455,0.00006066739,0.0015775382],"genre_scores_gemma":[0.98080635,0.001095612,0.013195039,0.000069151356,0.00001659419,0.00009661492,0.0010412944,0.000049643917,0.003629703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975437,0.00006608274,0.000021536394,0.0000390335,0.000078429264,0.00004051718],"domain_scores_gemma":[0.99985766,0.000052926796,0.000029601146,0.000016125388,0.000024508076,0.00001911343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034718157,0.00054366136,0.00036747885,0.0003273408,0.00023057288,0.0002529766,0.00032766332,0.0004706025,0.0007860591],"category_scores_gemma":[0.00023780412,0.00025250408,0.0005173213,0.00015976607,0.00023062105,0.00022996255,0.0001617619,0.0010432692,0.0003185433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041646854,0.000041646304,0.00007857837,0.000013165457,0.0000052727833,0.00003251575,0.000013631115,0.000070381866,0.9990088,0.000095222305,0.000022556447,0.0005765184],"study_design_scores_gemma":[0.000072924384,0.001712502,0.0024450931,0.000006329309,0.000048263966,0.00088549615,0.000037923157,0.0033161407,0.9884631,0.00007181146,0.0029292426,0.000011165711],"about_ca_topic_score_codex":0.0020107515,"about_ca_topic_score_gemma":0.0012415177,"teacher_disagreement_score":0.0020107515,"about_ca_system_score_codex":0.00047559946,"about_ca_system_score_gemma":0.00025495733,"threshold_uncertainty_score":0.0039981008},"labels":[],"label_agreement":null},{"id":"W2009282612","doi":"10.3851/imp1418","title":"Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Simon Fraser University; St. Paul's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Discontinuation; Hazard ratio; Dosing; Nevirapine; Cohort; Logistic regression; Proportional hazards model; Odds ratio; Cohort study; Viral load; Confidence interval; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.022198433971798034,"score_gpt":0.30640844060340283,"score_spread":0.2842100066316048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009282612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99931276,0.0003024217,0.00009243284,0.000013335939,0.0000064319293,0.000030555948,0.00011694606,0.0000023259565,0.0001227259],"genre_scores_gemma":[0.9994797,0.00008304329,0.00009681727,0.000026153242,0.000013923238,0.000019744008,0.00019218329,0.0000023565344,0.00008604868],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974273,0.0011908248,0.00020880875,0.0005868178,0.00044589135,0.00014033417],"domain_scores_gemma":[0.9941175,0.0015280786,0.0023674057,0.0010413993,0.0004563995,0.0004892174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043464536,0.0005325876,0.0006669174,0.0006770574,0.0004851424,0.0008674415,0.0005678651,0.000853075,0.0016137648],"category_scores_gemma":[0.0065083564,0.0005572851,0.0010937883,0.0007119054,0.00040861862,0.000688137,0.00039620977,0.0005943117,0.0002745714],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003842521,0.00045543007,0.99165124,0.000030211733,0.0009206497,0.0001314233,0.00017355455,0.00008445879,0.000430485,0.000029560922,0.00009028242,0.00216019],"study_design_scores_gemma":[0.0004364606,0.0026415228,0.99460185,0.000014759514,0.00041017737,0.0006731522,0.00012295565,0.00066252257,0.00014201472,0.00007096183,0.00020632085,0.0000173956],"about_ca_topic_score_codex":0.0013001579,"about_ca_topic_score_gemma":0.0009681392,"teacher_disagreement_score":0.0043464536,"about_ca_system_score_codex":0.00035680854,"about_ca_system_score_gemma":0.00032970263,"threshold_uncertainty_score":0.022986531},"labels":[],"label_agreement":null},{"id":"W2014281142","doi":"10.3851/imp1462","title":"Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Cart; Hazard ratio; Internal medicine; Incidence (geometry); Confidence interval; Viral load; Lymphoma; Prospective cohort study; Non-Hodgkin's lymphoma; Immunology; Gastroenterology; Human immunodeficiency virus (HIV)","score_opus":0.012030129115145559,"score_gpt":0.27215869634274165,"score_spread":0.2601285672275961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014281142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983878,0.00096866436,0.00011352197,0.000017484997,0.000004009035,0.00002083045,0.00031594717,0.0000030285025,0.00016877342],"genre_scores_gemma":[0.9989496,0.00036192822,0.00011165607,0.000038576007,0.000011756493,0.000021151862,0.00041257314,0.0000019610288,0.0000908984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855477,0.00067196257,0.00017051717,0.0003145481,0.00018469596,0.00010346908],"domain_scores_gemma":[0.9980148,0.00044501963,0.00084459747,0.00024440672,0.00020249897,0.00024873164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018590364,0.000512231,0.0007665348,0.0010708031,0.00037092617,0.0010395943,0.00041141687,0.00081800646,0.00090522825],"category_scores_gemma":[0.0024672048,0.0005344878,0.0008548244,0.001627219,0.00026923927,0.0006646243,0.000499726,0.00035334006,0.00018881005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003690626,0.000050055478,0.9980122,0.000016678707,0.00029322578,0.000116264775,0.00006824503,0.00004192187,0.00009607403,0.00000889694,0.00005893771,0.00086841645],"study_design_scores_gemma":[0.000052484007,0.00026659833,0.99784553,0.000013431414,0.00017167977,0.00096408435,0.00017339016,0.00024994081,0.00004667374,0.000020657239,0.00018738708,0.000008058369],"about_ca_topic_score_codex":0.0021469216,"about_ca_topic_score_gemma":0.0014512554,"teacher_disagreement_score":0.0021469216,"about_ca_system_score_codex":0.00032585496,"about_ca_system_score_gemma":0.00019724086,"threshold_uncertainty_score":0.009831667},"labels":[],"label_agreement":null},{"id":"W2015222119","doi":"10.3851/imp2851","title":"Antiviral Therapy for Human Rabies","year":2014,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Rabies epidemiology and control","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Rabies; Favipiravir; Rabies virus; Amantadine; Medicine; Ribavirin; Immunology; Virology; Lyssavirus; Pharmacotherapy; Intensive care medicine; Rabies vaccine; Disease; Virus; Rhabdoviridae; Internal medicine; Infectious disease (medical specialty); Hepatitis C virus; Coronavirus disease 2019 (COVID-19)","score_opus":0.07060817184077141,"score_gpt":0.3716293609952929,"score_spread":0.30102118915452153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015222119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009686946,0.99743634,0.00013385755,0.00023661324,0.00026149343,0.0000049657997,0.000011205939,0.000010025176,0.0018086315],"genre_scores_gemma":[0.0010059949,0.9963626,0.00027563653,0.00028124833,0.00021008134,0.000008795916,0.000032632113,0.000002839003,0.0018201913],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998105,0.000035980713,0.00002480363,0.000026821086,0.00008433824,0.000017537304],"domain_scores_gemma":[0.9998665,0.00005068685,0.000022042648,0.000008159655,0.000037843594,0.000014819792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045853032,0.00074083137,0.0007648854,0.0017765725,0.0003185117,0.00069941813,0.0005963999,0.0009929597,0.004811937],"category_scores_gemma":[0.00049412565,0.00018158008,0.0004436837,0.0011898142,0.00043342548,0.0008814579,0.00061734096,0.0020178047,0.003613643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041582553,0.00006790008,0.00012245464,0.0069458494,0.000052958905,0.00017429645,0.00006041185,0.00016332386,0.002184082,0.00333843,0.045956574,0.9408923],"study_design_scores_gemma":[0.000010645778,0.000037399594,0.00034955467,0.0016034426,0.000033071537,0.0009880525,0.000022759039,0.000033109154,0.00033712867,0.0011939512,0.9953843,0.000006538851],"about_ca_topic_score_codex":0.0009052072,"about_ca_topic_score_gemma":0.0014933783,"teacher_disagreement_score":0.004811937,"about_ca_system_score_codex":0.00052449235,"about_ca_system_score_gemma":0.0007016868,"threshold_uncertainty_score":0.016097546},"labels":[],"label_agreement":null},{"id":"W2021523247","doi":"10.3851/imp1565","title":"Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; Gilead Sciences","keywords":"Foscarnet; Recombinant DNA; Biology; Molecular biology; DNA polymerase; Virology; Polymerase; Ganciclovir; Aphidicolin; Human cytomegalovirus; Mutant; Virus; Enzyme; Wild type; Gene; Biochemistry","score_opus":0.027512844795580433,"score_gpt":0.34544414407019064,"score_spread":0.3179312992746102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021523247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770266,0.0013033004,0.0004242389,0.000029432433,0.000012546393,0.000010816131,0.00011479017,0.000023751674,0.000378564],"genre_scores_gemma":[0.9988071,0.00021895213,0.00060052506,0.000015975591,0.0000055037,0.0000074915656,0.00013696591,0.000006882696,0.00020062155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994973,0.000095228264,0.00007113037,0.000133223,0.00012019866,0.000082945335],"domain_scores_gemma":[0.9991805,0.0003511546,0.00016031318,0.00009615697,0.00008196802,0.00012989805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003200791,0.0004677706,0.00041190523,0.00027145544,0.00008533828,0.00047407413,0.00028645288,0.0005223754,0.0015705724],"category_scores_gemma":[0.0007498554,0.00016014952,0.00027354556,0.00012882985,0.00036756432,0.0002733761,0.00022441146,0.0005887224,0.00029889992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040865506,0.000054360098,0.001974765,0.00006584312,0.000019739626,0.00018234845,0.000017548937,0.00015191373,0.99500906,0.00005418764,0.000020915437,0.002040693],"study_design_scores_gemma":[0.00002440159,0.0009660031,0.0061466554,0.000007135407,0.000038327813,0.0015581709,0.000021329284,0.0008035158,0.9899361,0.000035208934,0.00045678148,0.0000062562826],"about_ca_topic_score_codex":0.00028943364,"about_ca_topic_score_gemma":0.00028533995,"teacher_disagreement_score":0.0015705724,"about_ca_system_score_codex":0.00030401273,"about_ca_system_score_gemma":0.0001633843,"threshold_uncertainty_score":0.0052541494},"labels":[],"label_agreement":null},{"id":"W2022895457","doi":"10.3851/imp1953","title":"A Case of a Potential Drug Interaction between Clobazam and Etravirine-Based Antiretroviral Therapy","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Maple Leaf Medical Clinic; St. Michael's Hospital","funders":"","keywords":"Etravirine; Clobazam; Pharmacology; CYP3A4; CYP2C19; Metabolite; Reverse-transcriptase inhibitor; Drug; Active metabolite; Drug interaction; Pharmacokinetics; Cytochrome P450; Medicine; Internal medicine; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Metabolism; Virology; Epilepsy","score_opus":0.043888118196605555,"score_gpt":0.2934531332387544,"score_spread":0.24956501504214884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022895457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8731184,0.0111615285,0.013149727,0.038425237,0.0024081923,0.0007135793,0.00059701665,0.0005217808,0.059904534],"genre_scores_gemma":[0.98173654,0.0020108672,0.0035031205,0.005832732,0.0016067282,0.000063599044,0.00014209154,0.000052976313,0.005051397],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99809235,0.00035065328,0.00017870973,0.0004387951,0.0003106773,0.00062882586],"domain_scores_gemma":[0.9960665,0.001569762,0.00060903444,0.00030592416,0.0002601867,0.0011886978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079454866,0.0025189982,0.001634163,0.0043304,0.004664259,0.002014763,0.0026317942,0.01320253,0.004705754],"category_scores_gemma":[0.0065933936,0.0016535257,0.0021529498,0.0024733066,0.0027897737,0.0039801276,0.0029460452,0.009007025,0.0013423043],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003657026,0.00005517355,0.0013621013,0.000013533876,0.00000792368,0.9970862,0.00012533365,0.000048653634,0.0002195273,0.00022643968,0.00020610608,0.0006124735],"study_design_scores_gemma":[0.000021999329,0.00008046851,0.00093870703,0.000013402047,0.000014606548,0.99732023,0.00008898894,0.00034099873,0.00027852875,0.0002519667,0.0006403764,0.000009732472],"about_ca_topic_score_codex":0.006551432,"about_ca_topic_score_gemma":0.009069087,"teacher_disagreement_score":0.01320253,"about_ca_system_score_codex":0.0038115706,"about_ca_system_score_gemma":0.0018365915,"threshold_uncertainty_score":0.027655005},"labels":[],"label_agreement":null},{"id":"W2039639216","doi":"10.3851/imp2821","title":"Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; National Institute on Drug Abuse; National Medical Research Council; National Health and Medical Research Council; National Institutes of Health; Bristol-Myers Squibb; National Health Research Institutes; Australian Government; Gilead Sciences","keywords":"Viral quasispecies; NS5A; Sofosbuvir; Virology; Drug resistance; NS5B; Genotype; Hepatitis C virus; Pyrosequencing; Biology; Hepatitis C; Resistance mutation; Genetics; Hepacivirus; Medicine; Gene; Ribavirin; Polymerase chain reaction; Virus; Reverse transcriptase","score_opus":0.02077903399981855,"score_gpt":0.3186742726906186,"score_spread":0.29789523869080003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039639216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986285,0.00053667405,0.00024028104,0.00004307821,0.0000035583034,0.000008888165,0.000048388792,0.0000039466804,0.0004866053],"genre_scores_gemma":[0.9996202,0.00008877172,0.00016259016,0.0000284685,0.000005199095,0.000002458714,0.000038224727,0.0000015553259,0.00005242164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990928,0.00028725652,0.00008676758,0.00022839729,0.00021082099,0.00009386376],"domain_scores_gemma":[0.99683857,0.00086675445,0.0014828767,0.00026054165,0.00035950358,0.00019168678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011992994,0.00011257978,0.00032864785,0.00042066182,0.000281128,0.0004040593,0.00024846854,0.00038647253,0.0015809557],"category_scores_gemma":[0.0034460188,0.00013654096,0.00013011815,0.0003631879,0.00043003392,0.00026938436,0.00024593042,0.00032481775,0.00018445837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006630321,0.00008547644,0.9639355,0.00010586799,0.00008724273,0.00071226875,0.0003313803,0.00011687156,0.015065514,0.00011647433,0.0002192088,0.018561129],"study_design_scores_gemma":[0.000031883283,0.00050839875,0.98790795,0.000034291967,0.00008065251,0.0060968297,0.00023597325,0.0005921785,0.0031857118,0.00026500408,0.0010526935,0.000008388067],"about_ca_topic_score_codex":0.00083251967,"about_ca_topic_score_gemma":0.002091143,"teacher_disagreement_score":0.0015809557,"about_ca_system_score_codex":0.00020430052,"about_ca_system_score_gemma":0.0002519219,"threshold_uncertainty_score":0.00634259},"labels":[],"label_agreement":null},{"id":"W2040200721","doi":"10.3851/imp1959","title":"Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Janssen Canada","keywords":"Rilpivirine; Efavirenz; Pharmacokinetics; Medicine; Pharmacology; Ex vivo; Internal medicine; In vivo; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Biology","score_opus":0.057001649691341326,"score_gpt":0.32261737048495226,"score_spread":0.26561572079361095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040200721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998604,0.0004215593,0.00029520516,0.000009041068,0.0000036621827,0.000024014009,0.00025493116,0.00002128264,0.00036628693],"genre_scores_gemma":[0.9989365,0.000099014316,0.00034725535,0.00002211901,0.0000064322244,0.00002037658,0.0002897774,0.000003392639,0.00027504706],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997608,0.000062791754,0.000013881936,0.00008404157,0.000056940196,0.000021582113],"domain_scores_gemma":[0.99966836,0.00010079046,0.000101753554,0.000034363296,0.000040206924,0.00005454751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004105596,0.00022943933,0.00033902065,0.00018639027,0.00016759233,0.00029130423,0.00011182069,0.00032982556,0.00085047656],"category_scores_gemma":[0.0010254899,0.00014171872,0.00015560919,0.00015523068,0.00013382238,0.00017524358,0.000081427184,0.00034663838,0.00027929133],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03934383,0.002191622,0.69162655,0.00020476236,0.0006743413,0.00091410906,0.0006959656,0.0025593194,0.16995287,0.00015605942,0.0010611272,0.090619445],"study_design_scores_gemma":[0.0003135001,0.014442288,0.9682188,0.000008379269,0.00016202939,0.0020966562,0.000094667594,0.0025878462,0.010918685,0.00008452438,0.0010474088,0.000025151969],"about_ca_topic_score_codex":0.00086916867,"about_ca_topic_score_gemma":0.0005324604,"teacher_disagreement_score":0.00086916867,"about_ca_system_score_codex":0.00020719504,"about_ca_system_score_gemma":0.00015383646,"threshold_uncertainty_score":0.0028451085},"labels":[],"label_agreement":null},{"id":"W2051094729","doi":"10.3851/imp2670","title":"CD4 <sup>+</sup> T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: A prospective cohort analysis","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of Ottawa; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cohort; Antiretroviral therapy; Internal medicine; T cell; Immunology; Cohort study; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Immune system","score_opus":0.014171368955396378,"score_gpt":0.2852360725111386,"score_spread":0.2710647035557422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051094729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998803,0.00018461102,0.00011698064,0.000033032837,0.000005237751,0.000036116122,0.0006957553,0.0000033760396,0.00012180512],"genre_scores_gemma":[0.99863106,0.00012486635,0.00021176488,0.000040854404,0.000010731011,0.000046899073,0.0008343149,0.0000045757965,0.0000949397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832994,0.00056577194,0.0001617278,0.00044331257,0.00015262177,0.00034667866],"domain_scores_gemma":[0.996036,0.00071941107,0.0014618392,0.00086182327,0.00034696667,0.0005739536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030614848,0.00063422037,0.0007878806,0.00079382485,0.0013439582,0.0016161458,0.0010408334,0.0007311671,0.0016610745],"category_scores_gemma":[0.0048396466,0.000976716,0.0012183423,0.0015875992,0.0005626568,0.0011475082,0.0015021539,0.0017073083,0.00044921692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037089802,0.00008208127,0.9982059,0.000015718057,0.00016596835,0.0001570684,0.00014168177,0.000043699092,0.00008063282,0.000020603382,0.00017750685,0.000538191],"study_design_scores_gemma":[0.000076280274,0.00061999017,0.99630773,0.00003069901,0.00024851112,0.00075130904,0.0008222062,0.00061134866,0.00006193906,0.000049606897,0.00040047904,0.000019841556],"about_ca_topic_score_codex":0.010099255,"about_ca_topic_score_gemma":0.009946513,"teacher_disagreement_score":0.010099255,"about_ca_system_score_codex":0.00067848206,"about_ca_system_score_gemma":0.0010940603,"threshold_uncertainty_score":0.020080984},"labels":[],"label_agreement":null},{"id":"W2051548413","doi":"10.3851/imp1839","title":"Next-Generation Sequencing of Dried Blood Spot Specimens: A Novel Approach to HIV Drug-Resistance Surveillance","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Sanger sequencing; Dried blood spot; Pyrosequencing; Genotyping; Multiplex; DNA sequencing; Dried blood; Human immunodeficiency virus (HIV); Drug resistance; Medicine; HIV drug resistance; Genotype; Virology; Biology; Genetics; Viral load; DNA; Gene; Antiretroviral therapy; Chemistry","score_opus":0.10091096437737697,"score_gpt":0.2592985268608887,"score_spread":0.15838756248351177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051548413","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2866656,0.01760463,0.68149734,0.0012527822,0.0005951796,0.0004890445,0.0034991424,0.00241082,0.005985511],"genre_scores_gemma":[0.28319696,0.0060744286,0.70411205,0.0011724851,0.0004206662,0.0002910726,0.0016091012,0.00013191161,0.0029913485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886286,0.00027628976,0.000052425155,0.00034893936,0.0004237806,0.00003570914],"domain_scores_gemma":[0.99925584,0.00024187606,0.00020717837,0.00010367423,0.00014774944,0.000043698397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011206116,0.00049489655,0.000652652,0.001386213,0.00026167836,0.0007364355,0.00067885424,0.0008415242,0.0007739338],"category_scores_gemma":[0.0014714614,0.00035981828,0.0003929632,0.0008654593,0.00040134136,0.0005540343,0.0005437552,0.0007570992,0.0005176105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023406639,0.00011976121,0.007848345,0.000460747,0.00022593369,0.00022338053,0.00016320143,0.002041201,0.8210677,0.0009744093,0.0014824459,0.16515888],"study_design_scores_gemma":[0.00013735455,0.001505095,0.0577414,0.0003129858,0.00056543376,0.0065465514,0.00025733307,0.109603785,0.7597821,0.0067279898,0.056604605,0.00021539791],"about_ca_topic_score_codex":0.0005984115,"about_ca_topic_score_gemma":0.0013077491,"teacher_disagreement_score":0.001386213,"about_ca_system_score_codex":0.0003700587,"about_ca_system_score_gemma":0.00031193852,"threshold_uncertainty_score":0.00592643},"labels":[],"label_agreement":null},{"id":"W2052762873","doi":"10.3851/imp2597","title":"Distribution of Viral Hepatitis in Indigenous Populations of North America and the Circumpolar Arctic","year":2005,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Public Health Agency","keywords":"Circumpolar star; Indigenous; Epidemiology; Arctic; Incidence (geometry); Hepatitis B; Outbreak; Virology; Hepatitis C; Viral hepatitis; Hepatitis A; Demography; Immunology; Medicine; Biology; Hepatitis; Ecology; Internal medicine","score_opus":0.06085193099193643,"score_gpt":0.37598066186094153,"score_spread":0.3151287308690051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052762873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024921953,0.9993338,0.000010105479,0.00006512961,0.000023953853,0.0000018489505,0.0000092873815,0.0000012466677,0.00030533096],"genre_scores_gemma":[0.0010068772,0.99875546,0.000035362227,0.00002803787,0.000018989998,0.000002327339,0.0000116059955,1.8700683e-7,0.00014114221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984705,0.000031029274,0.000029692663,0.000022287186,0.00005559962,0.00001442866],"domain_scores_gemma":[0.9997538,0.000085821535,0.0000612263,0.000004851019,0.00007455487,0.000019649531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005574259,0.0004582192,0.0014070985,0.002781946,0.00023758387,0.0006675107,0.00052350963,0.00049072824,0.0021112363],"category_scores_gemma":[0.00076468865,0.00020407663,0.00042172385,0.003613046,0.00029857355,0.00056287245,0.00036331877,0.00034656207,0.0004101719],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010397078,0.000028983979,0.0012490381,0.02808944,0.00017126263,0.0002188461,0.00020771055,0.00020168969,0.00068582146,0.000596845,0.009255091,0.9591914],"study_design_scores_gemma":[0.00007102767,0.00036481404,0.03621909,0.041140713,0.0013658217,0.005007832,0.0008790455,0.00017425706,0.0006627542,0.0011022432,0.9129674,0.0000450598],"about_ca_topic_score_codex":0.015678912,"about_ca_topic_score_gemma":0.02583593,"teacher_disagreement_score":0.9843211,"about_ca_system_score_codex":0.00087274046,"about_ca_system_score_gemma":0.001707808,"threshold_uncertainty_score":0.031175315},"labels":[],"label_agreement":null},{"id":"W2054957721","doi":"10.3851/imp2715","title":"Amiodarone and Concurrent Antiretroviral Therapy: A Case Report and Review of the Literature","year":2013,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; St. Michael's Hospital","funders":"","keywords":"Antiretroviral therapy; Medicine; Reverse-transcriptase inhibitor; Amiodarone; Human immunodeficiency virus (HIV); Internal medicine; Intensive care medicine; Viral load; Virology; Atrial fibrillation","score_opus":0.06310276160165854,"score_gpt":0.3746321253345754,"score_spread":0.31152936373291684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054957721","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039886877,0.9446347,0.0023427224,0.0037464628,0.0018534058,0.00015715563,0.00025051803,0.000106972126,0.007021176],"genre_scores_gemma":[0.21695678,0.76378554,0.0036952111,0.004327504,0.0076963124,0.0001351746,0.000509359,0.00003937559,0.0028546837],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99895287,0.0001419408,0.00038392792,0.00020450824,0.00018690036,0.00012986484],"domain_scores_gemma":[0.99830806,0.00064737006,0.000650976,0.000054660257,0.00015772409,0.00018125598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005246316,0.0019321938,0.0021552644,0.010238333,0.0015728815,0.0019208117,0.0019942608,0.0039943606,0.0033527873],"category_scores_gemma":[0.002390008,0.00078773795,0.001401238,0.008828028,0.0015149039,0.0041754935,0.0015023499,0.0021600309,0.0013678378],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036079073,0.00008167895,0.0057564066,0.004390304,0.00013977867,0.9460119,0.0005899129,0.00018007979,0.0009653277,0.0005793814,0.0061610485,0.035108116],"study_design_scores_gemma":[0.0000079819965,0.000025694992,0.00201768,0.0010916909,0.00011777107,0.9845034,0.00045382456,0.00008938982,0.00011492678,0.00039582152,0.011156511,0.000025325568],"about_ca_topic_score_codex":0.0013845725,"about_ca_topic_score_gemma":0.0026542635,"teacher_disagreement_score":0.010238333,"about_ca_system_score_codex":0.0009867563,"about_ca_system_score_gemma":0.0014252343,"threshold_uncertainty_score":0.011216223},"labels":[],"label_agreement":null},{"id":"W2060458916","doi":"10.3851/imp2742","title":"A Systematic Review of the Use of Atazanavir in Women Infected with HIV-1","year":2013,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Gilead Sciences","keywords":"Atazanavir; Medicine; Ritonavir; Discontinuation; Tolerability; Regimen; Systematic review; Human immunodeficiency virus (HIV); MEDLINE; Clinical trial; Adverse effect; Family medicine; Antiretroviral therapy; Intensive care medicine; Viral load; Internal medicine","score_opus":0.053926122615212825,"score_gpt":0.3084194161421629,"score_spread":0.25449329352695005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060458916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004973667,0.99870646,0.000063366584,0.00010787679,0.00006170115,0.0001579138,0.00015858434,0.000003812223,0.00024302921],"genre_scores_gemma":[0.005016421,0.99416935,0.00026662266,0.00016663576,0.000032354597,0.00019219647,0.00008124974,0.0000018628871,0.00007320448],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99535465,0.0016919404,0.0016660412,0.0003314875,0.0008232411,0.00013261492],"domain_scores_gemma":[0.9880946,0.008269049,0.0022289753,0.00012804342,0.001135494,0.00014381886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047167125,0.0013368801,0.0065715048,0.007732666,0.0006155628,0.0020689534,0.0015611501,0.0015125487,0.005099347],"category_scores_gemma":[0.020017501,0.0007575553,0.0044725286,0.010667854,0.00067091105,0.0017085626,0.0010593004,0.0008058329,0.0003559086],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012437424,0.000010278456,0.00028554688,0.9535007,0.0029960766,0.00010971374,0.00012971032,0.00004940255,0.000109783876,0.000114972005,0.0011753321,0.041394096],"study_design_scores_gemma":[0.00018466689,0.00027327728,0.0028122365,0.918432,0.048917934,0.0005851581,0.00028514318,0.00006726097,0.00018233992,0.0001915513,0.028039254,0.000029238616],"about_ca_topic_score_codex":0.0076750787,"about_ca_topic_score_gemma":0.02080593,"teacher_disagreement_score":0.007732666,"about_ca_system_score_codex":0.0025779894,"about_ca_system_score_gemma":0.009977544,"threshold_uncertainty_score":0.024944663},"labels":[],"label_agreement":null},{"id":"W2070371941","doi":"10.3851/imp1769","title":"Mutations in Gp41 are Correlated with Coreceptor Tropism but Do Not Improve Prediction Methods Substantially","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Canadian Institutes of Health Research; GlaxoSmithKline; Pfizer","keywords":"Maraviroc; Tropism; Gp41; Receiver operating characteristic; Mutation; Biology; Virology; Computational biology; Genetics; Statistics; Human immunodeficiency virus (HIV); Virus; Mathematics; Gene","score_opus":0.017756729943312004,"score_gpt":0.3033436694869285,"score_spread":0.28558693954361647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070371941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9128312,0.010210244,0.060899604,0.0022170756,0.00048268895,0.00025526012,0.0018836498,0.0026338357,0.008586343],"genre_scores_gemma":[0.9881677,0.00059096253,0.008340527,0.00035216712,0.0001443174,0.000038817394,0.001510764,0.00014653137,0.00070818415],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98944736,0.005386698,0.0008235358,0.0022833785,0.0015500513,0.0005090259],"domain_scores_gemma":[0.94485617,0.045507576,0.0033440585,0.0032925399,0.0022709938,0.0007286656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021707047,0.0026808672,0.0016239354,0.0020000183,0.0006720482,0.0029277632,0.00080870336,0.0017358838,0.0019030835],"category_scores_gemma":[0.0443525,0.0005988411,0.0020841893,0.0011100925,0.00087535253,0.002132355,0.0013948964,0.0023716255,0.0015657829],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002134651,0.00046201976,0.665491,0.0005430804,0.005299748,0.0004060446,0.00029425204,0.10631757,0.0048338976,0.0005692606,0.0076501234,0.20599838],"study_design_scores_gemma":[0.0002512921,0.0024715934,0.27335072,0.00044768496,0.0023961582,0.0012283777,0.00024792668,0.70075816,0.0073267217,0.005679877,0.005659033,0.00018244653],"about_ca_topic_score_codex":0.0022770478,"about_ca_topic_score_gemma":0.0033572593,"teacher_disagreement_score":0.021707047,"about_ca_system_score_codex":0.0005634559,"about_ca_system_score_gemma":0.0011017119,"threshold_uncertainty_score":0.1147992},"labels":[],"label_agreement":null},{"id":"W2071800230","doi":"10.3851/imp2709","title":"The Cost of Antiretroviral Drug Resistance in HIV-Positive Patients","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"Alberta Health Services","keywords":"Medicine; HIV drug resistance; Drug resistance; Dosing; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Biology","score_opus":0.007901470614739147,"score_gpt":0.2416222029467469,"score_spread":0.23372073233200777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071800230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97571564,0.006035899,0.00021782213,0.0016681097,0.000037911315,0.00012476841,0.009833484,0.000013770432,0.006352657],"genre_scores_gemma":[0.9946307,0.0018726975,0.00030300385,0.00018343022,0.00005267336,0.000032787175,0.002589586,0.0000026135012,0.00033251592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915266,0.00025425156,0.0000874119,0.000051861753,0.0002839147,0.00016982383],"domain_scores_gemma":[0.9987,0.00025499382,0.00062547455,0.000028727272,0.00018210629,0.00020856499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005042076,0.00024346789,0.0002827257,0.0007373643,0.00045986468,0.0009228891,0.00049585465,0.00029496415,0.0025579322],"category_scores_gemma":[0.003711041,0.00014529163,0.0004477676,0.0018351898,0.00026784724,0.00037140067,0.000502403,0.00046143227,0.00014085005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029969652,0.000070652364,0.9513086,0.00028286807,0.00030022662,0.00035496155,0.000119880955,0.0020793662,0.00010751226,0.00061880535,0.004531947,0.039925497],"study_design_scores_gemma":[0.000033245182,0.0001458285,0.9918916,0.00018720696,0.00016532147,0.0011316608,0.0003028829,0.0025189335,0.00007287848,0.00029773792,0.0032401094,0.00001249625],"about_ca_topic_score_codex":0.15323934,"about_ca_topic_score_gemma":0.17999727,"teacher_disagreement_score":0.15323934,"about_ca_system_score_codex":0.0050947205,"about_ca_system_score_gemma":0.0031288825,"threshold_uncertainty_score":0.30469477},"labels":[],"label_agreement":null},{"id":"W2073567614","doi":"10.3851/imp2434","title":"Changes in Metabolic, Inflammatory and Coagulation Biomarkers after HIV Seroconversion – the Health in Men (Him) Biomarker Substudy","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Australian Government","keywords":"Medicine; Seroconversion; Internal medicine; Immunology; Fibrinogen; Population; Vitamin D and neurology; Biomarker; C-reactive protein; Gastroenterology; Inflammation; Human immunodeficiency virus (HIV); Biology","score_opus":0.028104985822752757,"score_gpt":0.3167124335622282,"score_spread":0.28860744773947544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073567614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94063455,0.037067864,0.00076187064,0.00028152624,0.00023445667,0.0029978775,0.015192846,0.00008331008,0.0027456498],"genre_scores_gemma":[0.97019166,0.006131042,0.0012120983,0.00049604586,0.00040048614,0.0042493846,0.014788399,0.000023541905,0.0025073248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982039,0.00096000615,0.0002470118,0.0002270492,0.00017225697,0.00018972915],"domain_scores_gemma":[0.9976845,0.0005523407,0.00085414015,0.00034250115,0.00027900012,0.00028752207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035098202,0.0009403582,0.0024901396,0.0012408445,0.0013049839,0.0013655768,0.0007126592,0.0012264549,0.002174699],"category_scores_gemma":[0.002890628,0.0007626608,0.0027375526,0.0019659803,0.00041406817,0.0007373695,0.0011164508,0.0011942657,0.00038568745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06709237,0.0015767945,0.86759627,0.004408822,0.023170669,0.00026066074,0.0007391261,0.0003785408,0.001794289,0.00021234255,0.004678828,0.028091341],"study_design_scores_gemma":[0.004697684,0.008525107,0.96406376,0.00045230688,0.017229691,0.00035597172,0.0001886474,0.00024149919,0.0006626449,0.000151333,0.0033772818,0.000054071847],"about_ca_topic_score_codex":0.006948035,"about_ca_topic_score_gemma":0.013786499,"teacher_disagreement_score":0.006948035,"about_ca_system_score_codex":0.0006110141,"about_ca_system_score_gemma":0.00067105266,"threshold_uncertainty_score":0.0185619},"labels":[],"label_agreement":null},{"id":"W2088637525","doi":"10.3851/imp2484","title":"Who Needs Direct-Acting Antivirals for HCV? Challenges Faced in Advancing HCV Therapy for HIV–HCV-Coinfected Individuals","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's & Women's Health Centre of British Columbia; University of Ottawa; AIDS Vancouver; University of British Columbia; Toronto General Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Telaprevir; Boceprevir; Hepatitis C; Internal medicine; Coinfection; Simeprevir; Cohort; Hepatitis C virus; Ribavirin; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.09838915629328554,"score_gpt":0.3840883664835276,"score_spread":0.2856992101902421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088637525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82178307,0.031004522,0.00038877796,0.13602358,0.00055391766,0.00009388922,0.0004499052,0.000021335794,0.009681035],"genre_scores_gemma":[0.95965356,0.018337276,0.00096827315,0.018459475,0.00080821436,0.00002527201,0.00020210851,0.000013450849,0.001532347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989485,0.00020528957,0.00006088515,0.00009388296,0.00035700438,0.00033452743],"domain_scores_gemma":[0.9975393,0.00046716837,0.0004479678,0.000055574917,0.0004441482,0.0010458472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020937098,0.00013963101,0.0005698897,0.00022205252,0.0016464988,0.0013580918,0.0007019443,0.0011310353,0.0041170395],"category_scores_gemma":[0.005824613,0.00012866792,0.00033921574,0.00046238775,0.0009932338,0.0012498689,0.0006070475,0.0011057267,0.00044337564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035501167,0.00019010181,0.7991456,0.00039557606,0.00009692058,0.0014969938,0.0027068679,0.00018789136,0.0008997403,0.00074210064,0.021343103,0.17244016],"study_design_scores_gemma":[0.00007724769,0.00044911786,0.93500763,0.0017185443,0.00018001028,0.0042544603,0.020977207,0.0005681184,0.00027623549,0.001984221,0.034438718,0.0000685357],"about_ca_topic_score_codex":0.21960323,"about_ca_topic_score_gemma":0.43947953,"teacher_disagreement_score":0.21960323,"about_ca_system_score_codex":0.0024908385,"about_ca_system_score_gemma":0.009404052,"threshold_uncertainty_score":0.43665004},"labels":[],"label_agreement":null},{"id":"W2091650571","doi":"10.3851/imp1887","title":"Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Pegylated interferon; Medicine; Immunology; Hepatitis B; Antigen; Virology; Chronic hepatitis; Hepatitis B virus; Interferon; Ribavirin; Virus","score_opus":0.020816713282991006,"score_gpt":0.25945547526346485,"score_spread":0.23863876198047385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091650571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996624,0.00017260759,0.000019985844,0.000015513791,0.0000021596657,0.000004177129,0.000022537995,9.716938e-7,0.0000996809],"genre_scores_gemma":[0.9998031,0.000035398305,0.000016779795,0.000016522907,0.0000065457807,0.0000033420208,0.00006766495,5.0302924e-7,0.000050111074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996736,0.00012315276,0.000038438102,0.000056704288,0.00004831639,0.000059771384],"domain_scores_gemma":[0.9985758,0.00045822904,0.00054763816,0.00005971121,0.000088918285,0.00026970156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067397463,0.00018137452,0.0004661108,0.0002913378,0.00026544937,0.00039239344,0.00014430183,0.0004369138,0.0008888342],"category_scores_gemma":[0.0021939445,0.00016167555,0.00029540318,0.00033918535,0.00025395898,0.0003278952,0.00019435449,0.00044173628,0.00016405151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035908304,0.00012847422,0.9883802,0.000021930688,0.00006200941,0.00012984157,0.00012416005,0.00008090698,0.0013235077,0.0000071108207,0.000050072707,0.006100951],"study_design_scores_gemma":[0.00008081887,0.0011987368,0.99779356,0.0000053103777,0.000031246953,0.0003410444,0.00007765859,0.0002047054,0.00013783883,0.000013757872,0.00011243159,0.0000029580053],"about_ca_topic_score_codex":0.000871254,"about_ca_topic_score_gemma":0.0010147372,"teacher_disagreement_score":0.0008888342,"about_ca_system_score_codex":0.0002940418,"about_ca_system_score_gemma":0.0001608937,"threshold_uncertainty_score":0.0035643578},"labels":[],"label_agreement":null},{"id":"W2111047626","doi":"10.1177/135965350701200708","title":"External Quality Assessment of <i>HLA-B*5701</i> Reporting: An International Multicentre Survey","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Royal Victoria Hospital; Health Sciences Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; University of Calgary","funders":"","keywords":"Abacavir; HLA-B; Medicine; Typing; Human leukocyte antigen; Biology; Genetics; Human immunodeficiency virus (HIV); Family medicine; Viral load; Immunology","score_opus":0.1739402511964074,"score_gpt":0.4780670647630059,"score_spread":0.30412681356659854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111047626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539727,0.00033104522,0.0010466244,0.00013055168,0.000010538087,0.00013253032,0.001125142,0.000035994275,0.0017904004],"genre_scores_gemma":[0.99823123,0.000120976525,0.00045355057,0.00009554564,0.000009855973,0.00005950588,0.0008647818,0.000012333134,0.00015218665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98902965,0.005087996,0.0018009761,0.0014339244,0.0020871556,0.0005603228],"domain_scores_gemma":[0.95451987,0.0073798406,0.024934663,0.0041551134,0.0074176323,0.0015929369],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014553895,0.00037498932,0.0003862587,0.0024111771,0.00037476522,0.0012019108,0.00094711763,0.00060707587,0.001322671],"category_scores_gemma":[0.01983062,0.00039086834,0.0004602938,0.0027683172,0.0010705614,0.00065694517,0.0013073221,0.00048768046,0.0005416271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004255003,0.000021364549,0.996872,0.000026156426,0.000026598322,0.000011996878,0.0001660565,0.000032549346,0.00021995264,0.000013261564,0.00017274129,0.002394752],"study_design_scores_gemma":[0.000004577079,0.000101225116,0.99881566,0.000015784457,0.000016120786,0.0000978324,0.00020212062,0.00013297354,0.00023187016,0.000007962867,0.00036845988,0.0000053885315],"about_ca_topic_score_codex":0.004699037,"about_ca_topic_score_gemma":0.001842277,"teacher_disagreement_score":0.9854461,"about_ca_system_score_codex":0.0007468011,"about_ca_system_score_gemma":0.00063089764,"threshold_uncertainty_score":0.076969266},"labels":[],"label_agreement":null},{"id":"W2116758166","doi":"10.1177/135965350801302s07","title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Antiretroviral therapy; Population; Public health; Human immunodeficiency virus (HIV); Environmental health; Viral load; Family medicine; Internal medicine; Pathology","score_opus":0.028690203976617243,"score_gpt":0.29083398245131176,"score_spread":0.2621437784746945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116758166","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38421875,0.0030478053,0.023870362,0.0019757727,0.00061505265,0.038997646,0.48141107,0.0012333145,0.06463028],"genre_scores_gemma":[0.48423117,0.0047487016,0.06828931,0.0030351519,0.0005497861,0.084337115,0.34371406,0.00016518563,0.010929569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98991895,0.004663616,0.001671044,0.0006990191,0.0024398537,0.0006075704],"domain_scores_gemma":[0.9817012,0.0021080668,0.007223342,0.0012340546,0.006578841,0.0011545415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009199786,0.000998051,0.00079843815,0.005446518,0.0006092303,0.0006712183,0.0010850799,0.0007253969,0.003316039],"category_scores_gemma":[0.014459963,0.0006167846,0.00079793955,0.0060510314,0.00025465048,0.0010888496,0.0016187724,0.0008981105,0.0016511235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026532152,0.0009613548,0.82036644,0.0013205803,0.0005117727,0.00015226082,0.0013938429,0.0012286972,0.0010128939,0.0013475117,0.093067974,0.07837137],"study_design_scores_gemma":[0.0001550425,0.00054857257,0.9467334,0.0003100893,0.00007839081,0.00019508375,0.0012786281,0.0010215137,0.00057686586,0.0004896581,0.048567217,0.00004554804],"about_ca_topic_score_codex":0.014245991,"about_ca_topic_score_gemma":0.009830112,"teacher_disagreement_score":0.014245991,"about_ca_system_score_codex":0.0010248398,"about_ca_system_score_gemma":0.0021686195,"threshold_uncertainty_score":0.048653662},"labels":[],"label_agreement":null},{"id":"W2137554174","doi":"10.1177/135965350801302s05","title":"World Health Organization/HIVResNet Drug Resistance Laboratory Strategy","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Accreditation; Quality assurance; Medicine; Human immunodeficiency virus (HIV); Developing country; Population; External quality assessment; Operations research; Environmental health; Antiretroviral therapy; Viral load; Virology; Engineering; Economic growth; Medical education; Pathology","score_opus":0.021361288121692214,"score_gpt":0.2737638945577415,"score_spread":0.25240260643604934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137554174","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008366829,0.029366873,0.022484364,0.13370968,0.012529997,0.009527556,0.038386844,0.003962972,0.7416649],"genre_scores_gemma":[0.082981594,0.03459822,0.13892251,0.1912908,0.003961907,0.00961721,0.11976891,0.0011253715,0.41773352],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950478,0.0019981263,0.0002850018,0.00031684127,0.0018221041,0.00053011713],"domain_scores_gemma":[0.9936672,0.00042423373,0.0006674305,0.0002818722,0.0036637562,0.0012955283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010379684,0.0013920837,0.00054695876,0.002844661,0.0006044682,0.0023798202,0.003417344,0.0024124666,0.02023023],"category_scores_gemma":[0.0054273577,0.00034896552,0.00056980527,0.0017261921,0.00070266175,0.0015028629,0.0027754335,0.0020781355,0.010131296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015206523,0.00030687964,0.0031514885,0.0010399198,0.000033628716,0.00021705573,0.00013090728,0.00068605226,0.0008278899,0.01696851,0.8385117,0.13797382],"study_design_scores_gemma":[0.00006621307,0.000105678904,0.0031336762,0.00057319994,0.000013818537,0.00013361691,0.00008091516,0.00030978306,0.000461911,0.00093260105,0.99417615,0.000012359364],"about_ca_topic_score_codex":0.016637681,"about_ca_topic_score_gemma":0.009753622,"teacher_disagreement_score":0.02023023,"about_ca_system_score_codex":0.0030961377,"about_ca_system_score_gemma":0.022454953,"threshold_uncertainty_score":0.0676769},"labels":[],"label_agreement":null},{"id":"W2151298956","doi":"10.1177/135965350300800601","title":"Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Medicine; Viral load; Internal medicine; Odds ratio; Population; Logistic regression; Immunology; Lentivirus; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.02188071117907574,"score_gpt":0.26681899492091177,"score_spread":0.24493828374183602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151298956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99961853,0.00009861029,0.00002798318,0.000030554427,0.0000035234916,0.000004884709,0.00006440814,0.000001570748,0.00014992473],"genre_scores_gemma":[0.9997224,0.000049743085,0.000033641067,0.000019190034,0.00001070254,0.0000047165045,0.0000695439,7.311285e-7,0.000089291374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996687,0.00012264535,0.000029428147,0.000048044094,0.00007467832,0.000056492907],"domain_scores_gemma":[0.9987821,0.00038206702,0.0004921336,0.000048269987,0.0000599669,0.00023547348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007557001,0.00024687106,0.00031804322,0.0004681288,0.00030753072,0.000540811,0.00026344648,0.0005103357,0.0016379615],"category_scores_gemma":[0.0033587932,0.0003248407,0.0003274441,0.00045072465,0.00024545137,0.00048471944,0.00031150552,0.0005338409,0.0002686275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007810152,0.00003790111,0.99917114,0.0000025748725,0.000020731883,0.00001853986,0.000035353667,0.000013680165,0.00005804206,0.0000035542155,0.000032108695,0.0005282346],"study_design_scores_gemma":[0.00000931845,0.00015175727,0.9993298,0.000003775594,0.000016150358,0.00009747791,0.00010667524,0.0002070588,0.000018449477,0.000009177971,0.000049090944,0.0000012851104],"about_ca_topic_score_codex":0.0017197529,"about_ca_topic_score_gemma":0.0020456316,"teacher_disagreement_score":0.0017197529,"about_ca_system_score_codex":0.000120159726,"about_ca_system_score_gemma":0.00020714685,"threshold_uncertainty_score":0.0054795146},"labels":[],"label_agreement":null},{"id":"W2166415870","doi":"10.1177/135965350100600103","title":"Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"HIV drug resistance; Drug resistance; Medicine; Drug; Intensive care medicine; Human immunodeficiency virus (HIV); Quality assurance; Antiretroviral therapy; Viral load; Pharmacology; External quality assessment; Immunology; Pathology; Biology; Genetics","score_opus":0.08782025257169648,"score_gpt":0.3617538820014005,"score_spread":0.273933629429704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166415870","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011278759,0.061497033,0.28544694,0.2315192,0.017617727,0.01827131,0.012554799,0.022757417,0.33905682],"genre_scores_gemma":[0.05744705,0.04566528,0.67323035,0.08149803,0.0068979515,0.030998455,0.013909371,0.0030759005,0.08727768],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9478091,0.027820446,0.008509452,0.0014786547,0.01272111,0.0016613232],"domain_scores_gemma":[0.9191334,0.029411254,0.0065825046,0.0087874355,0.033996914,0.0020885447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.033529826,0.0017325429,0.0019726784,0.0047084866,0.0024161555,0.0048798406,0.0057685217,0.009209527,0.02821628],"category_scores_gemma":[0.078281395,0.0013045458,0.002294163,0.0033409202,0.0021473456,0.00293163,0.0026977335,0.007965906,0.039541554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035996447,0.0008278357,0.0046803867,0.0013976472,0.000056362253,0.0016977898,0.0010921509,0.0007780221,0.0031666483,0.00938344,0.7026174,0.2739424],"study_design_scores_gemma":[0.00019652955,0.00035269337,0.006169268,0.00427163,0.00007349616,0.0026936142,0.0005721979,0.0008919234,0.0034896228,0.005145336,0.97602934,0.0001142398],"about_ca_topic_score_codex":0.0050525093,"about_ca_topic_score_gemma":0.0065948837,"teacher_disagreement_score":0.033529826,"about_ca_system_score_codex":0.002022982,"about_ca_system_score_gemma":0.0072126826,"threshold_uncertainty_score":0.17732483},"labels":[],"label_agreement":null},{"id":"W2170104292","doi":"10.1177/135965350400900512","title":"Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nevirapine; Efavirenz; Medicine; Internal medicine; Stavudine; Adverse effect; Lamivudine; Quality of life (healthcare); Health related quality of life; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Disease","score_opus":0.03863834630585736,"score_gpt":0.29900894697576225,"score_spread":0.2603706006699049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170104292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983902,0.00093206734,0.000037488255,0.00008155922,0.000011106167,0.000016403399,0.00016677732,0.000001862275,0.00036266784],"genre_scores_gemma":[0.99937195,0.00020092654,0.00007079703,0.000060297163,0.000010530569,0.000015293419,0.00019564434,5.0238964e-7,0.00007419989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994954,0.00022690716,0.000049951006,0.000052778003,0.00011767557,0.000057254256],"domain_scores_gemma":[0.99888486,0.00022436379,0.0005653414,0.000031121694,0.00007072852,0.00022359416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077096105,0.0002768259,0.0005057438,0.00031380367,0.00023346952,0.0004629514,0.00017915537,0.00037309143,0.0013273142],"category_scores_gemma":[0.002588484,0.00015191971,0.0005116813,0.0004015888,0.00016019717,0.00035764204,0.00025617858,0.00046330102,0.00012969092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022069614,0.00054819975,0.9867725,0.00010327772,0.0005894068,0.00011904539,0.000114300245,0.00018662003,0.00047199897,0.000023798772,0.00029667083,0.008567137],"study_design_scores_gemma":[0.00030755973,0.001996674,0.9963213,0.000023193155,0.00015606004,0.0002882827,0.000093374874,0.00043375583,0.000094749295,0.000030370462,0.00024714417,0.0000075110606],"about_ca_topic_score_codex":0.00095417514,"about_ca_topic_score_gemma":0.0012915855,"teacher_disagreement_score":0.0013273142,"about_ca_system_score_codex":0.00031214647,"about_ca_system_score_gemma":0.00016538684,"threshold_uncertainty_score":0.0044403076},"labels":[],"label_agreement":null},{"id":"W2182593161","doi":"10.1177/135965350701200112","title":"The Development of Artificial Neural Networks to Predict Virological response to Combination HIV Therapy","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Viral load; Regimen; Medicine; Combination therapy; Artificial neural network; Machine learning; Internal medicine; Artificial intelligence; Human immunodeficiency virus (HIV); Statistics; Immunology; Computer science; Mathematics","score_opus":0.030144911094992646,"score_gpt":0.3029147908529278,"score_spread":0.27276987975793515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182593161","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45211226,0.0031104693,0.5334742,0.0014241417,0.00026971477,0.00021925378,0.0009794426,0.001556904,0.006853586],"genre_scores_gemma":[0.906311,0.00087881996,0.08988337,0.00018612844,0.00007688239,0.00019680071,0.00068402797,0.000040862004,0.001742082],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99949265,0.00025349637,0.000036675836,0.00008053113,0.000104566556,0.000031984746],"domain_scores_gemma":[0.9972421,0.0019872223,0.00017757577,0.000091982794,0.00045386708,0.000047203328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017223868,0.00079920655,0.00040059828,0.0005936105,0.00014805303,0.00072701945,0.000510921,0.00060486846,0.00091178797],"category_scores_gemma":[0.0071883206,0.00031999368,0.000441714,0.00039325756,0.00016574551,0.0005514643,0.00036348458,0.00091760146,0.00030213056],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018784273,0.00015399123,0.019509675,0.00006138751,0.00024529843,0.00006237652,0.000032946507,0.84933764,0.002150828,0.0006381441,0.0010953348,0.12652446],"study_design_scores_gemma":[0.0000035701562,0.000037081587,0.0012051375,0.0000105575145,0.000012851907,0.000010949052,0.0000030747215,0.9978897,0.00032112427,0.00035111123,0.0001507563,0.0000041896556],"about_ca_topic_score_codex":0.0058262153,"about_ca_topic_score_gemma":0.004618378,"teacher_disagreement_score":0.0058262153,"about_ca_system_score_codex":0.0005827028,"about_ca_system_score_gemma":0.0006470994,"threshold_uncertainty_score":0.01158458},"labels":[],"label_agreement":null},{"id":"W2214017990","doi":"10.1177/135965350901400104","title":"Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Gastroenterology; Medicine; Internal medicine; Hepatitis C virus; Adverse effect; Placebo; Population; Pharmacokinetics; Hepatitis C; Viral load; Pharmacology; Immunology; Virology; Virus; Pathology","score_opus":0.02176250953072437,"score_gpt":0.33295685861030033,"score_spread":0.31119434907957594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214017990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978637,0.0015014783,0.00011131186,0.000047339538,0.00001933056,0.0000548698,0.000099779114,0.000022292392,0.00027983476],"genre_scores_gemma":[0.99865437,0.00041349724,0.00015831842,0.000056899862,0.00004092071,0.00007564912,0.0002240655,0.000004839556,0.0003714157],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994479,0.00029400064,0.000034792105,0.000080676415,0.00007974267,0.00006296456],"domain_scores_gemma":[0.9993761,0.00015148334,0.00022045238,0.000054291824,0.000035725618,0.00016197356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007126752,0.0004954384,0.001108754,0.00022423071,0.00022292524,0.00048086644,0.0005523189,0.00075533835,0.0017569998],"category_scores_gemma":[0.0014600307,0.000284983,0.00048309742,0.00020690505,0.000752137,0.0005007996,0.00017060839,0.0010373851,0.000506424],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7960115,0.010548682,0.014818212,0.0005334648,0.00073736813,0.00027780014,0.00022481725,0.0013305267,0.072403796,0.0001254544,0.00096615916,0.102022104],"study_design_scores_gemma":[0.14838286,0.72008634,0.092242904,0.000080197,0.0011594481,0.000851899,0.000156903,0.003398034,0.030220602,0.0001752285,0.0031752868,0.00007030835],"about_ca_topic_score_codex":0.0005495499,"about_ca_topic_score_gemma":0.0004457172,"teacher_disagreement_score":0.0017569998,"about_ca_system_score_codex":0.0005348486,"about_ca_system_score_gemma":0.00034928572,"threshold_uncertainty_score":0.005877733},"labels":[],"label_agreement":null},{"id":"W2313239396","doi":"10.3851/imp2536","title":"Article Commentary: Long-Term Adherence to Antiretroviral Therapy in Resource-Limited Settings: A Bitter Pill to Swallow","year":2013,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Pill; Medicine; Psychological intervention; Intensive care medicine; Antiretroviral therapy; Medication adherence; Pharmacotherapy; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Family medicine; Psychiatry; Pharmacology","score_opus":0.03994279566461841,"score_gpt":0.3342235241138344,"score_spread":0.294280728449216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313239396","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005884652,0.0010274606,0.000083856205,0.97278816,0.02234196,0.00002672548,0.000070493894,0.000054781773,0.0030181038],"genre_scores_gemma":[0.0044624805,0.0011375765,0.00025428494,0.9305702,0.057315875,0.000070103175,0.000038455266,0.000027902886,0.006123054],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99685633,0.001342765,0.00032017956,0.00036347363,0.0007887748,0.0003284915],"domain_scores_gemma":[0.99225384,0.004503702,0.0005375041,0.00015231417,0.0016094382,0.00094325107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028156543,0.0012145605,0.0019431962,0.0006543046,0.0030488002,0.0025100303,0.002732674,0.055187646,0.009291827],"category_scores_gemma":[0.020431245,0.00066471746,0.0013192131,0.0007883463,0.0024906702,0.003850309,0.0009163115,0.034456976,0.0081422385],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006186154,0.00004945238,0.00034864398,0.000086554166,0.000013186554,0.002307715,0.00011929481,0.000055937744,0.000094833056,0.0005513809,0.9913412,0.0049700253],"study_design_scores_gemma":[0.00035286497,0.00026504285,0.0025701676,0.0010573829,0.00010978091,0.011707669,0.00085370115,0.0012790877,0.00042696617,0.0058268155,0.9754225,0.00012805114],"about_ca_topic_score_codex":0.0077170474,"about_ca_topic_score_gemma":0.008313541,"teacher_disagreement_score":0.055187646,"about_ca_system_score_codex":0.0049140113,"about_ca_system_score_gemma":0.004441739,"threshold_uncertainty_score":0.03565383},"labels":[],"label_agreement":null},{"id":"W2314467161","doi":"10.3851/imp2711","title":"Presence of Anti-Interferon Antibodies is Not Associated with Non-Response to Pegylated Interferon Treatment in Chronic Hepatitis B","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Bristol-Myers Squibb","keywords":"Medicine; Antibody; Pegylated interferon; HBsAg; Immunology; HBeAg; Interferon; Internal medicine; Gastroenterology; Hepatitis B; Chronic hepatitis; Hepatitis B virus; Virology; Virus; Ribavirin","score_opus":0.03615289961723678,"score_gpt":0.33223118749327124,"score_spread":0.29607828787603446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314467161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990344,0.00059258146,0.000063068896,0.00004605576,0.000005957753,0.0000044744747,0.000043211443,0.0000014970472,0.00020871901],"genre_scores_gemma":[0.9998122,0.000056874847,0.000026060421,0.000016484702,0.000008427635,0.0000022446031,0.000038411694,7.325482e-7,0.000038636503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991136,0.00038117322,0.00012726946,0.00010460528,0.00016473129,0.000108574226],"domain_scores_gemma":[0.99300873,0.0024255225,0.0035629184,0.00020901527,0.0003314498,0.00046246639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013471742,0.00017444184,0.0003388494,0.00040612297,0.00025384207,0.00033730906,0.00023618624,0.0005390235,0.0019110853],"category_scores_gemma":[0.004223366,0.0001649185,0.00045307403,0.0005272364,0.0003011838,0.00028083817,0.00020162859,0.00063029,0.00022624164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072575087,0.00005062288,0.9960147,0.000026581987,0.00006677315,0.00006800564,0.00003128801,0.000029258345,0.0004947086,0.0000069348157,0.00003723599,0.0024480561],"study_design_scores_gemma":[0.000015923144,0.0002552516,0.99892324,0.000008359788,0.000037812468,0.00039898223,0.000026701671,0.00013281865,0.00008677693,0.000012686517,0.0000998424,0.0000016635948],"about_ca_topic_score_codex":0.00080649625,"about_ca_topic_score_gemma":0.000861792,"teacher_disagreement_score":0.0019110853,"about_ca_system_score_codex":0.0002410516,"about_ca_system_score_gemma":0.0002668081,"threshold_uncertainty_score":0.007124603},"labels":[],"label_agreement":null},{"id":"W2315153666","doi":"10.3851/imp2066","title":"Current research on respiratory viral infections: XIIth International Symposium","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Respiratory viral infections research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Pandemic; Epidemiology; Coronavirus disease 2019 (COVID-19); Virology; Infectious disease (medical specialty); Medicine; Disease; Pathology","score_opus":0.19864885518442296,"score_gpt":0.49266053730887477,"score_spread":0.29401168212445183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315153666","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002469783,0.75127,0.0013201182,0.04944482,0.15546834,0.000106248466,0.00027801053,0.00013420207,0.039508495],"genre_scores_gemma":[0.017778989,0.76036125,0.0027115687,0.017231917,0.107391745,0.0001837476,0.001156526,0.000072686096,0.09311161],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914193,0.00018022617,0.00009977801,0.00011953987,0.00028143908,0.00017697606],"domain_scores_gemma":[0.997964,0.00021399876,0.00014229205,0.00006645159,0.00094892265,0.00066434836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038817304,0.0011407324,0.00072262733,0.0015929602,0.00065922213,0.003883056,0.0010273091,0.0030552624,0.02423027],"category_scores_gemma":[0.0020142798,0.0003692952,0.0008865982,0.0011353549,0.00057602534,0.0022842935,0.001513883,0.003432379,0.008169518],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002566534,0.00022797106,0.0008592031,0.0022197624,0.0000522917,0.00021390479,0.00018470862,0.00009710958,0.0036887862,0.003848243,0.61980146,0.36854988],"study_design_scores_gemma":[0.000012734417,0.00012577076,0.0009297621,0.0009587587,0.00003348254,0.0001939745,0.000109019114,0.00003706547,0.00044065499,0.00069569156,0.9964529,0.00001007067],"about_ca_topic_score_codex":0.0006025827,"about_ca_topic_score_gemma":0.0015910395,"teacher_disagreement_score":0.02423027,"about_ca_system_score_codex":0.0012297151,"about_ca_system_score_gemma":0.0022587883,"threshold_uncertainty_score":0.08105832},"labels":[],"label_agreement":null},{"id":"W2318573097","doi":"10.3851/imp2685","title":"Significant Interaction between Activated Charcoal and Antiretroviral Therapy Leading to Subtherapeutic Drug Concentrations, Virological Breakthrough and Development of Resistance","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Poisoning and overdose treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Toronto General Hospital; University of Toronto","funders":"","keywords":"Antiretroviral therapy; Drug resistance; Drug; Charcoal; Medicine; Antiretroviral drug; Human immunodeficiency virus (HIV); Internal medicine; Pharmacology; Virology; Viral load; Intensive care medicine; Biology; Chemistry; Microbiology","score_opus":0.05142089867741031,"score_gpt":0.3157021093530544,"score_spread":0.26428121067564414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318573097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911142,0.001608242,0.0006562128,0.00089099345,0.000043342272,0.000047806898,0.0000921379,0.0000343381,0.0055127125],"genre_scores_gemma":[0.9987257,0.00025985236,0.00022363171,0.00015829848,0.000035976238,0.000002682101,0.000039182032,0.0000032971097,0.000551482],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9996238,0.00010864748,0.000044667493,0.0000403869,0.00010144923,0.00008107343],"domain_scores_gemma":[0.99906,0.00037932658,0.00026055163,0.000044509277,0.000088298315,0.0001673672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002571182,0.0003165498,0.00036560884,0.0004213752,0.000720276,0.00039117679,0.00020656345,0.0006668863,0.0017504842],"category_scores_gemma":[0.0014706869,0.00019363847,0.00044915744,0.0003926546,0.00025921213,0.00024719775,0.0002199624,0.00082965876,0.00021320199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002827131,0.0009321,0.47393233,0.00017301372,0.00031604987,0.48134074,0.00039399887,0.0005906512,0.011945295,0.00069845724,0.0014442905,0.025405882],"study_design_scores_gemma":[0.00018751436,0.003492683,0.34761712,0.00006796127,0.00039173255,0.6285044,0.00033646318,0.0037976676,0.007969973,0.0006078867,0.0069681066,0.000058488138],"about_ca_topic_score_codex":0.0023712814,"about_ca_topic_score_gemma":0.004353345,"teacher_disagreement_score":0.0023712814,"about_ca_system_score_codex":0.0005598758,"about_ca_system_score_gemma":0.00048446283,"threshold_uncertainty_score":0.0058559775},"labels":[],"label_agreement":null},{"id":"W2319508451","doi":"10.3851/imp2612","title":"Targeting Human Papillomavirus Genome Replication for Antiviral Drug Discovery","year":2013,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Biology; Drug discovery; Viral replication; Virology; Helicase; Genome; DNA replication; Computational biology; Virus; DNA; Bioinformatics; Genetics; Gene","score_opus":0.1264365398765943,"score_gpt":0.43935097641415943,"score_spread":0.3129144365375651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319508451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022689046,0.9958702,0.00033889248,0.00030629,0.0002815491,0.000014490008,0.000053772463,0.000024274761,0.002883655],"genre_scores_gemma":[0.000965851,0.99708575,0.00037531342,0.00020730829,0.00008896369,0.000013163406,0.000056128978,0.0000028093168,0.001204711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998441,0.000025904152,0.000016046288,0.000031502677,0.00006270632,0.000019753728],"domain_scores_gemma":[0.99978715,0.000090269146,0.000027682048,0.000009171467,0.000068009664,0.00001766628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004228675,0.0008063594,0.0010982826,0.002133115,0.00031188675,0.0009986983,0.0006268083,0.00096515566,0.00630642],"category_scores_gemma":[0.00051440444,0.00025658263,0.00055327016,0.002088797,0.00034991698,0.0013789698,0.0006032558,0.0020122554,0.0038251579],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006616462,0.00010079668,0.00012746804,0.021320656,0.00008082636,0.00019474627,0.000087290005,0.00056797307,0.005676514,0.0068296925,0.03609964,0.9288484],"study_design_scores_gemma":[0.000012551527,0.000089339264,0.00027457564,0.0024010956,0.00006739477,0.000522004,0.00003527297,0.00008934063,0.0008422106,0.0016241684,0.99403,0.000012093488],"about_ca_topic_score_codex":0.00085989723,"about_ca_topic_score_gemma":0.0016650399,"teacher_disagreement_score":0.00630642,"about_ca_system_score_codex":0.00070125656,"about_ca_system_score_gemma":0.0010428086,"threshold_uncertainty_score":0.021097064},"labels":[],"label_agreement":null},{"id":"W2322898079","doi":"10.3851/imp2724","title":"Risk of Cardiovascular Disease Associated with HCV and HBV Coinfection among Antiretroviral-Treated HIV-Infected Individuals","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Public Health Ontario; St. Michael's Hospital; Ontario HIV Treatment Network; McMaster University; St. Paul's Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Coinfection; Medicine; Internal medicine; Hepatitis C; Myocardial infarction; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.011094386408624332,"score_gpt":0.24713375567505994,"score_spread":0.2360393692664356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322898079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824595,0.0008009007,0.000045583056,0.00007339098,0.0000065326253,0.0000067051615,0.00025907147,0.000002696045,0.0005592329],"genre_scores_gemma":[0.99958247,0.0001261298,0.000033650573,0.000011006016,0.000007869818,0.0000025696463,0.00012873825,5.595007e-7,0.00010700456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961215,0.00009755512,0.00002844523,0.00006902721,0.00009832898,0.00009450606],"domain_scores_gemma":[0.9985129,0.00023994732,0.0007051987,0.00009314016,0.00013121334,0.0003176558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057244045,0.00018044612,0.0002360226,0.00044204778,0.0005139558,0.000595434,0.00031659895,0.00045105407,0.002169313],"category_scores_gemma":[0.0022998848,0.00021733792,0.00041553716,0.0005803613,0.00028458278,0.00023190123,0.0005012297,0.0006172374,0.00012349698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001041261,0.000010131278,0.99894935,0.0000056563026,0.000031335578,0.000041187483,0.000028934193,0.000026991735,0.000045877372,0.000010876078,0.00004247587,0.00070301205],"study_design_scores_gemma":[0.0000047403933,0.000034199646,0.9995009,0.000007025511,0.00002572287,0.0001477314,0.000041413434,0.00015422203,0.000009777575,0.000019848207,0.000052524116,0.0000018598998],"about_ca_topic_score_codex":0.02539102,"about_ca_topic_score_gemma":0.037551783,"teacher_disagreement_score":0.02539102,"about_ca_system_score_codex":0.00045132762,"about_ca_system_score_gemma":0.00052864186,"threshold_uncertainty_score":0.050486445},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2323648016","doi":"10.3851/imp2747","title":"Genome-Wide Association Study to Characterize Serum Bilirubin Elevations in Patients with HCV Treated with Gs-9256, An HCV Ns3 Serine Protease Inhibitor","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Heme Oxygenase-1 and Carbon Monoxide","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Gilead Sciences","keywords":"Bilirubin; Genotyping; Genotype; Biology; Genome-wide association study; Internal medicine; Single-nucleotide polymorphism; Population; Medicine; Gastroenterology; Genetics; Gene","score_opus":0.0071952887360460125,"score_gpt":0.21473513563083216,"score_spread":0.20753984689478613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323648016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987268,0.00032047942,0.00023715875,0.0000575439,0.000009401958,0.0000068490062,0.0002973849,0.000005952625,0.00033832365],"genre_scores_gemma":[0.99945134,0.000052859392,0.00012128332,0.000029732473,0.00000652939,0.000005309065,0.0002247991,0.0000028990353,0.00010524643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993918,0.00021172158,0.000057553232,0.0002003196,0.00008038842,0.000058220437],"domain_scores_gemma":[0.9991314,0.000297689,0.00026007518,0.00010111612,0.000071914976,0.0001377396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007256838,0.00030419423,0.000468785,0.00043217232,0.000382753,0.00050969794,0.00028444175,0.0005068035,0.0013922481],"category_scores_gemma":[0.0015810693,0.00018358859,0.00060342374,0.0010667309,0.00022025306,0.00018368122,0.00024115967,0.00064449286,0.00018328338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090206397,0.000051925417,0.99383885,0.00001588673,0.000537114,0.00022797952,0.000047176076,0.00010164031,0.0023092153,0.000039557664,0.00015151426,0.0017770173],"study_design_scores_gemma":[0.000039436964,0.00015422211,0.99828315,0.0000032147798,0.00021442375,0.00040701692,0.00004266548,0.00038831274,0.00017562316,0.00003728291,0.00025059952,0.0000040045456],"about_ca_topic_score_codex":0.0021564285,"about_ca_topic_score_gemma":0.002761944,"teacher_disagreement_score":0.0021564285,"about_ca_system_score_codex":0.0001670803,"about_ca_system_score_gemma":0.00023368554,"threshold_uncertainty_score":0.004657507},"labels":[],"label_agreement":null},{"id":"W2326321318","doi":"10.3851/imp1786","title":"Lopinavir Up-Regulates Expression of the Antiviral Protein Ribonuclease L in Human Papillomavirus-Positive Cervical Carcinoma Cells","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Thunder Bay Regional Research Institute","funders":"National Science Council; Cancer Prevention Research Trust; Humane Research Trust","keywords":"Lopinavir; Biology; Molecular biology; Western blot; Transfection; Proteasome inhibitor; Cell culture; Virology; Cancer research; Virus; Viral load; Gene; Biochemistry","score_opus":0.021040166907169103,"score_gpt":0.31189104919005645,"score_spread":0.29085088228288736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326321318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899088,0.0031143704,0.0023701095,0.00012211809,0.000043280972,0.000042522443,0.00094880315,0.00020663269,0.0032432713],"genre_scores_gemma":[0.9932902,0.0010756451,0.0017445198,0.000106315456,0.000013685984,0.00005489456,0.0013712193,0.000025156874,0.0023183262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998386,0.000021411683,0.000016413493,0.000033666067,0.000054533906,0.00003530119],"domain_scores_gemma":[0.9998723,0.000042867283,0.000024721303,0.00001833989,0.000023261593,0.000018541656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008870752,0.00021223251,0.00023570596,0.00024472698,0.0001630702,0.0003943545,0.00011176899,0.00024093673,0.0023159746],"category_scores_gemma":[0.00017742104,0.0001012972,0.00030379483,0.0001717226,0.00016772677,0.00013424862,0.0001906335,0.00037912137,0.0008162277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005606448,0.000020489735,0.0003115815,0.000049008107,0.000004036923,0.00005936228,0.000013686411,0.000027808457,0.9982917,0.00001467863,0.00005441527,0.0010972106],"study_design_scores_gemma":[0.000008664641,0.00034781743,0.0120624965,0.000011215457,0.000016701184,0.00044399363,0.000051956576,0.0005863595,0.98361015,0.000021967617,0.0028330614,0.0000056402228],"about_ca_topic_score_codex":0.00043336785,"about_ca_topic_score_gemma":0.00053820026,"teacher_disagreement_score":0.0023159746,"about_ca_system_score_codex":0.00025186545,"about_ca_system_score_gemma":0.00013116581,"threshold_uncertainty_score":0.0077477098},"labels":[],"label_agreement":null},{"id":"W2326748359","doi":"10.3851/imp1794","title":"Reduced Airborne Transmission of Oseltamivir-Resistant Pandemic A/H1N1 Virus in Ferrets","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Virology; Oseltamivir; Virus; Neuraminidase; Biology; Transmission (telecommunications); Influenza A virus; Microbiology; Mutant; Medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.07152097901518477,"score_gpt":0.3829970275423331,"score_spread":0.31147604852714833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326748359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991935,0.00016816173,0.00035999666,0.000019538316,0.000011006729,0.000014651215,0.000071651426,0.000019378227,0.00014210383],"genre_scores_gemma":[0.9981021,0.00015122906,0.00064635696,0.00003450651,0.000009530573,0.00005067588,0.0003359523,0.000013267689,0.00065643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974734,0.000042712905,0.00001543964,0.00009764036,0.00004416405,0.00005259763],"domain_scores_gemma":[0.9997745,0.000035419514,0.000068698675,0.000033367327,0.000032125758,0.000055851044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028395158,0.0006041972,0.0005760509,0.00039051098,0.00024967015,0.00046018237,0.0005052521,0.00069589436,0.0010911204],"category_scores_gemma":[0.00047724822,0.00015555667,0.00034204405,0.00007530233,0.00041023898,0.00057942723,0.00025584808,0.000505027,0.00024499663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009216536,0.00034991148,0.007711865,0.00008705423,0.00004862666,0.000229551,0.0001813589,0.00022840565,0.9855004,0.000051398114,0.00020827039,0.004481493],"study_design_scores_gemma":[0.00019818991,0.018297689,0.18711805,0.00007147381,0.0003035872,0.0035274345,0.0009989975,0.0053784233,0.7805038,0.00034496994,0.0032115034,0.00004590839],"about_ca_topic_score_codex":0.001129386,"about_ca_topic_score_gemma":0.0011733952,"teacher_disagreement_score":0.001129386,"about_ca_system_score_codex":0.00058620836,"about_ca_system_score_gemma":0.00015454275,"threshold_uncertainty_score":0.0042532682},"labels":[],"label_agreement":null},{"id":"W2327325395","doi":"10.3851/imp2956","title":"An Economic Evaluation of Conception Strategies for Heterosexual Serodiscordant Couples where the Male Partner is HIV-Positive","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Serodiscordant; Demography; Psychological intervention; Population; Cost-effectiveness analysis; Medicine; Gynecology; Family planning; Fertility; Sperm washing; Cost–benefit analysis; Unintended pregnancy; Cost effectiveness; Family medicine; Human immunodeficiency virus (HIV); Environmental health; Viral load; Antiretroviral therapy; Political science; Sociology","score_opus":0.06836961604135396,"score_gpt":0.40499909276457785,"score_spread":0.3366294767232239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327325395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87911594,0.015937345,0.03964409,0.0053463005,0.00031047934,0.012534995,0.008368167,0.00012036939,0.03862218],"genre_scores_gemma":[0.9866628,0.002494856,0.006660691,0.000269715,0.000026016958,0.0016266076,0.0008820843,0.000009815247,0.0013674372],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9895808,0.0083207805,0.0002525821,0.00030316098,0.000806753,0.00073597516],"domain_scores_gemma":[0.9775874,0.018920776,0.0012103701,0.0002880883,0.0012078517,0.0007856201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019150706,0.0016170955,0.0017717192,0.0017666027,0.0006751827,0.002159617,0.0017933847,0.0017645999,0.0062228846],"category_scores_gemma":[0.041415036,0.0008341316,0.003228606,0.0014062867,0.0009542347,0.0017481869,0.0013670746,0.0020290308,0.00017211965],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016203998,0.0015462087,0.016905533,0.004218767,0.0032797062,0.00026851072,0.000216622,0.88203275,0.0005238647,0.019936154,0.0024219365,0.052445833],"study_design_scores_gemma":[0.007111557,0.012108258,0.020692918,0.0022907364,0.0055839056,0.0002691373,0.00078909536,0.92686415,0.0012393878,0.013806137,0.009061158,0.00018358997],"about_ca_topic_score_codex":0.08130735,"about_ca_topic_score_gemma":0.048600867,"teacher_disagreement_score":0.08130735,"about_ca_system_score_codex":0.022339048,"about_ca_system_score_gemma":0.0156976,"threshold_uncertainty_score":0.1620819},"labels":[],"label_agreement":null},{"id":"W2330500715","doi":"10.3851/imp2567","title":"Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Ribavirin; Medicine; Genotype; Sofosbuvir; Internal medicine; Virology; Hepatitis C virus; Biology; Virus","score_opus":0.1219904933411081,"score_gpt":0.3699764390028687,"score_spread":0.24798594566176058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330500715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98553187,0.0068595023,0.00086585514,0.00054081896,0.00012820102,0.0020049023,0.000871245,0.000045495897,0.0031521153],"genre_scores_gemma":[0.98919606,0.00260348,0.0022685758,0.00062273524,0.00012172702,0.001116875,0.0018805012,0.000017746148,0.0021723718],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959165,0.0001838495,0.000031480307,0.000040482468,0.00007520922,0.00007736025],"domain_scores_gemma":[0.9994568,0.00013762662,0.00008485272,0.000028029315,0.00006669331,0.00022595433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001341183,0.0005248777,0.00087583734,0.00018639008,0.0002886634,0.00040265848,0.0003475114,0.00042463074,0.0028837726],"category_scores_gemma":[0.0009378059,0.0001962511,0.0006437835,0.00017323993,0.00036664828,0.00020632666,0.00020353832,0.0010669673,0.00027867613],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43338814,0.019242568,0.016679198,0.0021782587,0.0019641186,0.00073368486,0.00035683496,0.0024286422,0.059089225,0.00084446603,0.0096181715,0.4534767],"study_design_scores_gemma":[0.34315443,0.55495733,0.0486896,0.00042042992,0.0018665453,0.0016918188,0.0001402264,0.0013878213,0.026600592,0.00038630597,0.020632938,0.000071995506],"about_ca_topic_score_codex":0.0015449991,"about_ca_topic_score_gemma":0.0029484045,"teacher_disagreement_score":0.0028837726,"about_ca_system_score_codex":0.0006788785,"about_ca_system_score_gemma":0.0014463788,"threshold_uncertainty_score":0.009647131},"labels":[],"label_agreement":null},{"id":"W2331891559","doi":"10.3851/imp1912","title":"Telbivudine Exerts no Antiviral Activity against HIV-1 <i>In Vitro</i> and in Humans","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Telbivudine; Virology; In vivo; In vitro; Drug resistance; Antiviral drug; Human immunodeficiency virus (HIV); Biology; Drug; Genotype; Virus; Medicine; Hepatitis B virus; Pharmacology; Lamivudine; Microbiology; Genetics; Gene","score_opus":0.027933703811589442,"score_gpt":0.26063006942563127,"score_spread":0.23269636561404183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331891559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703349,0.020543357,0.001804165,0.0002149284,0.00004892354,0.000054393375,0.0006342057,0.000064377135,0.0063007497],"genre_scores_gemma":[0.9951835,0.0023013134,0.00038047924,0.00011449084,0.00002216105,0.00002829707,0.00065468944,0.0000065975214,0.0013084364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974173,0.000085663596,0.000022094195,0.000054246048,0.00006413098,0.000032174066],"domain_scores_gemma":[0.99979097,0.00009224955,0.000039772418,0.000030736937,0.000022218388,0.000024037301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021898349,0.00019807954,0.00029759706,0.00011920737,0.00011157454,0.00051576225,0.0001358866,0.00036715684,0.0025300558],"category_scores_gemma":[0.00043285135,0.00009044618,0.00015298846,0.000078933714,0.0002585171,0.00016885839,0.000106924876,0.00040272603,0.00058291835],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019751617,0.00025676895,0.015503886,0.0005519152,0.00012299343,0.0006281398,0.00023902433,0.00024052894,0.9446851,0.00041279322,0.0006083743,0.034775317],"study_design_scores_gemma":[0.00038055918,0.020491311,0.089373015,0.000176538,0.0003777356,0.012796807,0.00044323716,0.0014041407,0.8242157,0.00036089492,0.0499451,0.00003498716],"about_ca_topic_score_codex":0.00042475358,"about_ca_topic_score_gemma":0.0003493833,"teacher_disagreement_score":0.0025300558,"about_ca_system_score_codex":0.0001594135,"about_ca_system_score_gemma":0.00015234765,"threshold_uncertainty_score":0.008463919},"labels":[],"label_agreement":null},{"id":"W2334045336","doi":"10.3851/imp2973","title":"Description and Consequences of Prescribing Off-Label Antiretrovirals in the Madrid Cohort of HIV-Infected Children over a Quarter of a Century (1988–2012)","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fundación Para La Innovación Y La Prospectiva En Salud En España","keywords":"Human immunodeficiency virus (HIV); Medicine; Quarter (Canadian coin); Cohort; Antiretroviral therapy; Antiretroviral treatment; Cohort study; Virology; Viral load; Pediatrics; Internal medicine; History","score_opus":0.07465229108370537,"score_gpt":0.3437738206433544,"score_spread":0.269121529559649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334045336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990507,0.00014064906,0.000011260904,0.00001751061,0.0000017993063,0.0000057413304,0.00059807615,0.0000015449723,0.00017279586],"genre_scores_gemma":[0.99857056,0.00027841903,0.00005792381,0.000023111097,0.0000073763104,0.0000117370355,0.00092160463,0.000002593181,0.00012664917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994729,0.00009465345,0.000060023318,0.00012040051,0.00013080999,0.00012119737],"domain_scores_gemma":[0.9973652,0.0002417331,0.0018715964,0.00012732427,0.00016451611,0.00022961598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007375045,0.00023887742,0.00033192386,0.0012296214,0.00042808318,0.00075892167,0.00049557304,0.00040761835,0.0012453579],"category_scores_gemma":[0.0019456595,0.00026823775,0.00046406014,0.0011618913,0.00032744068,0.000411916,0.00055740116,0.0005586604,0.00015809004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025575813,0.000010881471,0.99932086,0.0000036333279,0.000007311148,0.000088102395,0.00007607,0.000016818245,0.00003213826,0.000004261981,0.000043965643,0.00037034455],"study_design_scores_gemma":[0.000002308278,0.000034497327,0.99921346,0.0000051275692,0.000004968626,0.0003679911,0.00021013923,0.000031401098,0.000018409313,0.000003275297,0.00010648515,0.0000019224626],"about_ca_topic_score_codex":0.025404347,"about_ca_topic_score_gemma":0.022379367,"teacher_disagreement_score":0.025404347,"about_ca_system_score_codex":0.00087884424,"about_ca_system_score_gemma":0.000606078,"threshold_uncertainty_score":0.05051291},"labels":[],"label_agreement":null},{"id":"W2338781044","doi":"10.1177/135965350601100310","title":"Association of Apolipoproteins C3 and E with Metabolic Changes in HIV-Infected Adults Treated with a Protease-Inhibitor-Containing Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Protease inhibitor (pharmacology); Antiretroviral therapy; Lentivirus; Medicine; Human immunodeficiency virus (HIV); Virology; Sida; Internal medicine; Viral load; Immunology; Pharmacology; Viral disease","score_opus":0.01028567247314771,"score_gpt":0.2554069928589985,"score_spread":0.24512132038585077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338781044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99957794,0.0001844518,0.00001832084,0.000018277226,0.0000024059825,0.000004292606,0.00006829945,0.0000012305843,0.0001247403],"genre_scores_gemma":[0.9996711,0.000066559354,0.000050861367,0.000028114175,0.0000081819335,0.0000039042734,0.00010999317,5.672843e-7,0.00006064311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973017,0.000070238966,0.00003513113,0.000047898542,0.00006692375,0.00004952601],"domain_scores_gemma":[0.9989219,0.00022568999,0.00050355005,0.0000437053,0.00010350495,0.00020167902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044379281,0.0003200727,0.00034962187,0.0006051914,0.00044325477,0.00052326644,0.00019117302,0.0006015756,0.0010095249],"category_scores_gemma":[0.0017476535,0.00023895461,0.0002889145,0.0007465279,0.0002121429,0.0002878768,0.00020777906,0.0005811847,0.00011608626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022326458,0.000030795894,0.9988707,0.0000033124463,0.000039295875,0.00008004967,0.000026269954,0.000016081534,0.00020243734,0.0000035622088,0.000021280408,0.0004829156],"study_design_scores_gemma":[0.000012115788,0.0001299188,0.9993383,0.0000031099928,0.000017424569,0.0002792548,0.000046593625,0.000091948925,0.000034884964,0.0000050186204,0.00003971917,0.0000016601202],"about_ca_topic_score_codex":0.0038968876,"about_ca_topic_score_gemma":0.0047628176,"teacher_disagreement_score":0.0038968876,"about_ca_system_score_codex":0.00024248032,"about_ca_system_score_gemma":0.00023547752,"threshold_uncertainty_score":0.007748425},"labels":[],"label_agreement":null},{"id":"W2340099473","doi":"10.1177/135965350701200315","title":"Five-Year Follow up of Once-Daily Therapy with Emtricitabine, Didanosine and Efavirenz (Montana ANRS 091 Trial)","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Emtricitabine; Efavirenz; Didanosine; Tolerability; Medicine; Regimen; Internal medicine; Adverse effect; Lipodystrophy; Gastroenterology; Immunology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.018782236023382425,"score_gpt":0.27160611842065696,"score_spread":0.25282388239727455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340099473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507856,0.0027188798,0.00019908107,0.00017069929,0.00007282114,0.00030576327,0.00046255632,0.000028814355,0.00096268585],"genre_scores_gemma":[0.99680626,0.0004299827,0.0002716539,0.00022869816,0.00010024267,0.0002887318,0.001048225,0.00000415141,0.0008220001],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992686,0.0004044298,0.000035754183,0.0001132395,0.00005256843,0.0001254284],"domain_scores_gemma":[0.99912554,0.00017213097,0.0002539788,0.00008939249,0.00005639855,0.0003025485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027631603,0.000731432,0.0015087023,0.0002366127,0.00046291348,0.0007776691,0.0005080706,0.001316596,0.0026702846],"category_scores_gemma":[0.001408289,0.00027483096,0.0011231889,0.0002589547,0.0004187282,0.0006283784,0.00034384272,0.0016186136,0.000373409],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89667195,0.012169948,0.016073152,0.0003624039,0.0016982986,0.00014616318,0.00010528441,0.0011803485,0.0062636146,0.00009533122,0.001377161,0.063856326],"study_design_scores_gemma":[0.42237514,0.45236716,0.115241215,0.000105678286,0.0019983998,0.00041306482,0.000057102592,0.002094471,0.0025225787,0.00020737131,0.0025710238,0.000046864192],"about_ca_topic_score_codex":0.0007738556,"about_ca_topic_score_gemma":0.0014037838,"teacher_disagreement_score":0.0027631603,"about_ca_system_score_codex":0.00040549453,"about_ca_system_score_gemma":0.00045064904,"threshold_uncertainty_score":0.014613211},"labels":[],"label_agreement":null},{"id":"W2345024104","doi":"10.3851/imp3042","title":"Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Regimen; Hepacivirus; TaqMan; Antigen; Internal medicine; Hepatitis C; Gastroenterology; Chronic hepatitis; Virology; Immunology; Hepatitis C virus; Biology; Real-time polymerase chain reaction; Virus","score_opus":0.12082622205251256,"score_gpt":0.39204449028015853,"score_spread":0.27121826822764594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345024104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872421,0.0042141885,0.0023726684,0.0007823379,0.00010420474,0.00012129902,0.00015518302,0.00009129163,0.0049167313],"genre_scores_gemma":[0.99650854,0.0003632635,0.0025098238,0.00023904376,0.00006935855,0.000022552049,0.00006251257,0.000003977895,0.0002208863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898034,0.0005295164,0.000087866,0.00010072848,0.00025921434,0.00004220213],"domain_scores_gemma":[0.9972663,0.0016436973,0.00037704041,0.00008054923,0.00041435406,0.00021808795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024409485,0.00040164066,0.00031572452,0.00051874534,0.00018914051,0.0005266111,0.00025678135,0.00059866934,0.00072836544],"category_scores_gemma":[0.00873028,0.00018134408,0.00011849496,0.00023671988,0.00033381427,0.0003986624,0.00020688197,0.0004634587,0.00031682933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023791322,0.00032854747,0.91394067,0.00010657264,0.0000417198,0.000417921,0.00017454133,0.00067404466,0.0062921476,0.00007262246,0.0014148679,0.07415735],"study_design_scores_gemma":[0.00021173085,0.0031554787,0.97209924,0.00011855432,0.00009706742,0.0023770742,0.00026179652,0.011838064,0.0068511916,0.0002818466,0.002676049,0.00003195131],"about_ca_topic_score_codex":0.0008212012,"about_ca_topic_score_gemma":0.0012015897,"teacher_disagreement_score":0.0024409485,"about_ca_system_score_codex":0.00031859978,"about_ca_system_score_gemma":0.00033325524,"threshold_uncertainty_score":0.012909114},"labels":[],"label_agreement":null},{"id":"W2395716928","doi":"10.1177/135965350501000210","title":"Dynamic Changes in Clinical Features and Cytokine/Chemokine Responses in Sars Patients Treated with Interferon Alfacon-1 plus Corticosteroids","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; North York General Hospital; Toronto General Hospital; University of Toronto","funders":"","keywords":"CXCL10; Viral load; Cytokine; Immunology; Medicine; Interferon; Chemokine; CCL5; Tumor necrosis factor alpha; Inflammation; Virus; Immune system; T cell","score_opus":0.04254191401554771,"score_gpt":0.37323302649172185,"score_spread":0.33069111247617416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395716928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99949527,0.00013672022,0.000021253667,0.000028238926,0.0000034377063,0.0000094355655,0.000037935395,0.0000019596018,0.000265711],"genre_scores_gemma":[0.9997075,0.00006411919,0.000022888864,0.000028461456,0.000009085651,0.000005107727,0.00007321608,6.023204e-7,0.00008900973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976474,0.000042982978,0.000027111326,0.00004431312,0.000049578288,0.00007134693],"domain_scores_gemma":[0.99942327,0.0000847415,0.00016345744,0.000017453076,0.00008722428,0.00022389056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017183546,0.00025939135,0.00063443015,0.0004002845,0.00064263435,0.00048027321,0.00013222228,0.00034172402,0.00069886475],"category_scores_gemma":[0.0009241403,0.00019023076,0.00022477699,0.00041661796,0.0003486631,0.00022857857,0.0001897373,0.00035926214,0.00015141658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010004588,0.00012810867,0.98648953,0.000018483917,0.00004475419,0.0032103711,0.0005450081,0.00008126442,0.0047299406,0.000012173707,0.00015292558,0.0035870182],"study_design_scores_gemma":[0.00004439043,0.000976278,0.994779,0.000008554517,0.000032628475,0.00297768,0.00047101357,0.00014861622,0.00028509603,0.000011527673,0.00025792414,0.0000072272132],"about_ca_topic_score_codex":0.009472004,"about_ca_topic_score_gemma":0.014584669,"teacher_disagreement_score":0.009472004,"about_ca_system_score_codex":0.0006441852,"about_ca_system_score_gemma":0.00046885244,"threshold_uncertainty_score":0.018833756},"labels":[],"label_agreement":null},{"id":"W2397692736","doi":"10.3851/imp3010","title":"Efficacy and Safety of a Switch to Rilpivirine-Based Regimens in Treatment-Experienced HIV-1-Infected Patients: A Cohort Study","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rilpivirine; Medicine; Human immunodeficiency virus (HIV); Cohort; Internal medicine; Cohort study; Antiretroviral therapy; Viral load; Oncology; Virology","score_opus":0.024745624430365838,"score_gpt":0.3018561189093522,"score_spread":0.2771104944789864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397692736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99956614,0.00007520285,0.000040986048,0.000010749226,0.000004465169,0.000034633897,0.00015847219,0.0000014555933,0.00010798839],"genre_scores_gemma":[0.9992016,0.000076016826,0.00008364339,0.000038983613,0.000017066106,0.000033505556,0.0004496415,0.0000025593217,0.000097090335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879766,0.0003874317,0.000089678775,0.0003596379,0.00019585478,0.00016977079],"domain_scores_gemma":[0.9961133,0.00072432426,0.0015057228,0.00065102207,0.00032002694,0.0006855753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002178423,0.00054428406,0.00077077735,0.00050211983,0.0007517891,0.0010978124,0.00055831147,0.00069820444,0.0017949269],"category_scores_gemma":[0.0046883686,0.0004376543,0.0010608182,0.0005849152,0.0004517051,0.0008710705,0.00055989024,0.0009918724,0.00036375597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009753312,0.0013598709,0.98279774,0.000028989998,0.00044995215,0.0003106546,0.0002911419,0.00010250517,0.0010579398,0.000021013277,0.00017117732,0.0036558285],"study_design_scores_gemma":[0.0010261491,0.012145182,0.9836309,0.000017318522,0.00030772528,0.0010348007,0.00035846946,0.0006918384,0.0003094177,0.000037259855,0.0004072198,0.000033754444],"about_ca_topic_score_codex":0.00197359,"about_ca_topic_score_gemma":0.0015247333,"teacher_disagreement_score":0.002178423,"about_ca_system_score_codex":0.0005198135,"about_ca_system_score_gemma":0.00056073215,"threshold_uncertainty_score":0.011520684},"labels":[],"label_agreement":null},{"id":"W2398926585","doi":"10.1177/135965350100600108","title":"Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Antiretroviral drug; Drug resistance; Human immunodeficiency virus (HIV); Medicine; Drug-naïve; Internal medicine; Drug; Antiretroviral therapy; HIV drug resistance; Didanosine; Viral load; Efavirenz; Pharmacology; Virology; Biology; Genetics","score_opus":0.011982501845383724,"score_gpt":0.26320116213799166,"score_spread":0.2512186602926079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398926585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985851,0.0004529032,0.00004835214,0.000067494984,0.000005385613,0.000015391966,0.00017764696,0.000003483825,0.00064421335],"genre_scores_gemma":[0.9988405,0.00032236995,0.00012200105,0.00008511573,0.0000139931535,0.000016586548,0.00034444663,0.0000027342096,0.00025228845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966216,0.00012693947,0.00003674746,0.00005218446,0.0000657837,0.000056242676],"domain_scores_gemma":[0.99955016,0.000085100044,0.00015769369,0.000021825046,0.00007767232,0.00010755294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023934066,0.00025045598,0.00052215316,0.0005263308,0.00041034888,0.00043617343,0.00012901166,0.0002808004,0.0010738412],"category_scores_gemma":[0.0014603587,0.00018541607,0.000113516326,0.00039102786,0.00018862724,0.00016528295,0.00012992078,0.00022706762,0.00017875778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004536069,0.00013989389,0.98463905,0.00003927099,0.00003808439,0.00076383114,0.0004906082,0.00006928699,0.0020900967,0.000030558418,0.00055789785,0.010687868],"study_design_scores_gemma":[0.00004960591,0.00032271043,0.9962889,0.00001536743,0.000021866594,0.0016425946,0.0002862502,0.00016712373,0.00012631628,0.000017973116,0.0010554363,0.0000059227455],"about_ca_topic_score_codex":0.012998401,"about_ca_topic_score_gemma":0.013221796,"teacher_disagreement_score":0.012998401,"about_ca_system_score_codex":0.00049946056,"about_ca_system_score_gemma":0.00016385312,"threshold_uncertainty_score":0.025845468},"labels":[],"label_agreement":null},{"id":"W2400934244","doi":"10.1177/135965350400900215","title":"Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Amprenavir; Univariate analysis; Medicine; Regimen; Lentivirus; Multivariate analysis; Virology; Internal medicine; Protease; Biology; Molecular biology; Gastroenterology; Human immunodeficiency virus (HIV); HIV-1 protease; Viral disease","score_opus":0.04791851658269943,"score_gpt":0.33075501861853995,"score_spread":0.28283650203584054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400934244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999169,0.0004886223,0.00009763889,0.000025915933,0.000005077775,0.0000058316327,0.00003537366,0.000004283474,0.00016818168],"genre_scores_gemma":[0.9997414,0.000056547575,0.00009186222,0.000025515592,0.000008997061,0.0000027083804,0.000039099385,0.0000017025301,0.000032201468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991534,0.00043261005,0.0000807125,0.000115026836,0.00014592905,0.0000722887],"domain_scores_gemma":[0.9990606,0.000497189,0.00024176283,0.00004827115,0.000032113843,0.00012006643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006743936,0.00019276363,0.00043018663,0.0001165918,0.000083640756,0.00036855874,0.0001263497,0.0002895239,0.0009170815],"category_scores_gemma":[0.0017746033,0.000090567184,0.00037520335,0.00014909173,0.00024390726,0.00021636719,0.00013660321,0.00037393588,0.00014756384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037820533,0.0009897525,0.6705617,0.00023530608,0.0012251588,0.00268478,0.00018179178,0.0040895315,0.18477055,0.0001848812,0.0003346462,0.09692141],"study_design_scores_gemma":[0.00097234396,0.02924692,0.92585456,0.00004111123,0.000588985,0.0060303807,0.00014217467,0.005121267,0.030085701,0.00019647293,0.001685447,0.00003458039],"about_ca_topic_score_codex":0.0001790394,"about_ca_topic_score_gemma":0.000242258,"teacher_disagreement_score":0.0009170815,"about_ca_system_score_codex":0.00011933269,"about_ca_system_score_gemma":0.00013130596,"threshold_uncertainty_score":0.0035666227},"labels":[],"label_agreement":null},{"id":"W2401749080","doi":"10.1177/135965350901400304","title":"Predictive value of immune parameters before treatment interruption (TI) for CD4 <sup>+</sup> T-cell count change during TI in HIV infection","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; McGill University Health Centre","funders":"","keywords":"CD8; Peripheral blood mononuclear cell; T cell; Immunology; Cart; Viral load; Immune system; Medicine; Surrogate endpoint; Internal medicine; CD28; Gastroenterology; Biology; Human immunodeficiency virus (HIV); In vitro","score_opus":0.04319101484268174,"score_gpt":0.2893590897591211,"score_spread":0.24616807491643938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401749080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99905866,0.00033711857,0.00010846818,0.000016928938,0.0000052233067,0.0000069036478,0.00008836643,0.0000053849817,0.0003728388],"genre_scores_gemma":[0.99974054,0.000034336525,0.00006189646,0.000007475205,0.0000072928556,0.0000041763524,0.00009833355,0.0000011626381,0.000044806256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976283,0.00006554002,0.000028731034,0.000046584086,0.000047106107,0.000049198894],"domain_scores_gemma":[0.9975551,0.0011465839,0.0007593385,0.000093089344,0.00018603855,0.00025995699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045098166,0.00023118242,0.00022125411,0.00037375145,0.00021920261,0.00041364328,0.0001737791,0.00039695814,0.0015076532],"category_scores_gemma":[0.002716145,0.00012268196,0.00021710679,0.0003395427,0.00018913041,0.0002185469,0.0001373663,0.0005803046,0.00018933376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003571894,0.000026925618,0.99627244,0.000007733117,0.000013687519,0.00007772692,0.000025843467,0.00011007134,0.0005205246,0.0000059520635,0.00004479165,0.0025370137],"study_design_scores_gemma":[0.000007883439,0.00041525796,0.9976011,0.0000073163433,0.00003366712,0.00065494276,0.000076675824,0.0005580102,0.00046031084,0.00002091775,0.00016009506,0.0000038993117],"about_ca_topic_score_codex":0.0006935545,"about_ca_topic_score_gemma":0.0006058251,"teacher_disagreement_score":0.0015076532,"about_ca_system_score_codex":0.00016362032,"about_ca_system_score_gemma":0.00020001974,"threshold_uncertainty_score":0.005043566},"labels":[],"label_agreement":null},{"id":"W2405604868","doi":"10.1177/135965350300800202","title":"Prevalence and clinical implications of insertions in the HIV-1 p6 <sup>Gag</sup> N-terminal region in drug-naive individuals initiating antiretroviral therapy","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Virology; Lentivirus; Drug resistance; Zidovudine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Proportional hazards model; Medicine; Viral load; Biology; Hazard ratio; Internal medicine; Immunology; Confidence interval; Viral disease; Genetics","score_opus":0.05621731728574788,"score_gpt":0.3470232791541528,"score_spread":0.29080596186840496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405604868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996119,0.00015670093,0.000014369672,0.000026349688,9.897245e-7,0.0000032140986,0.000047084133,0.0000014626092,0.00013800379],"genre_scores_gemma":[0.9997845,0.00006203026,0.000032685624,0.000017459684,0.000002926875,0.0000021025912,0.00005219553,6.51176e-7,0.000045424313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992913,0.00017993244,0.000059773258,0.00013153159,0.0001796432,0.00015775695],"domain_scores_gemma":[0.99751306,0.0007719706,0.0010148195,0.00007843499,0.0002461129,0.00037555522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047926523,0.00023147225,0.0003048126,0.0004857333,0.00053846836,0.00058850273,0.00034178022,0.00061090547,0.000686107],"category_scores_gemma":[0.0035963508,0.00025126943,0.000120511206,0.00061599974,0.0006897926,0.0002679425,0.0002174285,0.0004740269,0.00012720766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016784883,0.00002083623,0.9971802,0.000007812887,0.000009495066,0.0001861468,0.00010719454,0.000032413576,0.0005184867,0.000004980306,0.000037321464,0.0017271653],"study_design_scores_gemma":[0.000004593576,0.000090243506,0.9989876,0.0000037526193,0.0000065784816,0.00053308276,0.000121442274,0.00010149746,0.00008495373,0.0000055928317,0.00005765969,0.0000029899065],"about_ca_topic_score_codex":0.050792485,"about_ca_topic_score_gemma":0.0614436,"teacher_disagreement_score":0.050792485,"about_ca_system_score_codex":0.0007952944,"about_ca_system_score_gemma":0.0005622711,"threshold_uncertainty_score":0.10099369},"labels":[],"label_agreement":null},{"id":"W2406362442","doi":"10.3851/imp2908","title":"Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Nevirapine; Tolerability; Medicine; Internal medicine; Adverse effect; Population; Pharmacology; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy; Environmental health","score_opus":0.0043824124745371,"score_gpt":0.22208401534603697,"score_spread":0.21770160287149987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406362442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776566,0.0003161411,0.000026683372,0.00012682605,0.000004105643,0.00004075622,0.00068642874,0.0000044319104,0.0010289855],"genre_scores_gemma":[0.99800736,0.00040776844,0.000057722445,0.00014592482,0.0000057147677,0.000015057828,0.0005624704,0.00000489288,0.0007930878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901307,0.0000908663,0.00005891922,0.00014764663,0.00042228092,0.00026719572],"domain_scores_gemma":[0.9978023,0.00015951828,0.0004431964,0.00006965449,0.0008887039,0.0006366302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056695245,0.00030202055,0.0004716752,0.00068760343,0.0021413595,0.0014880344,0.0010647334,0.0005036485,0.0018091757],"category_scores_gemma":[0.0020735452,0.00035436693,0.00038749885,0.0021222015,0.0006832337,0.00041738083,0.000496584,0.00091025117,0.00040860928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016899308,0.00014508009,0.9930074,0.000022834873,0.000044944107,0.00024778832,0.0009536679,0.000045621233,0.00030764437,0.000017354634,0.0005692225,0.0044694706],"study_design_scores_gemma":[0.000011648783,0.00008285151,0.99849606,0.0000104408955,0.00001609956,0.00013363888,0.0007597348,0.000108017004,0.000031825126,0.000004793273,0.00033811666,0.0000067421],"about_ca_topic_score_codex":0.9654848,"about_ca_topic_score_gemma":0.9687733,"teacher_disagreement_score":0.034515202,"about_ca_system_score_codex":0.011955204,"about_ca_system_score_gemma":0.00912393,"threshold_uncertainty_score":0.08674145},"labels":[],"label_agreement":null},{"id":"W2409673291","doi":"10.1177/135965350901400408","title":"Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Abbott Laboratories","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Medicine; Tolerability; Regimen; Pharmacokinetics; Gastroenterology; Internal medicine; Area under the curve; Interquartile range; Pharmacology; Viral load; Human immunodeficiency virus (HIV); Adverse effect; Antiretroviral therapy; Immunology","score_opus":0.0372966081615957,"score_gpt":0.30808345389957575,"score_spread":0.27078684573798006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409673291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898785,0.0006143709,0.00006465049,0.000027626145,0.000005698119,0.000017131084,0.000107904096,0.000007650696,0.00016704419],"genre_scores_gemma":[0.99898046,0.00032505416,0.00027412878,0.00005062315,0.000014715257,0.000038214548,0.00017750487,0.000007158681,0.0001321043],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995115,0.00021333809,0.000028861434,0.0000767244,0.000084440886,0.00008511679],"domain_scores_gemma":[0.99897027,0.0003315688,0.0003596613,0.000046670193,0.000044979082,0.00024685307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007708494,0.0002899786,0.0009121113,0.00011658913,0.00016990189,0.0005307978,0.0002721393,0.00045248878,0.0014096636],"category_scores_gemma":[0.0020755897,0.00020550577,0.00044862425,0.00021821087,0.00044858322,0.00042892463,0.00018724243,0.0008355316,0.00020107567],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34054884,0.0053775394,0.37387487,0.0009697782,0.0012019728,0.0013296851,0.0014820177,0.007285443,0.0754233,0.00039770818,0.0020668793,0.19004208],"study_design_scores_gemma":[0.019041708,0.2241432,0.71487945,0.00016092103,0.0010663577,0.0035124074,0.00088523753,0.0052876035,0.026978707,0.00017619578,0.003755441,0.00011278626],"about_ca_topic_score_codex":0.0009913893,"about_ca_topic_score_gemma":0.0012432702,"teacher_disagreement_score":0.0014096636,"about_ca_system_score_codex":0.00056579907,"about_ca_system_score_gemma":0.00041142094,"threshold_uncertainty_score":0.0047157407},"labels":[],"label_agreement":null},{"id":"W2410585105","doi":"10.3851/imp3028","title":"Artesunate Demonstrates <i>in vitro</i> Synergism with Several Antiviral Agents against Human Cytomegalovirus","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Foscarnet; Ganciclovir; Human cytomegalovirus; Cidofovir; Artesunate; Pharmacology; Virology; In vitro; Biology; Virus; Immunology; Biochemistry","score_opus":0.05600981701911194,"score_gpt":0.32991627976030635,"score_spread":0.2739064627411944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410585105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977976,0.012350476,0.002411384,0.0002327574,0.000121917605,0.000079178055,0.0005994691,0.00020392585,0.0060248473],"genre_scores_gemma":[0.99339163,0.0020144465,0.0020401669,0.000082401784,0.000046165987,0.00004335528,0.0008638104,0.000026174512,0.0014918403],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99959475,0.00015100438,0.000051253915,0.000055370416,0.00010159994,0.000045949495],"domain_scores_gemma":[0.99974996,0.000103340426,0.00004154973,0.000030800933,0.0000359441,0.000038320726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035740546,0.00061648194,0.00050941453,0.00028816846,0.00015766971,0.00030855037,0.00022742533,0.00026037652,0.002012968],"category_scores_gemma":[0.00028233646,0.00017109745,0.00052624027,0.00023724792,0.00021798711,0.00022259603,0.00023346861,0.00047996885,0.0005277226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006796022,0.00014091229,0.00042429837,0.00015335818,0.00003758885,0.000045223605,0.000023485069,0.0001434251,0.9931492,0.00007062376,0.0002645078,0.004867886],"study_design_scores_gemma":[0.00005181211,0.0023248463,0.002725014,0.000011066471,0.000056121768,0.0002714263,0.000012148497,0.00038300327,0.9916768,0.000019739971,0.0024608616,0.000007224532],"about_ca_topic_score_codex":0.0004982969,"about_ca_topic_score_gemma":0.0010319159,"teacher_disagreement_score":0.002012968,"about_ca_system_score_codex":0.0002221294,"about_ca_system_score_gemma":0.0002092441,"threshold_uncertainty_score":0.006734073},"labels":[],"label_agreement":null},{"id":"W2411572535","doi":"10.1177/135965350701200417","title":"Recent Advances in the Search for Antiviral Agents against Human Papillomaviruses","year":2007,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Genital warts; Medicine; HPV vaccines; Sex organ; HPV infection; Cervical cancer; Immunology; Virology; Papillomaviridae; Anal cancer; Human papillomavirus; Cancer; Bioinformatics; Biology; Internal medicine; Genetics","score_opus":0.301906594557629,"score_gpt":0.5257281152180348,"score_spread":0.22382152066040573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411572535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024939276,0.9979894,0.00014312641,0.00019100137,0.00014657325,0.000004299523,0.000009232422,0.000009009587,0.0012579495],"genre_scores_gemma":[0.0010705119,0.9970988,0.0003975081,0.00023750197,0.0001840275,0.0000070242713,0.00002579615,0.0000016662165,0.00097716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997768,0.00003942593,0.00002974794,0.000042822205,0.00009041398,0.000020706084],"domain_scores_gemma":[0.9995914,0.00021829497,0.00004704461,0.0000135561495,0.00009622522,0.00003341334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006353826,0.0008190325,0.0011505592,0.0017426669,0.00032974978,0.000790477,0.00072073226,0.0009106476,0.0045644343],"category_scores_gemma":[0.0007019252,0.00024725313,0.00041771695,0.0018447934,0.00042755398,0.0012658776,0.00048866344,0.0013944143,0.0026785133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116543895,0.00012227213,0.00022186936,0.012978666,0.000079325044,0.00028365347,0.00008467443,0.0004135664,0.0048399577,0.0029323495,0.016912295,0.9610148],"study_design_scores_gemma":[0.000026975247,0.00018629133,0.00073641754,0.0016630733,0.00011282278,0.0013061282,0.00006104393,0.00008731208,0.0014701666,0.0014046903,0.9929288,0.000016195949],"about_ca_topic_score_codex":0.0007772463,"about_ca_topic_score_gemma":0.001429855,"teacher_disagreement_score":0.0045644343,"about_ca_system_score_codex":0.00053097896,"about_ca_system_score_gemma":0.0008280985,"threshold_uncertainty_score":0.0152695775},"labels":[],"label_agreement":null},{"id":"W2412571829","doi":"10.1177/135965350400900407","title":"Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Amprenavir; Lopinavir; Ritonavir; Lopinavir/ritonavir; Medicine; Virology; Reverse-transcriptase inhibitor; Viral load; Internal medicine; Gastroenterology; Biology; Virus; Antiretroviral therapy; Protease; HIV-1 protease; Enzyme","score_opus":0.01476171776978681,"score_gpt":0.25943529803548254,"score_spread":0.24467358026569574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412571829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946242,0.004321399,0.00013934569,0.000103811006,0.00006205706,0.000305889,0.00008546797,0.000016703067,0.0003411166],"genre_scores_gemma":[0.9962035,0.0016519947,0.0006575989,0.0003209417,0.00018891135,0.00037313136,0.0002552772,0.0000039683355,0.00034458135],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994974,0.00022989564,0.00005061342,0.00009320684,0.0000407761,0.000088094355],"domain_scores_gemma":[0.99934226,0.00013098326,0.00014808045,0.000032255753,0.000024358791,0.00032214334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001100774,0.0007983662,0.0025311871,0.00037673087,0.00026626402,0.00056622416,0.00068059197,0.0010417987,0.0022627949],"category_scores_gemma":[0.001204221,0.00041259453,0.0010688896,0.00029688634,0.00041592927,0.00057690364,0.00025523262,0.0012428553,0.00035561112],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83586895,0.01733093,0.011336436,0.0008155487,0.0012186428,0.00039636347,0.00018346767,0.0015108928,0.014650004,0.000095667914,0.00066387386,0.1159292],"study_design_scores_gemma":[0.45352638,0.51369125,0.02612661,0.00017093182,0.0007340361,0.0005425714,0.00008851282,0.0012711886,0.0024186291,0.00016152736,0.0012326872,0.00003572338],"about_ca_topic_score_codex":0.00041224915,"about_ca_topic_score_gemma":0.0009119449,"teacher_disagreement_score":0.0025311871,"about_ca_system_score_codex":0.000526067,"about_ca_system_score_gemma":0.00054874725,"threshold_uncertainty_score":0.0075698495},"labels":[],"label_agreement":null},{"id":"W2413643247","doi":"10.1177/135965350801301s03","title":"Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Hepatitis C virus; Medicine; Internal medicine; Viral load; Genotype; Hepatitis C; Hepacivirus; Chronic hepatitis; Gastroenterology; Virus; Immunology; Biology; Gene","score_opus":0.04796626981172269,"score_gpt":0.3164073012733263,"score_spread":0.2684410314616036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413643247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616332,0.014660251,0.0011917973,0.010427046,0.00046319314,0.0001250965,0.00077346945,0.0000536462,0.010672184],"genre_scores_gemma":[0.99160403,0.0038977705,0.00077944074,0.001573655,0.00043424673,0.000109863584,0.0008514204,0.0000103695,0.00073932734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995363,0.00019151883,0.000040557356,0.000036779787,0.0000485847,0.00014637112],"domain_scores_gemma":[0.9988324,0.00014011234,0.00034340998,0.000025263636,0.00010480567,0.0005541022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096573605,0.0002826882,0.0005496539,0.00038672664,0.00057017006,0.0008358016,0.00029299856,0.00041390635,0.0025713635],"category_scores_gemma":[0.003950027,0.00007153857,0.0007039094,0.0005421299,0.00019190756,0.0005543901,0.0009821141,0.00080223836,0.0004901995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005813319,0.0010375658,0.7348384,0.00050438533,0.00033690498,0.000769685,0.00039101197,0.0013658961,0.00048212445,0.0012956752,0.011496471,0.2416686],"study_design_scores_gemma":[0.0015973791,0.011008233,0.9438075,0.0012206746,0.0010248679,0.0017304305,0.0018596698,0.005090597,0.0009536262,0.011928237,0.01967553,0.000103221515],"about_ca_topic_score_codex":0.0014019114,"about_ca_topic_score_gemma":0.0021733036,"teacher_disagreement_score":0.0025713635,"about_ca_system_score_codex":0.0006015566,"about_ca_system_score_gemma":0.0010088917,"threshold_uncertainty_score":0.008602083},"labels":[],"label_agreement":null},{"id":"W2415009490","doi":"10.1177/135965350501000801","title":"TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals <i>in Vitro</i>","year":2005,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pharmacology; Drug; Protease inhibitor (pharmacology); CCR5 receptor antagonist; In vitro; Medicine; Human immunodeficiency virus (HIV); Chemistry; Internal medicine; Antiretroviral therapy; Virology; Viral load; Inflammation; Chemokine receptor; Biochemistry","score_opus":0.030810820858888907,"score_gpt":0.2673798028364486,"score_spread":0.23656898197755966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415009490","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059640557,0.003459772,0.00055599335,0.9554639,0.01961917,0.000037026493,0.00013972253,0.00006553655,0.014694773],"genre_scores_gemma":[0.044728097,0.005983311,0.0014810419,0.87145144,0.046702426,0.0000927188,0.00018099233,0.0000475035,0.02933248],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988564,0.00030284742,0.00014306168,0.000111266076,0.00038983216,0.00019655905],"domain_scores_gemma":[0.99814045,0.0012647889,0.00011928858,0.000043274016,0.00023853248,0.00019357666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012433176,0.00084230234,0.0013547952,0.00027042348,0.0019946918,0.0018619824,0.0008122714,0.021917373,0.0030832598],"category_scores_gemma":[0.0067452514,0.00031585008,0.001289666,0.00031019148,0.0010056046,0.0014045695,0.00038732376,0.013476224,0.0028800457],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005530495,0.00014008587,0.0018160341,0.00021308723,0.000058008438,0.030556101,0.0001629135,0.00043483227,0.0019224456,0.0047635194,0.9167086,0.042671222],"study_design_scores_gemma":[0.0010012956,0.0010820718,0.004073305,0.00029832713,0.00015040985,0.042113956,0.0004993841,0.0027445075,0.0031791124,0.008988477,0.9357634,0.00010577891],"about_ca_topic_score_codex":0.0032388975,"about_ca_topic_score_gemma":0.0067673153,"teacher_disagreement_score":0.021917373,"about_ca_system_score_codex":0.0025956144,"about_ca_system_score_gemma":0.0014336413,"threshold_uncertainty_score":0.018832624},"labels":[],"label_agreement":null},{"id":"W2415049193","doi":"10.1177/135965350400900414","title":"Predictive Value of HIV-1 Protease Genotype and Virtual Phenotype on the Virological Response to Lopinavir/Ritonavir-Containing Salvage Regimens","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University Health Network; McGill University; University of Toronto; Montreal General Hospital","funders":"","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Internal medicine; Virology; Viral load; Regimen; Odds ratio; Population; Univariate analysis; Genotype; Salvage therapy; Biology; Medicine; Oncology; Immunology; Multivariate analysis; Human immunodeficiency virus (HIV); Genetics; Antiretroviral therapy; Chemotherapy","score_opus":0.021165686277663992,"score_gpt":0.2760755676495867,"score_spread":0.2549098813719227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415049193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994273,0.000095366995,0.00007098349,0.000028520853,0.0000027030042,0.0000020143518,0.00006345769,0.0000042706215,0.00030531938],"genre_scores_gemma":[0.9998254,0.000015066812,0.000031662534,0.000006669771,0.0000037916434,6.71368e-7,0.00006542984,9.1816776e-7,0.000050248964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968946,0.00013003053,0.000020625268,0.0000411663,0.00007209617,0.000046685804],"domain_scores_gemma":[0.9978148,0.0011079151,0.00035778125,0.00010948434,0.000168641,0.00044136797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005420439,0.0002788324,0.00023879044,0.00035331832,0.00017877994,0.00040872206,0.00015841251,0.00028010228,0.00097139704],"category_scores_gemma":[0.0032262679,0.00011189524,0.00025660906,0.0002170178,0.0002795391,0.00015171747,0.00016461952,0.0003996007,0.00014606258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005209487,0.000020124511,0.9951243,0.0000038200847,0.00004153282,0.000108574,0.000019820747,0.00045815317,0.0009608364,0.000011892069,0.00006420422,0.0026658662],"study_design_scores_gemma":[0.000013069035,0.0002098321,0.9959155,0.0000041806056,0.000053130123,0.00039739168,0.000041939136,0.0027935277,0.00042112055,0.000029630168,0.00011540354,0.0000053568197],"about_ca_topic_score_codex":0.0059367907,"about_ca_topic_score_gemma":0.007816051,"teacher_disagreement_score":0.0059367907,"about_ca_system_score_codex":0.0001957695,"about_ca_system_score_gemma":0.00028393668,"threshold_uncertainty_score":0.0118044615},"labels":[],"label_agreement":null},{"id":"W2416661311","doi":"10.1177/135965350501000119","title":"Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Tolerability; Clinical trial; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Drug development; Clinical study design; Medicine; Pharmacodynamics; Pharmacology; Reverse-transcriptase inhibitor; Intensive care medicine; Biology; Drug; Human immunodeficiency virus (HIV); Bioinformatics; Pharmacokinetics; Virology; Antiretroviral therapy; Viral load; Adverse effect; Genetics; RNA","score_opus":0.12900661530849614,"score_gpt":0.3734704503012295,"score_spread":0.24446383499273336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416661311","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00968625,0.27901083,0.033927098,0.6305742,0.013337194,0.0015416769,0.0007113911,0.0008486253,0.03036272],"genre_scores_gemma":[0.12011091,0.4186266,0.19684988,0.20475961,0.033218246,0.004565899,0.0028581193,0.00081119174,0.018199602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9696078,0.014189733,0.0031016807,0.0018879568,0.009756805,0.0014561331],"domain_scores_gemma":[0.91525054,0.036211148,0.004997172,0.0042690216,0.025261898,0.014010136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11886105,0.0013015888,0.0025056766,0.0014108575,0.0016766054,0.010134491,0.004785349,0.008592373,0.019778132],"category_scores_gemma":[0.088583395,0.0011342609,0.0024516154,0.00092972454,0.006315678,0.008957863,0.0054520564,0.01541926,0.010872258],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013960435,0.0015174329,0.0019384087,0.0032429516,0.00019848661,0.0007023444,0.0008468337,0.0037970515,0.008823267,0.051465638,0.216408,0.70966357],"study_design_scores_gemma":[0.0009419415,0.0051546036,0.0023725617,0.0028118526,0.00011147113,0.0014684799,0.0008839836,0.0022745964,0.0018533414,0.032508958,0.94948703,0.0001311352],"about_ca_topic_score_codex":0.002285164,"about_ca_topic_score_gemma":0.00282142,"teacher_disagreement_score":0.11886105,"about_ca_system_score_codex":0.0039921016,"about_ca_system_score_gemma":0.017060688,"threshold_uncertainty_score":0.6286048},"labels":[],"label_agreement":null},{"id":"W2417874692","doi":"10.1177/135965350801300104","title":"The Prophylactic Administration of a Monoclonal Antibody against Human Metapneumovirus Attenuates viral Disease and Airways Hyperresponsiveness in Mice","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Respiratory viral infections research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Human metapneumovirus; Monoclonal antibody; Immunology; Respiratory disease; Respiratory tract; Respiratory system; Lung; Antibody; Respiratory tract infections; Internal medicine","score_opus":0.05465177580044545,"score_gpt":0.37142260249998305,"score_spread":0.3167708266995376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417874692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938355,0.0019747387,0.0016679647,0.0002092254,0.00009394434,0.000109928464,0.0005740859,0.00017043989,0.0013641507],"genre_scores_gemma":[0.9890798,0.0017847914,0.0036820646,0.00018831037,0.00007404559,0.00022484045,0.0010933626,0.000033925277,0.0038389182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997266,0.000042212476,0.000018915134,0.000058389876,0.00006780789,0.00008597338],"domain_scores_gemma":[0.99974746,0.000036345027,0.00008802139,0.00002151467,0.000022264274,0.00008435287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032149203,0.00068851287,0.00048881344,0.00052912073,0.00017644963,0.00033303295,0.00047115775,0.0007470535,0.0013106301],"category_scores_gemma":[0.00016393563,0.00026657723,0.0004175979,0.00015829368,0.00035804152,0.00032293703,0.00018396077,0.0016937775,0.00048345627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006216118,0.000507306,0.00024722674,0.000051141564,0.000009664374,0.00003599226,0.000014401441,0.00008224666,0.99680436,0.000057236077,0.00008367685,0.0014852374],"study_design_scores_gemma":[0.00036355114,0.015857061,0.008480646,0.000043489817,0.00006961547,0.0004268645,0.000033050335,0.0016733307,0.97000855,0.00007953127,0.0029527862,0.000011436922],"about_ca_topic_score_codex":0.00058518845,"about_ca_topic_score_gemma":0.0011842467,"teacher_disagreement_score":0.0013106301,"about_ca_system_score_codex":0.00042131337,"about_ca_system_score_gemma":0.00036981291,"threshold_uncertainty_score":0.004384458},"labels":[],"label_agreement":null},{"id":"W2418527354","doi":"10.1177/135965350100600105","title":"Predictors of Virological Response in HIV-Infected Patients to Salvage Antiretroviral Therapy that Includes Nelfinavir","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of Toronto; University Health Network","funders":"","keywords":"Nelfinavir; Salvage therapy; Medicine; Reverse transcriptase; Internal medicine; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Viral load; Virology; Indinavir; Zidovudine; Sida; Population; Lentivirus; Cohort; Human immunodeficiency virus (HIV); Gastroenterology; Biology; Viral disease; Antiretroviral therapy; Chemotherapy; RNA","score_opus":0.025609689694692822,"score_gpt":0.28316745155591944,"score_spread":0.2575577618612266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418527354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99968565,0.00013043579,0.0000430251,0.000022619808,0.0000023025118,0.0000050071153,0.000034178614,0.0000016260745,0.00007515714],"genre_scores_gemma":[0.99969304,0.000047154193,0.00006622479,0.000016866165,0.000009857678,0.000006776938,0.000099035075,0.0000011904433,0.0000598552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999597,0.00014645445,0.00004322238,0.000049602837,0.00007496637,0.000088721674],"domain_scores_gemma":[0.9978544,0.0010326984,0.000512509,0.00011799202,0.00011859354,0.00036386616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000962334,0.00030536405,0.0004350444,0.00040556333,0.00034040306,0.00049688894,0.00018556409,0.00050690235,0.00079331326],"category_scores_gemma":[0.004460613,0.00027406428,0.00034441933,0.00036353964,0.00024999576,0.00034007317,0.00022589958,0.00077457604,0.00018827882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010257327,0.000109070876,0.9941034,0.000008184443,0.00005051417,0.00013286216,0.000072341856,0.00014479063,0.0006938711,0.000011455361,0.000077183744,0.003570726],"study_design_scores_gemma":[0.00012604697,0.0016979739,0.99496424,0.000009784317,0.000078311605,0.0008322823,0.0001751961,0.0012350125,0.0005309682,0.000056403154,0.00028378103,0.000009910618],"about_ca_topic_score_codex":0.0006826056,"about_ca_topic_score_gemma":0.00075228786,"teacher_disagreement_score":0.000962334,"about_ca_system_score_codex":0.00017370455,"about_ca_system_score_gemma":0.00021181791,"threshold_uncertainty_score":0.0050893426},"labels":[],"label_agreement":null},{"id":"W2419179490","doi":"10.1177/135965350300800511","title":"HIV Lipodystrophy Case Definition using Artificial Neural Network Modelling","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Toronto Western Hospital; St. Paul's Hospital; Montreal General Hospital","funders":"","keywords":"Logistic regression; Lipodystrophy; Artificial neural network; Regression analysis; Regression; Statistics; Artificial intelligence; Machine learning; Computer science; Medicine; Human immunodeficiency virus (HIV); Mathematics; Antiretroviral therapy","score_opus":0.11529193465511006,"score_gpt":0.33139837626358815,"score_spread":0.21610644160847808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419179490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7438071,0.0019170615,0.24859297,0.0010610409,0.00010288674,0.00041274322,0.0008946097,0.0004932153,0.0027183688],"genre_scores_gemma":[0.94892037,0.000396365,0.048934717,0.00006869462,0.000040435047,0.00020260914,0.0009075356,0.0000124213675,0.0005169626],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989465,0.00059708004,0.00010843697,0.00018149818,0.00012331682,0.000043113756],"domain_scores_gemma":[0.9974704,0.0019561907,0.00029753015,0.000083795545,0.00015069985,0.00004143819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002622875,0.0006358678,0.0005866261,0.002282992,0.0002229429,0.0013163773,0.0008277593,0.0006549765,0.0010946702],"category_scores_gemma":[0.007684083,0.0002819061,0.00078382593,0.0009674388,0.00026629528,0.00069005264,0.0005598622,0.0007120055,0.00024216033],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010178154,0.00035563842,0.23060079,0.0003212919,0.0006402364,0.0011164639,0.00027207285,0.60955125,0.0021153884,0.0020879416,0.0023164896,0.14960466],"study_design_scores_gemma":[0.000014856424,0.000034863508,0.009654676,0.000046855093,0.000036224254,0.00018037384,0.000031914205,0.9883249,0.00033642814,0.0010586677,0.00026815943,0.000012093609],"about_ca_topic_score_codex":0.005441112,"about_ca_topic_score_gemma":0.0039307857,"teacher_disagreement_score":0.005441112,"about_ca_system_score_codex":0.0008363043,"about_ca_system_score_gemma":0.0005128522,"threshold_uncertainty_score":0.013871253},"labels":[],"label_agreement":null},{"id":"W2419820409","doi":"10.1177/135965350601100315","title":"Oligonucleotide-Based Therapeutic Options against Hepatitis C Virus Infection","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Ribozyme; Hepatitis C virus; Virology; Oligonucleotide; Biology; Computational biology; Hepatitis C; Virus; RNA; DNA; Genetics; Gene","score_opus":0.034396012841801465,"score_gpt":0.31922700220882977,"score_spread":0.28483098936702833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419820409","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26764178,0.5705932,0.050790902,0.0059820567,0.0029704138,0.0006030746,0.00070941064,0.001106527,0.09960263],"genre_scores_gemma":[0.63510746,0.3132637,0.020671787,0.002125147,0.0008135912,0.0005749891,0.00068876205,0.00004750129,0.026707029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999323,0.000021928672,0.0000046526957,0.000009461819,0.000019716155,0.000011996855],"domain_scores_gemma":[0.9999697,0.0000090247195,0.0000067163814,0.0000021948438,0.0000044373905,0.000007941837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024723995,0.00027587684,0.00029467465,0.0004075706,0.0001746742,0.0002908957,0.00022606937,0.0003723002,0.006280366],"category_scores_gemma":[0.00014813224,0.000076740354,0.00018368401,0.00019240189,0.00022183459,0.00022321216,0.00024367202,0.0005142307,0.0012369397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096415705,0.0006914145,0.00027658226,0.001687298,0.00006492405,0.0007449569,0.00013698556,0.0011500756,0.4393314,0.016775576,0.007583014,0.5305936],"study_design_scores_gemma":[0.0009882035,0.007680885,0.0018512585,0.00051788305,0.00025085855,0.005001788,0.00014274256,0.002116382,0.2609796,0.008835423,0.7115772,0.000057846613],"about_ca_topic_score_codex":0.0001478362,"about_ca_topic_score_gemma":0.0003263253,"teacher_disagreement_score":0.006280366,"about_ca_system_score_codex":0.00017783802,"about_ca_system_score_gemma":0.00015862336,"threshold_uncertainty_score":0.021009922},"labels":[],"label_agreement":null},{"id":"W2423411180","doi":"10.1177/135965350400900308","title":"The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Nelfinavir; Amprenavir; Saquinavir; Lopinavir; Indinavir; Ritonavir; Protease; Biology; Drug resistance; Virology; Protease inhibitor (pharmacology); Resistance mutation; Atazanavir; Lentivirus; Darunavir; Genetics; HIV-1 protease; Virus; Viral load; Gene; Viral disease; Reverse transcriptase; Antiretroviral therapy; Enzyme","score_opus":0.011686820211874805,"score_gpt":0.25909179243735847,"score_spread":0.24740497222548366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2423411180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955503,0.0010625877,0.00008309434,0.0003073988,0.000036033984,0.00001478774,0.00017766395,0.00000837532,0.0027597763],"genre_scores_gemma":[0.99944776,0.00012314266,0.00003111774,0.00013691843,0.000025784524,0.0000039191946,0.000090303925,0.0000045050842,0.00013670616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988153,0.00051607535,0.00013674099,0.00016148394,0.0002082863,0.00016226631],"domain_scores_gemma":[0.99544597,0.0019336274,0.0011635182,0.0001857653,0.00032019892,0.00095101126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095835887,0.00019630801,0.00042647647,0.00042973514,0.0006427152,0.0011628025,0.0002612847,0.0006034867,0.002415697],"category_scores_gemma":[0.008376967,0.0001325084,0.00042959096,0.0005467888,0.0002310621,0.00051897974,0.00023567607,0.0007312929,0.00047458409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013870422,0.00011058675,0.9864405,0.000016145697,0.00014502581,0.00041039617,0.00014887107,0.0001298022,0.00061476446,0.00007186217,0.00046113576,0.010063951],"study_design_scores_gemma":[0.00003869957,0.00063133455,0.9961843,0.000021248368,0.000105255145,0.0010896182,0.0002767455,0.00059000595,0.00021290955,0.00012013775,0.00071521127,0.000014593209],"about_ca_topic_score_codex":0.0015360271,"about_ca_topic_score_gemma":0.0018010691,"teacher_disagreement_score":0.002415697,"about_ca_system_score_codex":0.0003818672,"about_ca_system_score_gemma":0.00032233968,"threshold_uncertainty_score":0.008081257},"labels":[],"label_agreement":null},{"id":"W24266920","doi":"10.1177/135965350801300306","title":"Distinct Signature Type I Interferon Responses are Determined by the Infecting virus and the Target Cell","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Biology; Interferon; Sendai virus; Virus; Virology; Gene; Gene expression; Interferon-stimulated gene; Immunology; Immune system; Innate immune system; Genetics","score_opus":0.016249503477538205,"score_gpt":0.2440967339733823,"score_spread":0.2278472304958441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W24266920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918892,0.0017896312,0.0038393987,0.000049672522,0.000028558285,0.00004898565,0.00029408914,0.000038833005,0.0020216007],"genre_scores_gemma":[0.9914175,0.0016141268,0.004675141,0.000081102226,0.00003328927,0.00012696079,0.00060747087,0.00002730277,0.0014170249],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99961746,0.000083135164,0.0000400463,0.000085037864,0.00010638029,0.00006793642],"domain_scores_gemma":[0.999592,0.0001598105,0.00006752813,0.00004617891,0.00006163207,0.00007287077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041832527,0.00031346342,0.00039908467,0.00026317485,0.00015999979,0.00061593135,0.0001877541,0.00042673756,0.0011297221],"category_scores_gemma":[0.00045218912,0.00021864258,0.00026837637,0.0001788785,0.00031311275,0.00045936,0.00028845432,0.0005260399,0.00082691055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001270593,0.00001475774,0.0016010213,0.000028763712,0.0000028194231,0.000042244086,0.000022138258,0.000025939004,0.99702543,0.00009963788,0.00001283447,0.0009972564],"study_design_scores_gemma":[0.000031359898,0.0011031895,0.08937737,0.00005296863,0.000048463768,0.0014250271,0.000335789,0.001249748,0.9028109,0.0003485284,0.003193394,0.000023362332],"about_ca_topic_score_codex":0.00012935375,"about_ca_topic_score_gemma":0.0001857027,"teacher_disagreement_score":0.0011297221,"about_ca_system_score_codex":0.0002669618,"about_ca_system_score_gemma":0.00023208217,"threshold_uncertainty_score":0.003779292},"labels":[],"label_agreement":null},{"id":"W2427378135","doi":"10.1177/135965350601100516","title":"The Xivth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug resistance; HIV drug resistance; Human immunodeficiency virus (HIV); Resistance (ecology); Epidemiology; Medicine; Transmission (telecommunications); Antiretroviral therapy; Virology; Biology; Viral load; Pathology","score_opus":0.013942685347122959,"score_gpt":0.29621805326961176,"score_spread":0.2822753679224888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2427378135","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018073987,0.13437782,0.0036626589,0.20277095,0.05238286,0.0016148015,0.017417774,0.00057246815,0.5691267],"genre_scores_gemma":[0.020419942,0.019242842,0.001714292,0.00850934,0.001621948,0.00019741495,0.003581172,0.00008298083,0.9446302],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884593,0.0001230205,0.000020778964,0.00007608469,0.0005806654,0.00035344707],"domain_scores_gemma":[0.9982911,0.000062868115,0.000042175183,0.00002480749,0.0009357724,0.00064342207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001975715,0.00096776616,0.0004239941,0.00081623386,0.0040779407,0.0031545355,0.0014657805,0.0016423849,0.0671031],"category_scores_gemma":[0.0015536989,0.00032871586,0.00030937634,0.000854989,0.0007334995,0.0006311411,0.0013423894,0.0018711328,0.009994741],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057893078,0.000030462881,0.0006267061,0.000047216537,0.000005278446,0.000106776875,0.00014753261,0.000084672145,0.00025140002,0.0005668852,0.9741256,0.0239496],"study_design_scores_gemma":[0.000012065815,0.000013027309,0.0025097593,0.00010453237,0.000003921738,0.00003453808,0.0004091769,0.000046933143,0.0001438169,0.00009610834,0.9966174,0.000008751227],"about_ca_topic_score_codex":0.8132898,"about_ca_topic_score_gemma":0.95738834,"teacher_disagreement_score":0.18671018,"about_ca_system_score_codex":0.020941023,"about_ca_system_score_gemma":0.031897735,"threshold_uncertainty_score":0.37561947},"labels":[],"label_agreement":null},{"id":"W2461594029","doi":"10.3851/imp3059","title":"A Case of a Probable drug Interaction between Lurasidone and Atazanavir-Based Antiretroviral Therapy","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Atazanavir; Lurasidone; CYP3A4; Pharmacology; Ritonavir; Drug; Paliperidone; Protease inhibitor (pharmacology); Drug interaction; Therapeutic drug monitoring; Antipsychotic drug; Medicine; Antipsychotic; Cytochrome P450; Antiretroviral therapy; Internal medicine; Metabolism; Human immunodeficiency virus (HIV); Virology; Viral load","score_opus":0.062016771864384465,"score_gpt":0.3203811694096541,"score_spread":0.25836439754526963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461594029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89614594,0.012694176,0.015001351,0.029506639,0.0025855806,0.00073389855,0.000661428,0.00048567442,0.042185225],"genre_scores_gemma":[0.98198354,0.0022092278,0.0043599,0.004912322,0.0029803435,0.00008018629,0.00018156077,0.000056342396,0.0032365844],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99817765,0.00029742296,0.00021463083,0.00046723132,0.00025164132,0.0005914155],"domain_scores_gemma":[0.9954972,0.0019465614,0.0006507032,0.00040608976,0.00031863194,0.0011808653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008393267,0.0028048947,0.0019461144,0.0043325163,0.0049677906,0.0022642456,0.00324738,0.014384135,0.0035148321],"category_scores_gemma":[0.007418191,0.0019155901,0.0027160174,0.0027314513,0.0032794133,0.0043512066,0.0030819601,0.009916913,0.0013792115],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023937075,0.000045542045,0.0013596856,0.000012879163,0.000005798752,0.9975248,0.00010433371,0.00004779552,0.0001457875,0.00017219562,0.0001371451,0.00042006245],"study_design_scores_gemma":[0.00001563407,0.00006305339,0.0008824966,0.000013520989,0.0000119508395,0.99780065,0.00006958705,0.000278773,0.00019940075,0.000261676,0.00039299123,0.000010309295],"about_ca_topic_score_codex":0.005044416,"about_ca_topic_score_gemma":0.0057383673,"teacher_disagreement_score":0.014384135,"about_ca_system_score_codex":0.0032164673,"about_ca_system_score_gemma":0.0020040283,"threshold_uncertainty_score":0.023337185},"labels":[],"label_agreement":null},{"id":"W2465570878","doi":"10.1177/135965350200700104","title":"Prevalence and Response to Antiretroviral Therapy of Non-B Subtypes of HIV in Antiretroviral-Naive Individuals in British Columbia","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"Canadian Foundation for AIDS Research","keywords":"Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Biology; Lentivirus; Reverse-transcriptase inhibitor; Reverse transcriptase; Medicine; Viral disease; Immunology; Internal medicine; Polymerase chain reaction; Genetics","score_opus":0.01652190095736021,"score_gpt":0.2631948752469902,"score_spread":0.24667297428962998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465570878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993218,0.00019559143,0.0000070301235,0.000034796474,0.0000018613409,0.000005924097,0.0000888832,0.0000016363954,0.0003424678],"genre_scores_gemma":[0.9992244,0.00015523678,0.000024813402,0.0000496568,0.0000022200936,0.000004985398,0.00015104045,0.0000012366443,0.0003864569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996202,0.00007488786,0.000035720575,0.000055163102,0.00010130926,0.00011269758],"domain_scores_gemma":[0.9993772,0.000101745645,0.00012464175,0.000023415674,0.00016743566,0.00020562715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024183845,0.00016111216,0.0003064665,0.00059372204,0.0009078342,0.00055971654,0.00036553686,0.000360344,0.00081455556],"category_scores_gemma":[0.0014229212,0.00022208304,0.000111590285,0.0006915698,0.0003510008,0.00017962146,0.00020999479,0.00041021843,0.00016174986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004474768,0.0001610514,0.98869437,0.000026488504,0.000036001253,0.00029000093,0.000554827,0.000055036307,0.0013551642,0.000015436293,0.00034025102,0.008023904],"study_design_scores_gemma":[0.000011785117,0.00007924345,0.99909234,0.000007588028,0.000008346808,0.00014102994,0.000334257,0.00007406511,0.00007135628,0.000005328366,0.00017140484,0.0000034179943],"about_ca_topic_score_codex":0.62742245,"about_ca_topic_score_gemma":0.70252824,"teacher_disagreement_score":0.37257755,"about_ca_system_score_codex":0.002055079,"about_ca_system_score_gemma":0.001128931,"threshold_uncertainty_score":0.7495434},"labels":[],"label_agreement":null},{"id":"W2470502126","doi":"10.1177/135965350601100114","title":"Risks of Non-Accidental Mortality by Baseline CD4 <sup>+</sup> T-Cell Strata in Hepatitis-C-Positive and -Negative Individuals Initiating Highly Active Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Medicine; Hepatitis C virus; Hepatitis C; Hazard ratio; Internal medicine; Immunology; Proportional hazards model; Confidence interval; Hepacivirus; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Virus","score_opus":0.04707390294040986,"score_gpt":0.35880998018133814,"score_spread":0.3117360772409283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470502126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996278,0.00012678726,0.00008735595,0.000013350389,0.0000022841477,0.0000028823872,0.000057837842,0.000001914153,0.00007978532],"genre_scores_gemma":[0.9996927,0.00003536032,0.000069020134,0.000008250547,0.000006352102,0.000003608514,0.000118377255,0.0000010207774,0.00006544124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935156,0.0003285728,0.000037458456,0.000096817974,0.00006671491,0.00011889931],"domain_scores_gemma":[0.99712616,0.0010553452,0.001049778,0.00021716577,0.000102203354,0.00044930726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011313473,0.00030344023,0.00028520913,0.00047088027,0.00022893366,0.0004998661,0.00029812267,0.00045770057,0.0011218752],"category_scores_gemma":[0.0033618563,0.00026888604,0.00060301734,0.000284249,0.00030992395,0.00031076808,0.00049577997,0.0005535558,0.00016264193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015052293,0.000037184323,0.99629503,0.0000072658086,0.00009497052,0.000055075172,0.00003232636,0.00011307181,0.00024892585,0.000022801401,0.00003367535,0.0015544506],"study_design_scores_gemma":[0.000034347413,0.0005540215,0.99754095,0.000005382645,0.000073754796,0.0003486592,0.00006907299,0.0009708509,0.00022551646,0.00010423048,0.00006709426,0.00000617741],"about_ca_topic_score_codex":0.0011505624,"about_ca_topic_score_gemma":0.0010868168,"teacher_disagreement_score":0.0011505624,"about_ca_system_score_codex":0.00018084144,"about_ca_system_score_gemma":0.0002276642,"threshold_uncertainty_score":0.005983174},"labels":[],"label_agreement":null},{"id":"W2471505848","doi":"10.1177/135965350400900602","title":"Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Tolerability; Lamivudine; Regimen; Didanosine; Internal medicine; Efavirenz; Nelfinavir; Medicine; Stavudine; Zidovudine; Gastroenterology; Adverse effect; Viral load; Pharmacology; Immunology; Human immunodeficiency virus (HIV); Viral disease; Antiretroviral therapy; Virus","score_opus":0.019668753747712413,"score_gpt":0.2831689572905201,"score_spread":0.2635002035428077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471505848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789387,0.00083937246,0.00019369501,0.00004737389,0.000030326953,0.0004921323,0.0001797247,0.000008513702,0.00031496224],"genre_scores_gemma":[0.9958572,0.0006723262,0.0009957283,0.00014822782,0.00008561195,0.00095042377,0.00048039897,0.000005330649,0.00080482994],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99823725,0.0011815042,0.00015544561,0.00016432676,0.00015524248,0.00010622723],"domain_scores_gemma":[0.9984432,0.000312171,0.0005936504,0.00020399105,0.0001134697,0.00033353272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028427097,0.0008830673,0.0019978667,0.00037098277,0.0002528734,0.0005010384,0.0005955325,0.0008249666,0.0024331848],"category_scores_gemma":[0.0015479752,0.00042753038,0.0013865867,0.00038624712,0.0004142533,0.00067187013,0.00057502487,0.0011845981,0.00032152055],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93633765,0.015133737,0.011227191,0.0005778536,0.002279381,0.000045010962,0.00009103795,0.0006615858,0.0041066282,0.000095821575,0.00023733989,0.029206747],"study_design_scores_gemma":[0.46361527,0.4874417,0.041053656,0.00009206383,0.0019900242,0.00017677459,0.000080572194,0.001666589,0.002154272,0.00031266865,0.0013724182,0.00004413102],"about_ca_topic_score_codex":0.0005737052,"about_ca_topic_score_gemma":0.0007933926,"teacher_disagreement_score":0.0028427097,"about_ca_system_score_codex":0.0003207591,"about_ca_system_score_gemma":0.00052565825,"threshold_uncertainty_score":0.015033841},"labels":[],"label_agreement":null},{"id":"W2473682917","doi":"10.1177/135965350701200703","title":"Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Reverse transcriptase; Genotyping; Virology; Transmission (telecommunications); Protease; Biology; Integrase; Index case; Genotype; Viral load; Human immunodeficiency virus (HIV); Gp41; Drug resistance; Genetics; Polymerase chain reaction; Enzyme; Antibody; Epitope; Gene","score_opus":0.017663606525148735,"score_gpt":0.2910289731068751,"score_spread":0.27336536658172633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473682917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906088,0.0006065367,0.0011483587,0.0005732514,0.0000545871,0.000050037703,0.000050090268,0.00004089411,0.0068673883],"genre_scores_gemma":[0.99734443,0.0004357355,0.00087832066,0.0003726629,0.000088471184,0.000012371325,0.00002944564,0.000010598935,0.0008279917],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9995894,0.00009227108,0.00004036757,0.0000677306,0.000055078457,0.00015514043],"domain_scores_gemma":[0.9990932,0.00024016094,0.00029289347,0.00007780669,0.000082146864,0.00021384306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029933028,0.0011853465,0.0004013999,0.0006485657,0.003384539,0.0009008247,0.00077706046,0.0013131334,0.0038630918],"category_scores_gemma":[0.0030689265,0.0005269869,0.0003631718,0.00040999445,0.00090981636,0.00077237625,0.0008935554,0.0015758947,0.0008265344],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057667956,0.00009043815,0.10871274,0.000053979962,0.00001564733,0.8809742,0.0035538264,0.00009069147,0.00097548554,0.00034492908,0.0010446557,0.0040857447],"study_design_scores_gemma":[0.000009795874,0.00010922622,0.012992576,0.000089287474,0.000024337267,0.9814882,0.002635067,0.00036111905,0.00065321865,0.00015571699,0.0014682914,0.000013164276],"about_ca_topic_score_codex":0.0060369433,"about_ca_topic_score_gemma":0.0064212414,"teacher_disagreement_score":0.0060369433,"about_ca_system_score_codex":0.00075249077,"about_ca_system_score_gemma":0.0007441956,"threshold_uncertainty_score":0.01292336},"labels":[],"label_agreement":null},{"id":"W2523601083","doi":"10.3851/imp3089","title":"Interchangeability between First-Line Generic Antiretroviral Products Prequalified by WHO using Adjusted Indirect Comparisons","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Universiteit Utrecht; World Health Organization","keywords":"Interchangeability; Medicine; Statistics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Mathematics; Computer science; Viral load; Virology","score_opus":0.2677889492011937,"score_gpt":0.3342942277627913,"score_spread":0.06650527856159755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523601083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65757215,0.02901292,0.28225207,0.00052787934,0.00072867505,0.004676288,0.011784756,0.00032559628,0.013119589],"genre_scores_gemma":[0.9483538,0.0009615987,0.045861892,0.000119018965,0.000086828026,0.0016160811,0.0024580283,0.000073375115,0.0004693373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8207535,0.13206187,0.01672787,0.010881229,0.01810717,0.0014684533],"domain_scores_gemma":[0.7392174,0.20976144,0.027059667,0.016435986,0.007170687,0.0003548028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07952707,0.0017342352,0.0022109088,0.0034694162,0.00038685385,0.0024470552,0.0017355534,0.00086825155,0.0036757032],"category_scores_gemma":[0.15700822,0.00038339413,0.008379459,0.0048069092,0.0011927828,0.0019859362,0.0024263402,0.0018670976,0.00029992755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023782002,0.0005253757,0.4982992,0.011645077,0.11547731,0.0007924332,0.0037021548,0.019544307,0.005386583,0.017230943,0.0028062304,0.30080846],"study_design_scores_gemma":[0.00212704,0.020922327,0.729333,0.0022208402,0.063970976,0.0024762836,0.0018613397,0.07404183,0.03106179,0.038962603,0.032227676,0.0007942451],"about_ca_topic_score_codex":0.0015303456,"about_ca_topic_score_gemma":0.0011998924,"teacher_disagreement_score":0.07952707,"about_ca_system_score_codex":0.0014399292,"about_ca_system_score_gemma":0.0012192758,"threshold_uncertainty_score":0.42058438},"labels":[],"label_agreement":null},{"id":"W2547674430","doi":"10.3851/imp3105","title":"Reporting on the Prevalence of Antiretroviral Drug Resistance in a Regional HIV Population over 20 Years: A Word of Caution","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Hip and Knee Clinic","funders":"","keywords":"Medicine; Population; Drug resistance; Prevalence; HIV drug resistance; Internal medicine; Human immunodeficiency virus (HIV); Epidemiology; Viral load; Immunology; Antiretroviral therapy; Environmental health; Biology","score_opus":0.02995695752612521,"score_gpt":0.29092920642927816,"score_spread":0.26097224890315296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547674430","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02133857,0.06361048,0.021526245,0.8291816,0.054872505,0.00042773414,0.0031366409,0.000586311,0.005319908],"genre_scores_gemma":[0.20300294,0.045413703,0.06057631,0.6320561,0.051026765,0.0011884897,0.00219726,0.000605373,0.003933188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.83483714,0.09342409,0.04299618,0.0070494288,0.019713083,0.001980076],"domain_scores_gemma":[0.5941789,0.25632492,0.02660347,0.028533315,0.08752307,0.0068364097],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.15775527,0.0018340094,0.004437827,0.00645438,0.0034001896,0.009485261,0.009863874,0.0076285275,0.0018926311],"category_scores_gemma":[0.35304287,0.0014955635,0.003688268,0.0069441376,0.01060535,0.01651674,0.0044505196,0.022986857,0.0021609045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006703431,0.00022238845,0.21016698,0.009787258,0.0021389867,0.002118112,0.022911355,0.0012923549,0.0018248517,0.0186083,0.6069715,0.12328767],"study_design_scores_gemma":[0.00028088485,0.00096509664,0.16588053,0.07453779,0.0019782246,0.007547919,0.0520506,0.005823051,0.0040701353,0.067330055,0.6183365,0.0011992321],"about_ca_topic_score_codex":0.044492554,"about_ca_topic_score_gemma":0.0463787,"teacher_disagreement_score":0.84224474,"about_ca_system_score_codex":0.004034466,"about_ca_system_score_gemma":0.007914525,"threshold_uncertainty_score":0.83429956},"labels":[],"label_agreement":null},{"id":"W2560505321","doi":"10.3851/imp3114","title":"A Comparison of Virological Suppression and Rebound between Indigenous and Non-Indigenous Persons Initiating Combination Antiretroviral Therapy in a Multisite Cohort of Individuals Living with HIV in Canada","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; McGill University; McGill University Health Centre; Simon Fraser University; St. Michael's Hospital; Sunnybrook Hospital; AIDS Vancouver; Ontario HIV Treatment Network; Lakehead University; University of British Columbia; Public Health Ontario; CAAN Communities, Alliances & Network; 2-Spirited; Women's College Hospital; McMaster University; HIV Legal Network; Maple Leaf Medical Clinic; Ottawa Hospital; University Health Network; University of Toronto","funders":"Fonds de Recherche du Québec - Santé; Ministry of Health, British Columbia; Simon Fraser University; Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Medicine; Cart; Demography; Indigenous; Viral load; Incidence (geometry); Cumulative incidence; Cohort; Cohort study; Psychological intervention; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Gerontology; Biology","score_opus":0.029135764413091646,"score_gpt":0.32680175763325076,"score_spread":0.29766599322015913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560505321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893135,0.00025028823,0.000032275166,0.000032330063,0.000002512776,0.000012766505,0.00040528385,0.0000014883788,0.00033171687],"genre_scores_gemma":[0.9993431,0.00013282393,0.000040466035,0.000022707312,0.0000020814769,0.0000055927253,0.00032093358,0.0000012646353,0.0001310402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991315,0.000107504304,0.00005403053,0.0001774332,0.00023062668,0.00029894704],"domain_scores_gemma":[0.99808156,0.00026104844,0.0005696958,0.00010850387,0.0004994354,0.00047974888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092414167,0.0002860168,0.0004275326,0.0008446577,0.0015740553,0.0009780783,0.0009338124,0.0003876359,0.0009985394],"category_scores_gemma":[0.0027980185,0.00022896269,0.0007472656,0.0013699268,0.00045085483,0.00028207386,0.000627252,0.00052166986,0.00008950309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023429605,0.000027894188,0.9972799,0.000021339845,0.000117394455,0.000034364075,0.0004774473,0.000045361056,0.00015002328,0.00002129914,0.00007775686,0.0015129519],"study_design_scores_gemma":[0.0000070060128,0.000051191844,0.9989613,0.000009508652,0.000043130556,0.00003647678,0.0006093028,0.000120911536,0.000028187662,0.000008370997,0.000119933764,0.0000045699867],"about_ca_topic_score_codex":0.93541396,"about_ca_topic_score_gemma":0.9392658,"teacher_disagreement_score":0.06458604,"about_ca_system_score_codex":0.0058485516,"about_ca_system_score_gemma":0.0072446163,"threshold_uncertainty_score":0.12993276},"labels":[],"label_agreement":null},{"id":"W2569661228","doi":"10.3851/imp3123","title":"HCV Genotype-1 Subtypes and Resistance-Associated Substitutions in Drug-Naive and in Direct-Acting Antiviral Treatment Failure Patients","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"NS5A; NS3; Medicine; Internal medicine; Genotype; Drug resistance; Virology; Biology; Hepatitis C virus; Hepacivirus; Virus; Genetics; Gene","score_opus":0.02510943689565565,"score_gpt":0.297871199646457,"score_spread":0.27276176275080133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569661228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99975806,0.000074667616,0.0000098708515,0.00000847519,0.000001396267,0.0000024581554,0.0000624226,6.044974e-7,0.00008194645],"genre_scores_gemma":[0.9997546,0.00003650425,0.000017937127,0.000012246659,0.0000051122365,0.0000030571948,0.00011357271,8.261195e-7,0.00005612892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976176,0.00005838335,0.000028148463,0.00006603685,0.000031793374,0.000053933603],"domain_scores_gemma":[0.99909186,0.00020442379,0.00035853003,0.000050888597,0.00005203734,0.00024232717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045076225,0.00024721684,0.00034164777,0.0005834219,0.00042695264,0.00046145363,0.00019656969,0.0004567944,0.0021150352],"category_scores_gemma":[0.0014498761,0.00023855876,0.00026581105,0.0004955768,0.00023734613,0.00043443518,0.00023991389,0.00047109625,0.00029704458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039400885,0.000048750786,0.99833626,0.000005516925,0.000016556449,0.0001189499,0.00006493534,0.000036398196,0.0002620725,0.0000071860522,0.000046498546,0.00066280336],"study_design_scores_gemma":[0.000022970597,0.00034885766,0.9985781,0.0000050616536,0.000014344149,0.00052945357,0.00014446914,0.00020577059,0.000054596047,0.000019979556,0.00007233443,0.000004063462],"about_ca_topic_score_codex":0.0022819594,"about_ca_topic_score_gemma":0.0019308159,"teacher_disagreement_score":0.0022819594,"about_ca_system_score_codex":0.00025562447,"about_ca_system_score_gemma":0.00017573284,"threshold_uncertainty_score":0.0070754886},"labels":[],"label_agreement":null},{"id":"W2587896987","doi":"10.3851/imp3139","title":"Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Children's Hospital of Eastern Ontario; Université de Montréal; University Health Network; University of Toronto; Toronto General Hospital; McGill University Health Centre","funders":"Merck Canada; McGill University Health Centre; Gilead Sciences","keywords":"Raltegravir; Dosing; Medicine; Therapeutic drug monitoring; Drug; Gestational age; Pediatrics; Pregnancy; Drug resistance; Human immunodeficiency virus (HIV); Viral load; Pharmacology; Antiretroviral therapy; Immunology; Biology","score_opus":0.023197962399288497,"score_gpt":0.3033020600364695,"score_spread":0.28010409763718097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587896987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98539156,0.0029653679,0.0024180133,0.004167558,0.00018031763,0.00006687105,0.00006526731,0.00007113412,0.0046739643],"genre_scores_gemma":[0.994951,0.0015530741,0.0019009789,0.0006863668,0.00015101425,0.00001490177,0.000025077441,0.00001756551,0.00070006505],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996138,0.00008466814,0.000066857785,0.000057647547,0.00007608664,0.000100897094],"domain_scores_gemma":[0.99888843,0.0004655207,0.00029973208,0.000056119614,0.000055155535,0.00023507311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032965644,0.00055525545,0.0006922101,0.0010352525,0.0011899576,0.0007225389,0.0006443455,0.0021659352,0.0007505171],"category_scores_gemma":[0.004007129,0.0004536847,0.0006619251,0.00037137163,0.00074906374,0.0005447823,0.00082875724,0.002026356,0.00020738637],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036790676,0.000020106518,0.0073322207,0.000016679336,0.000003132756,0.9889965,0.00020189228,0.000049666392,0.00082555873,0.00015978063,0.000095003146,0.0022626037],"study_design_scores_gemma":[0.000007359643,0.00021413331,0.004576141,0.000033506534,0.000014449084,0.9921886,0.00023319908,0.00034577036,0.0018354988,0.00011984638,0.0004229751,0.00000851672],"about_ca_topic_score_codex":0.0016491485,"about_ca_topic_score_gemma":0.0027124472,"teacher_disagreement_score":0.0021659352,"about_ca_system_score_codex":0.000946126,"about_ca_system_score_gemma":0.0008383029,"threshold_uncertainty_score":0.0068646073},"labels":[],"label_agreement":null},{"id":"W2589708348","doi":"10.3851/imp3145","title":"Increases in CD4 <sup>+</sup> T-Cell Count at Antiretroviral Therapy Initiation among HIV-Positive Illicit Drug users during a Treatment-as-Prevention Initiative in Canada","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Simon Fraser University; University of Calgary","funders":"National Institutes of Health; International AIDS Society; National Institute on Drug Abuse; Canada Research Chairs; ViiV Healthcare; Gilead Sciences; Ministry of Health, British Columbia; Leverhulme Trust; Bristol-Myers Squibb","keywords":"Hazard ratio; Medicine; Proportional hazards model; Viral load; Treatment as prevention; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Cohort; Prospective cohort study; Cohort study; Immunology; Demography; Confidence interval","score_opus":0.013778993391863519,"score_gpt":0.24177840340967796,"score_spread":0.22799941001781443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589708348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954659,0.00048520142,0.00013702491,0.00047488793,0.0000089649,0.000036919693,0.0023872089,0.00001685669,0.0009869784],"genre_scores_gemma":[0.99849296,0.00023883801,0.00014459246,0.0000849371,0.0000048970073,0.0000088693305,0.00055926084,0.0000028633046,0.00046277442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999102,0.00008351455,0.000048122434,0.00013824589,0.00024852148,0.00037956162],"domain_scores_gemma":[0.9980629,0.0001709489,0.0005375095,0.00005308674,0.0005741149,0.0006014882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006393395,0.00023870257,0.0003042937,0.00081506727,0.0015238589,0.0012391419,0.0010949314,0.00038652463,0.0015408326],"category_scores_gemma":[0.0024751285,0.00030448844,0.00053058536,0.0020095024,0.00055202516,0.0003840337,0.0008574042,0.00085414737,0.000099784345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051878484,0.00001988953,0.9965996,0.000016480211,0.000018901197,0.00003386622,0.0002475116,0.00011106477,0.00009362881,0.00005584171,0.00034994757,0.002401405],"study_design_scores_gemma":[0.0000039291754,0.00001667238,0.9985607,0.000015582278,0.000019471143,0.000030313897,0.00052455225,0.00043223263,0.00006365641,0.000017954291,0.00030997026,0.000004945022],"about_ca_topic_score_codex":0.9922232,"about_ca_topic_score_gemma":0.9930155,"teacher_disagreement_score":0.023680795,"about_ca_system_score_codex":0.023680795,"about_ca_system_score_gemma":0.02972704,"threshold_uncertainty_score":0.17181695},"labels":[],"label_agreement":null},{"id":"W2591603178","doi":"","title":"Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression (Antiviral Theraphy (2007) 12 (1147-1156))","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Reproductive tract infections research","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Microbicides for sexually transmitted diseases; Herpes simplex virus; Virology; DNA; Gene; Biology; Virus; Medicine; Genetics; Population","score_opus":0.02200983258415449,"score_gpt":0.27325432576940867,"score_spread":0.25124449318525416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591603178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96181965,0.014535546,0.011984783,0.00038485456,0.0001621688,0.000095385956,0.00029142902,0.00017076865,0.0105555095],"genre_scores_gemma":[0.97518426,0.0050982507,0.008891236,0.00014892573,0.00008332199,0.000092873095,0.00035445855,0.000019670133,0.010126946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999361,0.000014578169,0.0000027478432,0.00000781542,0.000021860871,0.000016926686],"domain_scores_gemma":[0.9999112,0.000026007929,0.000031078234,0.000006026555,0.000008300157,0.000017328386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018765888,0.0002726616,0.00015021565,0.0002241204,0.00018301253,0.0002422548,0.00013993811,0.00032779487,0.0027658672],"category_scores_gemma":[0.0001884701,0.0001277465,0.00012597135,0.00013847467,0.00020146235,0.00019692442,0.00018607844,0.00045305048,0.0008916733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030952686,0.000047980957,0.00022873872,0.00005925236,0.000004887173,0.00006935076,0.00001193893,0.0002001475,0.969282,0.0008494947,0.00024123339,0.02869543],"study_design_scores_gemma":[0.00005999501,0.000831459,0.0019842787,0.00001038542,0.00001549693,0.0006040116,0.00001277894,0.0006109796,0.98729604,0.00018448809,0.008383495,0.0000065760646],"about_ca_topic_score_codex":0.00015765904,"about_ca_topic_score_gemma":0.00021867969,"teacher_disagreement_score":0.0027658672,"about_ca_system_score_codex":0.00012245498,"about_ca_system_score_gemma":0.0001362217,"threshold_uncertainty_score":0.009252727},"labels":[],"label_agreement":null},{"id":"W2600310501","doi":"10.3851/imp3158","title":"Peramivir Susceptibilities of Recombinant Influenza A and B Variants Selected with Various Neuraminidase Inhibitors","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Zanamivir; Neuraminidase; Neuraminidase inhibitor; Oseltamivir; Virology; Recombinant DNA; Influenzavirus B; Mutant; Influenza A virus; Hemagglutinin (influenza); Chemistry; Orthomyxoviridae; Biology; Virus; Microbiology; Medicine; Gene; Biochemistry; Coronavirus disease 2019 (COVID-19)","score_opus":0.05447669347885111,"score_gpt":0.3339081648260733,"score_spread":0.2794314713472222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600310501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867517,0.00029056796,0.00032811688,0.000014573913,0.000008643021,0.000014879326,0.00035490294,0.000012076911,0.00030095543],"genre_scores_gemma":[0.9968659,0.00026839194,0.0012744345,0.0000256885,0.000006323156,0.000033097684,0.001022992,0.000017129652,0.00048602239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99964666,0.000061510946,0.000061492356,0.00006500687,0.00011087905,0.000054541797],"domain_scores_gemma":[0.99970585,0.000072157745,0.00006461593,0.00003403741,0.00007174802,0.00005159213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026589466,0.00042389304,0.00027301014,0.0002423992,0.00012499366,0.00024672705,0.00033666607,0.0003325729,0.000748622],"category_scores_gemma":[0.00040034938,0.00014493824,0.00029496386,0.00032059554,0.00015620397,0.00019252907,0.00021521971,0.00061992137,0.00025948658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019578538,0.000080940976,0.0010190011,0.00002651937,0.000017482009,0.000031317923,0.000047836267,0.00020223987,0.9974254,0.000027343916,0.000039607006,0.0008865414],"study_design_scores_gemma":[0.000024356044,0.0017140524,0.01172442,0.000006551434,0.000055620156,0.00046238964,0.0000741971,0.001541276,0.9835128,0.000026180258,0.00084461237,0.000013513791],"about_ca_topic_score_codex":0.001254082,"about_ca_topic_score_gemma":0.00083200174,"teacher_disagreement_score":0.001254082,"about_ca_system_score_codex":0.00030270373,"about_ca_system_score_gemma":0.00013095922,"threshold_uncertainty_score":0.0025044084},"labels":[],"label_agreement":null},{"id":"W2601970093","doi":"10.3851/imp3162","title":"Progressive Multifocal Leukoencephalopathy due to John Cunningham (JC) virus following Allogeneic Haematopoietic Cell Transplantation","year":2016,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Progressive multifocal leukoencephalopathy; JC virus; Complication; Medicine; Transplantation; Leukoencephalopathy; Hematopoietic stem cell transplantation; Immunology; Virus; Pathology; Internal medicine; Disease","score_opus":0.033874558779755023,"score_gpt":0.3437304782448088,"score_spread":0.30985591946505375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601970093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011215364,0.9974093,0.000095589414,0.00020890038,0.000119661694,0.0000069979305,0.000013408575,0.0000052682785,0.0010193763],"genre_scores_gemma":[0.006377513,0.99276745,0.0001514715,0.00021668526,0.00017414289,0.0000043390623,0.000024232664,0.0000012836633,0.00028280527],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99976486,0.00003951701,0.00007234598,0.00003029019,0.00007360802,0.000019304933],"domain_scores_gemma":[0.9996649,0.00014101471,0.000108693304,0.000010082409,0.00005246945,0.00002286064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036869806,0.0005028165,0.0008925441,0.0028662726,0.00040339827,0.0007406616,0.00064817554,0.0008601541,0.0012098236],"category_scores_gemma":[0.0009775814,0.00018847962,0.0003752087,0.0027597712,0.00046855537,0.0009856861,0.00050776894,0.00085565314,0.0005111821],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115026814,0.00011345839,0.0025232146,0.04305567,0.00029507585,0.027760493,0.00042376335,0.00035059208,0.003825166,0.0016518626,0.019274136,0.9006115],"study_design_scores_gemma":[0.000053240692,0.0002972953,0.010286591,0.022709066,0.0009248696,0.29761767,0.0008004045,0.0002240803,0.0028818138,0.0029200688,0.6612013,0.00008357713],"about_ca_topic_score_codex":0.001688445,"about_ca_topic_score_gemma":0.0035078896,"teacher_disagreement_score":0.0028662726,"about_ca_system_score_codex":0.00034948374,"about_ca_system_score_gemma":0.0011325312,"threshold_uncertainty_score":0.0040472746},"labels":[],"label_agreement":null},{"id":"W2687319114","doi":"10.3851/imp3181","title":"Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir","year":2017,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ledipasvir; NS5A; Daclatasvir; Viral quasispecies; Sofosbuvir; Medicine; Population; Internal medicine; Virology; Gastroenterology; Hepatitis C virus; Ribavirin; Hepacivirus; Virus","score_opus":0.06577570250110594,"score_gpt":0.33958179904916264,"score_spread":0.2738060965480567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2687319114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995659,0.00015064892,0.000059543694,0.000016173504,0.0000015399629,0.0000040159675,0.000054659493,0.0000021932585,0.00014534623],"genre_scores_gemma":[0.9996574,0.00003150082,0.000049481518,0.00001770487,0.0000032072512,0.0000034456198,0.00011287118,0.0000011114004,0.00012335092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961805,0.000074565796,0.000036409638,0.000107677246,0.000081450155,0.000081710234],"domain_scores_gemma":[0.9982292,0.00035066222,0.0008474215,0.0001395828,0.00018771923,0.00024549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010761578,0.00013308659,0.00034180397,0.00018462095,0.0004350386,0.00046983178,0.0001673764,0.00026001234,0.0007583072],"category_scores_gemma":[0.0015935525,0.00011990277,0.00016260658,0.00023749394,0.00027922052,0.0004097235,0.00025822816,0.00056078826,0.00016500722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020811744,0.0002855797,0.9508568,0.000057887548,0.00009969835,0.00038892095,0.00045059354,0.00019744472,0.024408523,0.00003728469,0.00015794598,0.020978171],"study_design_scores_gemma":[0.000026825493,0.0024693792,0.99111956,0.000011809416,0.00007634391,0.0010519279,0.00020197326,0.00045495978,0.004128995,0.000034911478,0.0004141504,0.000009266161],"about_ca_topic_score_codex":0.0012997468,"about_ca_topic_score_gemma":0.0015112832,"teacher_disagreement_score":0.0012997468,"about_ca_system_score_codex":0.00036532417,"about_ca_system_score_gemma":0.0002688363,"threshold_uncertainty_score":0.0056913495},"labels":[],"label_agreement":null},{"id":"W2735274296","doi":"10.3851/imp3180","title":"<i>In vitro</i> Susceptibility of Geographically and Temporally Distinct Zika Viruses to Favipiravir and Ribavirin","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; Université Laval","funders":"","keywords":"Favipiravir; Zika virus; Ribavirin; Virology; In vitro; Meningoencephalitis; Biology; Virus; Medicine; Internal medicine; Disease; Coronavirus disease 2019 (COVID-19); Genetics","score_opus":0.014878541675537605,"score_gpt":0.28624494013483276,"score_spread":0.27136639845929517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735274296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990829,0.0044109276,0.0016140236,0.000056047746,0.000035204444,0.000051681047,0.00052727433,0.000026625154,0.0024491986],"genre_scores_gemma":[0.9946213,0.0015358939,0.0022779363,0.0000652001,0.000026976426,0.000035409965,0.00087800954,0.0000073843116,0.0005517921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99938965,0.0002448111,0.00010744321,0.00007932693,0.00010361229,0.00007503864],"domain_scores_gemma":[0.9996147,0.00016596104,0.000085681626,0.000039228355,0.000064143205,0.000030294597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004243111,0.0004282266,0.00031151087,0.0002702057,0.00013102705,0.0003304147,0.00025514895,0.000323533,0.000946492],"category_scores_gemma":[0.00063377956,0.00017127814,0.00045029476,0.00021597662,0.00019081663,0.00019121986,0.00024314126,0.00044339508,0.0002938675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046052586,0.00014012767,0.0035986237,0.00017479848,0.00006720342,0.0000660335,0.00009232947,0.0006431836,0.9902864,0.00006855483,0.00009107731,0.0043111704],"study_design_scores_gemma":[0.000024687602,0.005321034,0.03345293,0.000033707543,0.00013405064,0.0006373402,0.00014872338,0.0016340346,0.9570791,0.000038958948,0.001476935,0.000018512495],"about_ca_topic_score_codex":0.0020023172,"about_ca_topic_score_gemma":0.0016942242,"teacher_disagreement_score":0.0020023172,"about_ca_system_score_codex":0.00017072687,"about_ca_system_score_gemma":0.00015242727,"threshold_uncertainty_score":0.0039812922},"labels":[],"label_agreement":null},{"id":"W2736481878","doi":"10.3851/imp3185","title":"Frailty in Men Living with HIV: A Cross-Sectional Comparison of Three Frailty Instruments","year":2017,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"ViiV Healthcare; Gilead Sciences","keywords":"Medicine; Frailty Index; Frailty syndrome; Gerontology; Quality of life (healthcare); Cross-sectional study; Life expectancy; Logistic regression; Internal medicine; Population; Environmental health","score_opus":0.09134431394667682,"score_gpt":0.4006972473596791,"score_spread":0.3093529334130023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736481878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995621,0.00018171451,0.00006337069,0.0000120657305,0.0000024381616,0.000019344747,0.00007388372,6.250661e-7,0.0000844798],"genre_scores_gemma":[0.99948514,0.00010280414,0.000114324626,0.000014411846,0.000003868116,0.000025544303,0.00019439876,4.987209e-7,0.00005904823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998906,0.0005239426,0.00012081483,0.00014901208,0.00019841737,0.00010174327],"domain_scores_gemma":[0.9973194,0.00068499625,0.0010532278,0.00017301258,0.00034318832,0.0004261533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039048032,0.00039494384,0.00048037758,0.00095506286,0.0004949317,0.00083701743,0.00035618537,0.00052928925,0.00060063426],"category_scores_gemma":[0.0058023725,0.00036105356,0.0008286542,0.00086594967,0.00046244508,0.0005779559,0.0011423973,0.00059665856,0.00011128426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012131856,0.00003716905,0.9987411,0.000012364794,0.00011615999,0.000010972376,0.00021495625,0.000017312434,0.000047647874,0.000007007876,0.000015146903,0.0006589588],"study_design_scores_gemma":[0.000009439147,0.00027719012,0.9990721,0.000008648535,0.000053618427,0.000056707253,0.00031595273,0.00010860709,0.000021997972,0.000013199318,0.000059553222,0.00000302209],"about_ca_topic_score_codex":0.0069119637,"about_ca_topic_score_gemma":0.008724695,"teacher_disagreement_score":0.0069119637,"about_ca_system_score_codex":0.000359707,"about_ca_system_score_gemma":0.0003190667,"threshold_uncertainty_score":0.020650804},"labels":[],"label_agreement":null},{"id":"W2769969382","doi":"10.3851/imp3211","title":"Article Commentary: Frailty: Is Thy Name…..Universal? Evolving Challenges of Managing Effectively Treated Older People Living with HIV","year":2017,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Frailty Index; Operationalization; Gerontology; Vulnerability (computing); Human immunodeficiency virus (HIV); Medicine; Quality of life (healthcare); Population; Construct (python library); Scale (ratio); Computer science; Family medicine; Computer security; Environmental health","score_opus":0.022389776916153847,"score_gpt":0.2676678152981051,"score_spread":0.24527803838195128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769969382","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006345883,0.0011595428,0.00007134946,0.9706471,0.025674254,0.000020419418,0.00007942235,0.00004502487,0.001668286],"genre_scores_gemma":[0.0057113254,0.0016320075,0.0001739214,0.91942203,0.06931216,0.0000454693,0.000052857908,0.000031338874,0.0036188508],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759454,0.0009846725,0.00029440457,0.00029203162,0.00057342916,0.00026084943],"domain_scores_gemma":[0.9906713,0.0052378024,0.0006170938,0.00021442845,0.002224839,0.0010345712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027676392,0.0008881734,0.001531485,0.0008008964,0.0029542742,0.0021466366,0.003099041,0.043345112,0.008069774],"category_scores_gemma":[0.026579509,0.0006698808,0.0011851585,0.00073441153,0.00237786,0.0044636056,0.0011457435,0.036337722,0.007495387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004016751,0.0000293191,0.00053502753,0.000090211484,0.000012383531,0.0031102162,0.00019299888,0.000057320638,0.00008693112,0.00076784554,0.99053955,0.0045380825],"study_design_scores_gemma":[0.0002837701,0.00017770227,0.0021866667,0.0013160816,0.00007755194,0.016492492,0.0013241591,0.0010836245,0.0004922283,0.007780629,0.96862966,0.00015537697],"about_ca_topic_score_codex":0.006301148,"about_ca_topic_score_gemma":0.0059910854,"teacher_disagreement_score":0.043345112,"about_ca_system_score_codex":0.0041147587,"about_ca_system_score_gemma":0.0038933854,"threshold_uncertainty_score":0.029854834},"labels":[],"label_agreement":null},{"id":"W2890738265","doi":"10.3851/imp3265","title":"Substance use Patterns and HIV-1 RNA Viral Load Rebound among HIV-Positive Illicit Drug users in a Canadian Setting","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV, Drug Use, Sexual Risk","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"British Columbia Centre on Substance Use; St. Paul's Hospital; University of British Columbia; University of Alberta","funders":"National Institute on Drug Abuse","keywords":"Viral load; Medicine; Hazard ratio; Proportional hazards model; Internal medicine; Prospective cohort study; Cohort; Cohort study; Human immunodeficiency virus (HIV); Young adult; Confidence interval; Immunology","score_opus":0.024127953394166287,"score_gpt":0.29407368982739507,"score_spread":0.2699457364332288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890738265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221367,0.0009862742,0.00016497314,0.0003012106,0.000011363601,0.000086291446,0.004622251,0.000013745434,0.0016001912],"genre_scores_gemma":[0.9967242,0.0005634582,0.00027869167,0.000095584255,0.000006484034,0.000024425888,0.0016418977,0.000008032488,0.00065717066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868983,0.00013447249,0.00007449286,0.00022208813,0.00036392917,0.0005151928],"domain_scores_gemma":[0.99682343,0.00025520838,0.0007915093,0.00014180313,0.0011853141,0.0008026802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014202251,0.0006927394,0.0005791677,0.0019339425,0.0038449245,0.001906005,0.0020726465,0.0007568402,0.0030596969],"category_scores_gemma":[0.003608337,0.00072337594,0.0010954452,0.004579378,0.0010082115,0.0005344689,0.0014596629,0.0012482504,0.00029503193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110790905,0.000044691442,0.99587303,0.000050573457,0.000063032974,0.00009605397,0.0006221674,0.00013874803,0.00009779735,0.00009256353,0.0005296705,0.002280786],"study_design_scores_gemma":[0.00001752242,0.000049016795,0.9966486,0.00007183211,0.00007222179,0.00011162816,0.0013970137,0.0006195603,0.000049251787,0.000042715506,0.00089458947,0.000026012793],"about_ca_topic_score_codex":0.995708,"about_ca_topic_score_gemma":0.9972451,"teacher_disagreement_score":0.03445671,"about_ca_system_score_codex":0.03445671,"about_ca_system_score_gemma":0.033700332,"threshold_uncertainty_score":0.25000215},"labels":[],"label_agreement":null},{"id":"W2898149304","doi":"10.3851/imp3274","title":"Optimizing Concentrations of Concomitant Antiretrovirals by Reducing Etravirine Doses: Two Case Reports of Complex Drug-drug Interactions","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Etravirine; Darunavir; Elvitegravir; Dolutegravir; Raltegravir; Drug; Pharmacology; Medicine; Concomitant; Drug interaction; Enfuvirtide; Maraviroc; Human immunodeficiency virus (HIV); Internal medicine; Antiretroviral therapy; Virology; Viral load; Immunology","score_opus":0.03408805450868194,"score_gpt":0.33665609141918984,"score_spread":0.3025680369105079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898149304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593911,0.0056808703,0.011305354,0.0065151877,0.0009552538,0.00040668194,0.00023045077,0.0002237368,0.015291336],"genre_scores_gemma":[0.98887247,0.001735611,0.0037297448,0.0016222654,0.0012198436,0.000069064634,0.00011249526,0.00005490105,0.0025836877],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99858177,0.00022807198,0.00021136706,0.00030633213,0.00022511497,0.00044727675],"domain_scores_gemma":[0.9954723,0.0014951084,0.0011938349,0.00042407724,0.00029534663,0.0011193072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006749504,0.004219739,0.0013484913,0.0024108754,0.0024683622,0.0024128475,0.0018155212,0.008079108,0.0021108687],"category_scores_gemma":[0.0076505532,0.0018057714,0.0022407998,0.0012166852,0.0022996988,0.0026318016,0.002117228,0.006802904,0.00083559216],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004759544,0.000102106445,0.0063393293,0.000027012873,0.000021371692,0.9907736,0.00032927128,0.00013277575,0.00028125438,0.00025284605,0.0002883545,0.0014044465],"study_design_scores_gemma":[0.000012917299,0.000056010373,0.0013388096,0.000012062184,0.000019321235,0.99701715,0.00010146337,0.00024013252,0.0005552933,0.00012591822,0.0005047076,0.00001613631],"about_ca_topic_score_codex":0.0028018008,"about_ca_topic_score_gemma":0.002251572,"teacher_disagreement_score":0.008079108,"about_ca_system_score_codex":0.001376553,"about_ca_system_score_gemma":0.00079295726,"threshold_uncertainty_score":0.009987652},"labels":[],"label_agreement":null},{"id":"W2898792243","doi":"10.3851/imp3278","title":"Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Toronto General Hospital; University of Toronto; Regina General Hospital; University of Alberta; University of Saskatchewan; Research Canada","funders":"Daiichi Sankyo Europe; Gilead Sciences; Pfizer; Daiichi-Sankyo; Bristol-Myers Squibb","keywords":"Sofosbuvir; Daclatasvir; Ribavirin; Medicine; Internal medicine; Cirrhosis; Hepatitis C; Gastroenterology; Clinical endpoint; Adverse effect; Hepatitis C virus; Virology; Clinical trial; Virus","score_opus":0.027791113161629178,"score_gpt":0.3371077543208006,"score_spread":0.3093166411591714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898792243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636346,0.0014954574,0.00021127074,0.00019647763,0.000052062333,0.00095860264,0.00024943944,0.000030700583,0.00044251696],"genre_scores_gemma":[0.9923179,0.0012950227,0.0018007373,0.0005908435,0.00017930738,0.0019076326,0.0010758104,0.000017198337,0.0008154588],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985814,0.0008942005,0.00007525555,0.000109733584,0.00013047126,0.00020894692],"domain_scores_gemma":[0.99817073,0.00031253858,0.0002799505,0.00013626559,0.00015485495,0.0009456209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004560283,0.0013885649,0.0020474615,0.0004462403,0.00054423994,0.0007552804,0.00069065404,0.0012371154,0.0023813704],"category_scores_gemma":[0.0016604357,0.0005795156,0.0017796499,0.00061057747,0.0010622421,0.0006411872,0.00046010345,0.0021753532,0.00045012825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8335558,0.069469504,0.016948259,0.0007383475,0.0016187062,0.00019251525,0.00027360968,0.0013338785,0.012542867,0.00011413985,0.0013721846,0.06184014],"study_design_scores_gemma":[0.6978794,0.2842999,0.014815674,0.00003534805,0.00037307348,0.00017039888,0.000045784018,0.00066187937,0.00097022747,0.000054146018,0.0006722008,0.000021954173],"about_ca_topic_score_codex":0.0020005533,"about_ca_topic_score_gemma":0.0028278022,"teacher_disagreement_score":0.004560283,"about_ca_system_score_codex":0.0009255996,"about_ca_system_score_gemma":0.0026050939,"threshold_uncertainty_score":0.02411735},"labels":[],"label_agreement":null},{"id":"W2900996895","doi":"10.3851/imp3250","title":"Expert Opinion on Managing Chronic HCV in Patients with Non-Hodgkin Lymphoma and other Extrahepatic Malignancies","year":2018,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Lymphoma; Internal medicine; Epidemiology; Hepatitis C virus; Risk factor; Non-Hodgkin's lymphoma; Oncology; Immunology; Gastroenterology; Virus","score_opus":0.06293111279938804,"score_gpt":0.3728573706064033,"score_spread":0.3099262578070152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900996895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014435893,0.97728467,0.00031322052,0.011808837,0.0050025727,0.00003568366,0.0001445751,0.000023363116,0.005242746],"genre_scores_gemma":[0.0014158319,0.9812909,0.0005536977,0.008849284,0.0047040433,0.000039886694,0.0002093442,0.0000059149547,0.00293119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942386,0.00018211544,0.0001116489,0.00006018103,0.00018628259,0.000035926038],"domain_scores_gemma":[0.9983418,0.0007361194,0.0003217226,0.000026607198,0.00047068548,0.000103027305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079898577,0.0006384578,0.0010874097,0.0012560603,0.00028149007,0.0009569209,0.0012494499,0.0024325727,0.017938634],"category_scores_gemma":[0.004221537,0.00016230358,0.0009277588,0.0009483452,0.0003128105,0.0015322603,0.00062110095,0.0018652634,0.0056617092],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006157027,0.000038792605,0.00015508167,0.032720886,0.00013411169,0.00034988913,0.000084798114,0.00016363323,0.00035377388,0.0013010829,0.34404245,0.62059397],"study_design_scores_gemma":[0.000051760246,0.000037641836,0.0005683393,0.03411368,0.00024349878,0.0022557992,0.00008782138,0.000071500624,0.000120569384,0.0016638107,0.96076363,0.00002194578],"about_ca_topic_score_codex":0.0010005082,"about_ca_topic_score_gemma":0.0021531158,"teacher_disagreement_score":0.017938634,"about_ca_system_score_codex":0.000518909,"about_ca_system_score_gemma":0.0011440667,"threshold_uncertainty_score":0.06001073},"labels":[],"label_agreement":null},{"id":"W2909866007","doi":"10.3851/imp3287","title":"Impact of three Decades of Antiretroviral Therapy in a Longitudinal Population Cohort Study","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pill; Regimen; Population; Efavirenz; Viral load; Cohort study; Mortality rate; Internal medicine; Cohort; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Pharmacology; Environmental health","score_opus":0.03908051172415777,"score_gpt":0.3525158055405722,"score_spread":0.31343529381641444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909866007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944946,0.00074214075,0.00018251718,0.00059854664,0.000056374112,0.000023768442,0.003027097,0.000010998285,0.00086386496],"genre_scores_gemma":[0.9965837,0.0003126672,0.00018188285,0.0002957173,0.000038910373,0.00002571176,0.0021103702,0.000005470008,0.00044550994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837226,0.0005056166,0.000093376046,0.00029963377,0.00027168577,0.00045735555],"domain_scores_gemma":[0.9958851,0.00038385225,0.0012891649,0.00055601005,0.000775109,0.0011107636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040091984,0.00035162963,0.00036607214,0.00089273124,0.0013426635,0.0013679132,0.0007837292,0.0009815051,0.0013725857],"category_scores_gemma":[0.0042769997,0.00032627338,0.0011011064,0.0015502239,0.0003984132,0.00070172787,0.001114847,0.0013621963,0.00034396272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006813225,0.00002577492,0.9987097,0.0000029393818,0.00010807969,0.00004178969,0.0000861278,0.000025041969,0.000034075987,0.000026225745,0.00025201976,0.0006201729],"study_design_scores_gemma":[0.0000055002984,0.00004902068,0.9990202,0.000009380777,0.00005907144,0.000058119862,0.0002387755,0.00012361583,0.0000110739575,0.0000311889,0.00038945588,0.0000045777633],"about_ca_topic_score_codex":0.17520459,"about_ca_topic_score_gemma":0.21754554,"teacher_disagreement_score":0.17520459,"about_ca_system_score_codex":0.001790108,"about_ca_system_score_gemma":0.0026010703,"threshold_uncertainty_score":0.34836954},"labels":[],"label_agreement":null},{"id":"W2921597040","doi":"10.3851/imp3302","title":"Tenofovir and Emtricitabine Resistance among Antiretroviral-Naive Patients in the Canadian Observational Cohort Collaboration: Implications for PrEP","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University Health Network; Ottawa Hospital; Institute for Clinical Evaluative Sciences; Simon Fraser University; McGill University Health Centre; AIDS Vancouver; St. Michael's Hospital; University of British Columbia; Public Health Ontario; University of Toronto; HIV Legal Network; Maple Leaf Medical Clinic; Women's College Hospital","funders":"Canadian Institutes of Health Research; Ministry of Health, British Columbia; National Institute on Drug Abuse; McGill University","keywords":"Emtricitabine; Medicine; Internal medicine; Cumulative incidence; Drug resistance; Hazard ratio; Incidence (geometry); Cohort; Regimen; Cohort study; Viral load; Antiretroviral therapy; Virology; Human immunodeficiency virus (HIV); Confidence interval; Biology; Genetics","score_opus":0.04002693143752805,"score_gpt":0.3465619635941738,"score_spread":0.30653503215664574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921597040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709036,0.0065233028,0.001171423,0.005092869,0.00014479089,0.00016206472,0.0134891365,0.000039209564,0.0024736172],"genre_scores_gemma":[0.9941473,0.001332233,0.0010446509,0.00051345705,0.000054240245,0.00005516696,0.0025793384,0.000015626882,0.0002579635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938933,0.001335515,0.00043214168,0.0013230055,0.0013691932,0.0016468754],"domain_scores_gemma":[0.9883024,0.0017991483,0.0035250161,0.0010002267,0.0031599202,0.0022132804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007968193,0.000670872,0.0007691002,0.0015925568,0.0025530462,0.0016563911,0.0028031175,0.00093134755,0.0016794397],"category_scores_gemma":[0.01825345,0.00047731528,0.0017156393,0.004473469,0.00076187996,0.00069860346,0.0014749615,0.001368916,0.00010129922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016110265,0.000015228814,0.9953448,0.00005387449,0.00018993867,0.000058542315,0.00022105062,0.00009391892,0.000051870415,0.00021463205,0.0011908871,0.0024039964],"study_design_scores_gemma":[0.00002671705,0.000032684908,0.99668485,0.00009353811,0.00021128688,0.00013202187,0.00042712988,0.0010452813,0.00004752511,0.00012535488,0.0011531726,0.00002042611],"about_ca_topic_score_codex":0.9708926,"about_ca_topic_score_gemma":0.9661066,"teacher_disagreement_score":0.029107392,"about_ca_system_score_codex":0.011620889,"about_ca_system_score_gemma":0.031766232,"threshold_uncertainty_score":0.084315896},"labels":[],"label_agreement":null},{"id":"W2921686214","doi":"10.3851/imp3304","title":"Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data","year":2018,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"American Association for the Study of Liver Diseases","keywords":"Medicine; Meta-analysis; Chronic hepatitis; Internal medicine; Ribavirin; Gastroenterology; Virology; Virus","score_opus":0.4278429051974251,"score_gpt":0.44766296908937825,"score_spread":0.01982006389195312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921686214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037495617,0.99417734,0.00063454907,0.00021863732,0.00010394879,0.00027720866,0.0005935023,0.000023245464,0.00022203675],"genre_scores_gemma":[0.18305482,0.80875295,0.003483538,0.0011737902,0.0002079688,0.0016275743,0.0013765177,0.000046046378,0.00027680572],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98359066,0.008759021,0.0045169825,0.0013708877,0.0013693757,0.00039310707],"domain_scores_gemma":[0.96137476,0.02985355,0.005338271,0.0010393119,0.0021100147,0.00028407085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025111584,0.0025073325,0.017539335,0.006685222,0.00057221163,0.0033734094,0.0020152568,0.002080507,0.0023806307],"category_scores_gemma":[0.052139394,0.001470782,0.037333652,0.0072291247,0.0007409373,0.0017403292,0.0015127582,0.001578449,0.0002817841],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018996701,0.00002442595,0.0036200543,0.43538618,0.5405205,0.00010313125,0.00008210531,0.0007195367,0.0001899055,0.00018104052,0.0007310566,0.016542472],"study_design_scores_gemma":[0.00061210804,0.0001699732,0.0031730547,0.03892724,0.95447505,0.00008911782,0.000032294687,0.00020847408,0.00012320011,0.0003000321,0.0018629932,0.000026523647],"about_ca_topic_score_codex":0.007100381,"about_ca_topic_score_gemma":0.012786443,"teacher_disagreement_score":0.025111584,"about_ca_system_score_codex":0.002989014,"about_ca_system_score_gemma":0.004940214,"threshold_uncertainty_score":0.13280433},"labels":[],"label_agreement":null},{"id":"W2943441727","doi":"10.3851/imp3312","title":"Lean Mass Declines Consistently over 10 Years in People living with HIV on Antiretroviral Therapy, with Patterns Differing by Sex","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Institute on Aging; National Institutes of Health; Gilead Sciences","keywords":"Medicine; Cohort; Lean body mass; Integrase inhibitor; Antiretroviral therapy; Demography; Wasting; Viral load; Human immunodeficiency virus (HIV); Dolutegravir; Efavirenz; Internal medicine; Immunology","score_opus":0.017976438236219344,"score_gpt":0.2897836045540148,"score_spread":0.27180716631779545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943441727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939932,0.003113033,0.00024792954,0.00021738421,0.000022480304,0.000010869935,0.001312109,0.000022551574,0.0010603744],"genre_scores_gemma":[0.9976338,0.0007768597,0.00020834233,0.00008094361,0.00002529003,0.000012999508,0.00085890666,0.0000037824016,0.00039899466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974924,0.000057044115,0.000026057736,0.00006890638,0.000047270038,0.000051357798],"domain_scores_gemma":[0.9988588,0.00020039445,0.00066287833,0.00004525549,0.00012524528,0.00010742393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004995705,0.00018240992,0.00026140956,0.0006670598,0.00033041314,0.0005806612,0.00035178958,0.00036541876,0.0012210076],"category_scores_gemma":[0.0022968058,0.00017511379,0.00022724304,0.0010661895,0.0002711205,0.0004299714,0.000496118,0.00038763168,0.00020543778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113766386,0.000015570062,0.99114484,0.000031104282,0.000051065606,0.000057300284,0.0001054561,0.00005677894,0.000120513236,0.000021070311,0.00019863607,0.008083838],"study_design_scores_gemma":[0.0000024890116,0.000065831155,0.99908376,0.000017194388,0.00002073078,0.00016576314,0.0001241028,0.000096235075,0.000023445304,0.000050109415,0.00034825213,0.0000020620191],"about_ca_topic_score_codex":0.007157402,"about_ca_topic_score_gemma":0.011977107,"teacher_disagreement_score":0.007157402,"about_ca_system_score_codex":0.00023706365,"about_ca_system_score_gemma":0.00025965436,"threshold_uncertainty_score":0.014231503},"labels":[],"label_agreement":null},{"id":"W2965382341","doi":"10.3851/imp3326","title":"Antiviral drug Utilization and Annual Expenditures for Patients with Chronic HBV Infection in Guangzhou, China, in 2008–2015","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Drug; Medicine; Antiviral drug; Virology; Internal medicine; Hepatitis B virus; Environmental health; Pharmacology; Virus","score_opus":0.01799540470010741,"score_gpt":0.3100485782797768,"score_spread":0.29205317357966937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965382341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833316,0.00039724048,0.000029462242,0.0000723881,0.0000033253145,0.0000044755616,0.0009553977,0.000002846645,0.00020172363],"genre_scores_gemma":[0.9988444,0.00017872639,0.000034158744,0.000017186563,0.000006398119,0.000004877464,0.0008264434,5.0190033e-7,0.00008720228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961406,0.00006619443,0.0001029586,0.00006668886,0.000082047314,0.00006800645],"domain_scores_gemma":[0.99901974,0.00007890303,0.000649665,0.000036042748,0.00008961791,0.00012600064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004942625,0.00019771932,0.00014887283,0.0009178074,0.00025139572,0.00034108345,0.00025123468,0.00019114677,0.000872676],"category_scores_gemma":[0.0010432344,0.00018818531,0.00043306145,0.0010093186,0.00022567678,0.00035249256,0.00037199154,0.0002776008,0.00008029615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022417666,0.000005348246,0.99920267,0.000010952946,0.00002612177,0.000021909036,0.000025541565,0.000059478534,0.000035663797,0.000010535615,0.000085909385,0.00049354485],"study_design_scores_gemma":[0.0000016296499,0.0000133383965,0.99960464,0.0000046181403,0.000012734774,0.0000503624,0.000054560835,0.0001412742,0.000015511623,0.000004347383,0.000095886375,0.0000010622705],"about_ca_topic_score_codex":0.04463712,"about_ca_topic_score_gemma":0.04740247,"teacher_disagreement_score":0.04463712,"about_ca_system_score_codex":0.0014129948,"about_ca_system_score_gemma":0.0008623847,"threshold_uncertainty_score":0.088754594},"labels":[],"label_agreement":null},{"id":"W3004898529","doi":"10.3851/imp3344","title":"Molecular Pathway of Influenza Pan-neuraminidase Inhibitor Resistance in an Immunocompromised Patient","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Zanamivir; Oseltamivir; Neuraminidase; Virology; Neuraminidase inhibitor; Biology; Population; Virus; Microbiology; Medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.05973399212992531,"score_gpt":0.36574805558314716,"score_spread":0.30601406345322185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004898529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954406,0.000984952,0.0002783442,0.0003312823,0.000013654576,0.000039722057,0.000117458665,0.000011819214,0.0027822847],"genre_scores_gemma":[0.99870694,0.0003322362,0.00022727846,0.00014726353,0.0000191223,0.0000069394027,0.00008820938,0.000002077095,0.0004698571],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99991345,0.000011605664,0.000009547569,0.000021501462,0.000013361719,0.000030603984],"domain_scores_gemma":[0.99989665,0.00001621704,0.000033924123,0.000005731016,0.000012541481,0.000034866927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008631508,0.00022599695,0.0002283233,0.00029926831,0.00055485,0.00043131318,0.00016037568,0.00040206301,0.0027854976],"category_scores_gemma":[0.00033236557,0.00012884349,0.00024607326,0.00025239936,0.0002153632,0.00027746745,0.0002761413,0.0005405418,0.00046497345],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008638518,0.00032490835,0.73229784,0.000119490345,0.000042221494,0.22070917,0.00092646875,0.00028434966,0.027292324,0.00064384856,0.0011836599,0.015311841],"study_design_scores_gemma":[0.00008223578,0.0015494424,0.55990803,0.00010026516,0.00012671755,0.41503423,0.0021822965,0.0019494208,0.011015068,0.0007316751,0.007288387,0.0000322078],"about_ca_topic_score_codex":0.0008605853,"about_ca_topic_score_gemma":0.0007539734,"teacher_disagreement_score":0.0027854976,"about_ca_system_score_codex":0.00040282262,"about_ca_system_score_gemma":0.00022523996,"threshold_uncertainty_score":0.009318411},"labels":[],"label_agreement":null},{"id":"W3007322252","doi":"10.3851/imp3346","title":"The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Osteoporosis Canada; University Health Network; St. Michael's Hospital; Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Emtricitabine; Femoral neck; Osteoporosis; Bone mineral; Meta-analysis; Internal medicine; Randomized controlled trial; Tenofovir; Relative risk; Pre-exposure prophylaxis; Surgery; Human immunodeficiency virus (HIV); Confidence interval; Viral load; Antiretroviral therapy; Men who have sex with men","score_opus":0.06372267784972224,"score_gpt":0.38213684510129964,"score_spread":0.3184141672515774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007322252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002050514,0.9967359,0.000283242,0.00015175981,0.00011420702,0.00020729267,0.00028652395,0.000014342013,0.00015621656],"genre_scores_gemma":[0.104753755,0.88972175,0.0022011246,0.0009126845,0.00029774682,0.0012966074,0.0005338088,0.000022158667,0.00026031834],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98829937,0.005981492,0.0028747888,0.0012139825,0.001225941,0.00040440465],"domain_scores_gemma":[0.98024327,0.015152223,0.0028313047,0.00041921678,0.001141215,0.00021284823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016799401,0.0033025779,0.0240494,0.007786941,0.00069916353,0.0039782375,0.0025296502,0.002680741,0.0039580343],"category_scores_gemma":[0.040374324,0.0017593941,0.035712674,0.0076531754,0.0009922925,0.0019452169,0.001569611,0.0020856585,0.0002978267],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018129016,0.00002700261,0.0021829773,0.50502115,0.47752804,0.00012511674,0.0000582721,0.00056471524,0.00016671077,0.00015299524,0.00050801574,0.011852215],"study_design_scores_gemma":[0.00077149837,0.0002257759,0.0023033952,0.042435512,0.95194244,0.000100948775,0.000034020453,0.00018629631,0.000111216614,0.00022810572,0.0016382494,0.000022544185],"about_ca_topic_score_codex":0.0101358015,"about_ca_topic_score_gemma":0.018704763,"teacher_disagreement_score":0.0240494,"about_ca_system_score_codex":0.0035115867,"about_ca_system_score_gemma":0.005033505,"threshold_uncertainty_score":0.088844836},"labels":[],"label_agreement":null},{"id":"W3030986286","doi":"10.3851/imp3361","title":"Antiviral Activity of PLK1-Targeting siRNA Delivered by Lipid Nanoparticles in HBV-Infected Hepatocytes","year":2019,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"Agence Nationale de la Recherche","keywords":"cccDNA; Virology; HBsAg; Hepatitis B virus; PLK1; Viability assay; Small interfering RNA; Biology; Molecular biology; Chemistry; Cell; Cell culture; Transfection; Cell cycle; Virus; Biochemistry","score_opus":0.018159777990590365,"score_gpt":0.2744658199071646,"score_spread":0.25630604191657425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030986286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667716,0.000747865,0.0013961468,0.000031206277,0.000015426525,0.000018252556,0.000106822336,0.00004527894,0.0009618417],"genre_scores_gemma":[0.9965252,0.0004793613,0.0013649306,0.000021883965,0.0000057209,0.000025677027,0.00014884218,0.00001451527,0.0014137843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993837,0.000012323794,0.0000070279557,0.000012977143,0.000015624117,0.000013730471],"domain_scores_gemma":[0.9999502,0.000013813061,0.000010907582,0.0000049667633,0.000009911766,0.000010172746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001573126,0.00025302076,0.00021540181,0.0001196846,0.00008279231,0.0001625108,0.00010290401,0.00018391185,0.0007210029],"category_scores_gemma":[0.00007684881,0.00007700352,0.00017594275,0.000076560464,0.00014674313,0.00013037586,0.00010709039,0.00023693212,0.00026214484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014347999,0.0000200807,0.00006962719,0.000050623075,0.0000040123577,0.000020479101,0.000018203029,0.00011189184,0.99842846,0.000026500436,0.000018956083,0.0010877396],"study_design_scores_gemma":[0.000010278965,0.00037826755,0.00061525614,0.0000027721426,0.000009357061,0.000026521246,0.000009925928,0.0006800429,0.9980268,0.000007254198,0.00023162384,0.0000018188201],"about_ca_topic_score_codex":0.00051346683,"about_ca_topic_score_gemma":0.00047864162,"teacher_disagreement_score":0.0007210029,"about_ca_system_score_codex":0.00017724062,"about_ca_system_score_gemma":0.00015289075,"threshold_uncertainty_score":0.0024120212},"labels":[],"label_agreement":null},{"id":"W3046958273","doi":"10.3851/imp3367","title":"Hepatitis B Core-Related Antigen Levels Predict Pegylated Interferon-α Therapy Response in HBeAg-Positive Chronic Hepatitis B","year":2019,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"HBsAg; Medicine; Pegylated interferon; HBeAg; Internal medicine; Hepatitis B; Gastroenterology; Lamivudine; Antigen; Chronic hepatitis; Immunology; Hepatitis B virus; Virus; Ribavirin","score_opus":0.029778533878021547,"score_gpt":0.2980232733590482,"score_spread":0.2682447394810267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046958273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995055,0.00029092852,0.00006408521,0.000023452118,0.0000030567246,0.000009733039,0.000023951598,0.000001945828,0.00007724919],"genre_scores_gemma":[0.999666,0.000053309657,0.00012827103,0.000019225383,0.0000070721317,0.0000074778986,0.00007822893,0.0000010079407,0.000039497503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996275,0.00023528696,0.000029202998,0.000039418843,0.00003525673,0.00003339288],"domain_scores_gemma":[0.998072,0.00092204195,0.00060643564,0.00006756061,0.00011940709,0.00021246742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013974912,0.00034391668,0.00045237906,0.00030420526,0.00013915464,0.00035988243,0.00015844272,0.00052402064,0.00082545023],"category_scores_gemma":[0.0029366687,0.00023154443,0.00027920346,0.00021689327,0.00025279121,0.00026626987,0.00016643078,0.00044564347,0.00020888529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008243841,0.00020702156,0.9804688,0.00004930393,0.00012748926,0.000036241585,0.000059972288,0.00033346374,0.0020719646,0.000009395283,0.00009762717,0.00829484],"study_design_scores_gemma":[0.001001829,0.0042666136,0.9894873,0.000024095818,0.00019469437,0.0003723535,0.000080935526,0.002958238,0.0011981087,0.000070363756,0.00033739593,0.000008097872],"about_ca_topic_score_codex":0.00029230883,"about_ca_topic_score_gemma":0.00039641926,"teacher_disagreement_score":0.0013974912,"about_ca_system_score_codex":0.00019134134,"about_ca_system_score_gemma":0.00018476571,"threshold_uncertainty_score":0.0073907375},"labels":[],"label_agreement":null},{"id":"W3196876339","doi":"10.1177/135965350801302s03","title":"The World Health Organization's global strategy for prevention and assessment of HIV drug resistance","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Developing country; Public health; Resource (disambiguation); Human immunodeficiency virus (HIV); Environmental health; Antiretroviral therapy; Economic growth; Viral load; Family medicine; Nursing; Surgery; Computer science","score_opus":0.029745058370603223,"score_gpt":0.3470594945262849,"score_spread":0.31731443615568167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196876339","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009542534,0.2543572,0.030870082,0.18150537,0.03778197,0.023430517,0.15879223,0.0041040084,0.29961616],"genre_scores_gemma":[0.039915208,0.37622267,0.14517702,0.06804305,0.009172802,0.016572734,0.1545487,0.0010021004,0.18934575],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99460757,0.0027509762,0.00042871136,0.00016405497,0.0016793752,0.00036926052],"domain_scores_gemma":[0.9909657,0.0012458556,0.001186682,0.0003819964,0.005210381,0.001009464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009834053,0.0036419828,0.0026191927,0.004514265,0.0006509061,0.0028028972,0.0031658404,0.0027062034,0.014160725],"category_scores_gemma":[0.007829631,0.00073906354,0.0012505655,0.004885922,0.0010783287,0.001639941,0.0025078002,0.004084183,0.008568119],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014529101,0.00021523195,0.0030189855,0.0029159011,0.00012869049,0.0001621254,0.00018347737,0.0004145529,0.0007004626,0.0031150826,0.7510426,0.23795767],"study_design_scores_gemma":[0.00014533813,0.00022929512,0.014000912,0.0038665098,0.000117879266,0.00022853933,0.00023731242,0.00040028506,0.0005055143,0.001292258,0.9789336,0.000042521082],"about_ca_topic_score_codex":0.02276331,"about_ca_topic_score_gemma":0.012077174,"teacher_disagreement_score":0.02276331,"about_ca_system_score_codex":0.0023344506,"about_ca_system_score_gemma":0.020187402,"threshold_uncertainty_score":0.052008033},"labels":[],"label_agreement":null},{"id":"W338559656","doi":"10.1177/135965350801300116","title":"Characterization of drug Resistance in Antiretroviral-Treated Patients Infected with HIV-1 CRF02_AG and AGK Subtypes in Mali and Burkina Faso","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"U.S. Public Health Service","keywords":"Efavirenz; Nevirapine; Stavudine; Virology; Lamivudine; Drug resistance; Zidovudine; Genotype; Reverse transcriptase; Population; Internal medicine; Medicine; Didanosine; Cohort; Biology; Viral load; Viral disease; Human immunodeficiency virus (HIV); Antiretroviral therapy; Polymerase chain reaction; Virus; Genetics; Gene","score_opus":0.0077590531039058944,"score_gpt":0.2155871698676818,"score_spread":0.2078281167637759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W338559656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99967194,0.00010023772,0.000021283042,0.000018439658,0.0000010147278,0.000009383808,0.00009437373,6.712278e-7,0.00008254511],"genre_scores_gemma":[0.99963415,0.000058964008,0.000064559565,0.000027709399,0.0000033448578,0.000012833344,0.00014802627,5.8704217e-7,0.000049797876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960464,0.00012547382,0.00004853338,0.000071550465,0.000048082635,0.00010172184],"domain_scores_gemma":[0.9993499,0.00012029147,0.00031387372,0.000031415027,0.00006553889,0.00011900313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005161055,0.00027896932,0.00032518338,0.0009598882,0.00076303264,0.0007355546,0.00033319174,0.00045320232,0.00092307857],"category_scores_gemma":[0.0018266009,0.00022446751,0.000157946,0.00080058014,0.00040545568,0.00037344673,0.0004008661,0.0002613784,0.00015030059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006550007,0.000020106398,0.99802196,0.0000065501285,0.000009415442,0.000101184334,0.00027377383,0.000016779142,0.00044269697,0.000007113692,0.000030621894,0.0010042932],"study_design_scores_gemma":[0.000015997492,0.00013480111,0.99807334,0.000009885014,0.000008886546,0.0007878947,0.00056571874,0.00010309935,0.00009843955,0.000011634904,0.00018654998,0.0000035868268],"about_ca_topic_score_codex":0.009759054,"about_ca_topic_score_gemma":0.010276747,"teacher_disagreement_score":0.009759054,"about_ca_system_score_codex":0.0005867299,"about_ca_system_score_gemma":0.0003349498,"threshold_uncertainty_score":0.01940453},"labels":[],"label_agreement":null},{"id":"W41880533","doi":"10.1177/135965350601100804","title":"Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Zanamivir; Oseltamivir; Neuraminidase; Neuraminidase inhibitor; Virology; Biology; Mutation; Resistance mutation; Mutant; Virus; Influenza A virus; Wild type; Microbiology; Genetics; Gene; Medicine; Reverse transcriptase; Polymerase chain reaction; Coronavirus disease 2019 (COVID-19)","score_opus":0.06949167765261202,"score_gpt":0.39480818195310746,"score_spread":0.3253165043004954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W41880533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986846,0.00018554008,0.00023778102,0.000015010419,0.000008580325,0.000021641363,0.00013886321,0.0000084799885,0.0006994537],"genre_scores_gemma":[0.9980336,0.00020047574,0.0006670761,0.000027074524,0.0000050492495,0.000017048336,0.00031910976,0.000017058454,0.0007135559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99955004,0.00013214571,0.000060144677,0.000059579386,0.00013880577,0.000059171973],"domain_scores_gemma":[0.99973994,0.00006484575,0.00007281875,0.00002551765,0.00003253328,0.000064287444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003021631,0.0005507452,0.00033755516,0.0001852095,0.00014546311,0.00032648747,0.00029079642,0.00029500888,0.0012740848],"category_scores_gemma":[0.00032762522,0.00015913966,0.00032848874,0.00011732419,0.00020473187,0.00015411718,0.00029833967,0.0004461014,0.0002624667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030590798,0.00011157929,0.000860223,0.000023739438,0.000020273354,0.00010972001,0.00001568653,0.00016214252,0.997393,0.00003674,0.00002378104,0.0009370639],"study_design_scores_gemma":[0.00005137914,0.002522452,0.015532539,0.000011410091,0.00007953811,0.0009918793,0.000084296626,0.0022489112,0.9770602,0.00003117872,0.0013691679,0.000017076953],"about_ca_topic_score_codex":0.0022835233,"about_ca_topic_score_gemma":0.002208455,"teacher_disagreement_score":0.0022835233,"about_ca_system_score_codex":0.00031278396,"about_ca_system_score_gemma":0.00026645118,"threshold_uncertainty_score":0.0045404434},"labels":[],"label_agreement":null},{"id":"W4293221760","doi":"10.1177/13596535211067610","title":"Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada","year":2022,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; AIDS Vancouver; HIV Legal Network; St. Paul's Hospital; University of Ottawa; University of Calgary; McGill University; B.C. Women's Hospital & Health Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Cohort; Population; Proportional hazards model; Depression (economics); Hepatitis C; Prospective cohort study; Cohort study; Confidence interval; Psychiatry","score_opus":0.029970469060767405,"score_gpt":0.32066222118038823,"score_spread":0.29069175211962084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293221760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810196,0.002259124,0.00025456067,0.0015258107,0.00003717398,0.00005130963,0.005009247,0.000014674416,0.002746014],"genre_scores_gemma":[0.9972909,0.00092931965,0.00018600597,0.00017013837,0.000010176663,0.000010213532,0.0009781385,0.0000049640626,0.00041998297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911743,0.00008818575,0.000060277787,0.00015569518,0.00024351047,0.00033485313],"domain_scores_gemma":[0.9977852,0.0001843969,0.00051345926,0.00006775158,0.00071514293,0.0007339829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073568115,0.00022879793,0.00049007847,0.0007706199,0.0026288019,0.0015324748,0.0010198924,0.0003843967,0.0021513514],"category_scores_gemma":[0.0031576243,0.00036648576,0.0006858857,0.0030051959,0.00061434985,0.00033667716,0.0007634705,0.0009350044,0.0001041288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007868717,0.000021538479,0.9937966,0.000043817607,0.000076099845,0.00007028091,0.00036160837,0.00017902585,0.00010150764,0.0001484856,0.0011061571,0.0040162615],"study_design_scores_gemma":[0.000015208097,0.00001824079,0.99735874,0.000065847984,0.000071358525,0.00006418523,0.0007477337,0.00065895985,0.00005034095,0.00006620147,0.00086985313,0.000013293663],"about_ca_topic_score_codex":0.9963541,"about_ca_topic_score_gemma":0.9976762,"teacher_disagreement_score":0.026354413,"about_ca_system_score_codex":0.026354413,"about_ca_system_score_gemma":0.041317917,"threshold_uncertainty_score":0.19121557},"labels":[],"label_agreement":null},{"id":"W4298202204","doi":"10.1177/135965350501000711","title":"Association of the CCR5Δ32 Mutation with Clinical Response and &gt;5-year Survival following Initiation of First Triple Antiretroviral Regimen","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Internal medicine; Viral load; Context (archaeology); Medicine; Proportional hazards model; Regimen; Cohort; Population; Oncology; Immunology; Biology; Human immunodeficiency virus (HIV)","score_opus":0.023503737585542542,"score_gpt":0.3051901995619585,"score_spread":0.28168646197641595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298202204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99958783,0.000093437244,0.00002491927,0.000015630321,0.000001029389,0.0000021679277,0.00011550599,0.0000013505769,0.0001581676],"genre_scores_gemma":[0.99969256,0.000030446066,0.000015569292,0.000006724985,0.0000013590941,0.0000015336298,0.000112642236,3.8681165e-7,0.0001388253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977463,0.00003312822,0.000016393748,0.000058974485,0.000049023136,0.00006789773],"domain_scores_gemma":[0.9990208,0.00019858728,0.00043828337,0.000064983215,0.00010657627,0.00017076214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040961627,0.0001109616,0.00023003841,0.00024051694,0.00028015274,0.00043542153,0.00023395105,0.00024323145,0.0014843995],"category_scores_gemma":[0.0014784442,0.00009775855,0.00015466173,0.00029866237,0.00019073169,0.00016892781,0.00018926048,0.00034703632,0.0001556169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011725208,0.00000833488,0.99833846,0.000002668445,0.000012737968,0.000044197266,0.000024351666,0.000052313746,0.00019996539,0.0000044974922,0.000034138608,0.0011610552],"study_design_scores_gemma":[0.0000036896329,0.00007592786,0.99928457,0.0000033285025,0.000009618033,0.00020595742,0.000051914372,0.00020501012,0.000068571564,0.000011443349,0.000078311554,0.0000017496455],"about_ca_topic_score_codex":0.025893405,"about_ca_topic_score_gemma":0.030457484,"teacher_disagreement_score":0.025893405,"about_ca_system_score_codex":0.0003795457,"about_ca_system_score_gemma":0.00041239458,"threshold_uncertainty_score":0.05148536},"labels":[],"label_agreement":null},{"id":"W4298363631","doi":"10.1177/135965350300800506","title":"Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Nevirapine; Viral load; Reverse-transcriptase inhibitor; Internal medicine; Proportional hazards model; Virology; Medicine; Lentivirus; Efavirenz; Gastroenterology; Immunology; Biology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.049314907136050544,"score_gpt":0.32553297407748044,"score_spread":0.2762180669414299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298363631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99948114,0.00014652128,0.000023268241,0.000018584386,0.0000021727585,0.0000034157852,0.000076315024,0.0000012672223,0.0002473449],"genre_scores_gemma":[0.9998287,0.000027451004,0.000012673615,0.00001110412,0.0000029961645,0.0000010738569,0.000080894635,5.9832837e-7,0.000034394026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99965215,0.000070334834,0.00004881956,0.00006776302,0.00008562978,0.00007516465],"domain_scores_gemma":[0.9978908,0.0004878783,0.0009505254,0.00009474112,0.00016780576,0.0004082457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040190032,0.0001930029,0.00040882494,0.00027459,0.00033152505,0.00044167336,0.00016358367,0.00028434358,0.0008584236],"category_scores_gemma":[0.0031046767,0.00013289232,0.00019978722,0.0003547504,0.0002452039,0.00027991674,0.00017099958,0.0004248753,0.00019314667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003249675,0.000017099246,0.99774677,0.0000060277894,0.000020981086,0.0000837538,0.000047699505,0.000040663745,0.0004739976,0.000003971084,0.000030540752,0.0012034662],"study_design_scores_gemma":[0.00000607704,0.00016221945,0.9993186,0.0000030345166,0.000012127872,0.00021905571,0.00005467662,0.00010951673,0.000057390735,0.0000074892505,0.000047685062,0.0000020641114],"about_ca_topic_score_codex":0.008050586,"about_ca_topic_score_gemma":0.012245802,"teacher_disagreement_score":0.008050586,"about_ca_system_score_codex":0.000345457,"about_ca_system_score_gemma":0.0003426936,"threshold_uncertainty_score":0.016007483},"labels":[],"label_agreement":null},{"id":"W4299412210","doi":"10.1177/135965350200702s01","title":"Meeting Report from the 2Nd International HIV Workshop on Management of Treatment-Experienced Patients","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Internal medicine; Family medicine","score_opus":0.03668188375990694,"score_gpt":0.293695466110318,"score_spread":0.25701358235041105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299412210","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02345501,0.05053314,0.0044999677,0.53258294,0.32878518,0.0017412272,0.0022672415,0.00015648494,0.05597891],"genre_scores_gemma":[0.15877739,0.10381995,0.011959678,0.19314893,0.26775447,0.004584256,0.0063214847,0.00036108738,0.2532727],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987558,0.00033219068,0.00010929828,0.00015619643,0.00032544104,0.0003211116],"domain_scores_gemma":[0.99539965,0.00053544744,0.00028935375,0.00006669839,0.0013284377,0.0023805134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054288716,0.0015637982,0.000703555,0.0007757184,0.00188439,0.0017948775,0.0016807817,0.0065491823,0.016799448],"category_scores_gemma":[0.003914838,0.00047312383,0.0011017034,0.00046223373,0.0003598692,0.0011812886,0.0019390254,0.0063458607,0.0026313486],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009024414,0.00036810793,0.0033224951,0.0005465975,0.00005897711,0.0009990374,0.00048638578,0.00035251534,0.0016597512,0.0004549529,0.9244593,0.06638941],"study_design_scores_gemma":[0.00032652947,0.00044854576,0.013948621,0.0010303401,0.00010242664,0.00068526366,0.001276197,0.00032604154,0.0007553163,0.0004872105,0.9805597,0.000053871943],"about_ca_topic_score_codex":0.0055371937,"about_ca_topic_score_gemma":0.013543235,"teacher_disagreement_score":0.016799448,"about_ca_system_score_codex":0.0014798668,"about_ca_system_score_gemma":0.004324218,"threshold_uncertainty_score":0.05619973},"labels":[],"label_agreement":null},{"id":"W4302165968","doi":"10.1177/135965350801300207","title":"Amphipathic DNA Polymers are Candidate Vaginal Microbicides and Block Herpes Simplex virus Binding, Entry and Viral Gene Expression","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Microbicides for sexually transmitted diseases; Herpes simplex virus; Virology; DNA; Biology; Virus; Medicine; Population; Genetics","score_opus":0.02052160268144816,"score_gpt":0.27255495413443376,"score_spread":0.2520333514529856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302165968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676377,0.011520668,0.012461232,0.0003295923,0.00007969108,0.00016586445,0.0002669945,0.00013768046,0.007400553],"genre_scores_gemma":[0.9821752,0.0038411666,0.0066135563,0.000120402074,0.00003286061,0.000116813375,0.00018458332,0.00001779048,0.006897533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999933,0.000018718181,0.0000027685887,0.0000090067615,0.000018323046,0.00001819992],"domain_scores_gemma":[0.99989784,0.00003528793,0.000030106208,0.000007062124,0.000009031336,0.000020640942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001884162,0.00022284959,0.00015725802,0.00020211596,0.00017224031,0.00024964515,0.00012920077,0.00028121943,0.001548267],"category_scores_gemma":[0.00021743971,0.00013363468,0.000120904166,0.00012453005,0.00019651213,0.00019660662,0.00016793257,0.00044846756,0.00037396172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024565848,0.000039640796,0.00016046106,0.000068353715,0.0000033783192,0.00006525779,0.000017762426,0.00017052832,0.98081255,0.00059199845,0.00010268127,0.017721811],"study_design_scores_gemma":[0.00004545937,0.0009688486,0.0009499531,0.000010231271,0.000010951393,0.00030965422,0.000015976728,0.0004455675,0.99155676,0.00014782789,0.0055334633,0.0000052247447],"about_ca_topic_score_codex":0.00014565563,"about_ca_topic_score_gemma":0.00022801851,"teacher_disagreement_score":0.001548267,"about_ca_system_score_codex":0.00011102922,"about_ca_system_score_gemma":0.00015987962,"threshold_uncertainty_score":0.005179465},"labels":[],"label_agreement":null},{"id":"W4309322375","doi":"10.1177/13596535221127848","title":"EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B","year":2022,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Placebo; Gastroenterology; Adverse effect; Internal medicine; Dosing; Lamivudine; Hepatitis B; Hepatitis B virus; Viral load; Pharmacology; Reverse transcriptase; Reverse-transcriptase inhibitor; Immunology; Virus; Pathology; RNA; Chemistry","score_opus":0.0133994133639923,"score_gpt":0.2467197568985571,"score_spread":0.2333203435345648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309322375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984211,0.0008850628,0.000047518453,0.00004350287,0.000010473548,0.00005502672,0.00012598457,0.0000066083253,0.000404628],"genre_scores_gemma":[0.9988133,0.0003306052,0.0000964156,0.00016098756,0.000033728735,0.000052840358,0.00022210118,0.0000015930191,0.00028854408],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999627,0.00016804003,0.000032303557,0.000072331044,0.00003910539,0.00006124376],"domain_scores_gemma":[0.9993326,0.00018782406,0.00016345507,0.000031794883,0.00004394952,0.00024032184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000742394,0.00046639502,0.00056738977,0.00031312826,0.00041976254,0.00034780605,0.00014658034,0.00059036736,0.0014667545],"category_scores_gemma":[0.0010849817,0.00036573314,0.0002790531,0.00028260335,0.0003246837,0.00037319478,0.0002615312,0.00046062982,0.00027966997],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07877632,0.004579462,0.86336005,0.0002918629,0.0004156946,0.0019048739,0.0004722381,0.0003973912,0.01856504,0.00011418815,0.00072990113,0.030393044],"study_design_scores_gemma":[0.005420745,0.061851673,0.9260435,0.000025750633,0.0002721689,0.0018670391,0.00022193279,0.0005299333,0.001893337,0.00009262217,0.0017581781,0.000023062166],"about_ca_topic_score_codex":0.0011822545,"about_ca_topic_score_gemma":0.0010549523,"teacher_disagreement_score":0.0014667545,"about_ca_system_score_codex":0.00028813054,"about_ca_system_score_gemma":0.0003514098,"threshold_uncertainty_score":0.0049067736},"labels":[],"label_agreement":null},{"id":"W4379875283","doi":"10.1177/13596535231182505","title":"Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV","year":2023,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"LGBTQ Health, Identity, and Policy","field":"Psychology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Wellesley Institute; St. Michael's Hospital; Public Health Ontario; Toronto East General Hospital; Toronto General Hospital; University of Toronto; Women's College Hospital; Maple Leaf Medical Clinic","funders":"Canadian Institutes of Health Research; Canadian HIV Trials Network, Canadian Institutes of Health Research; Gilead Sciences","keywords":"Cobicistat; Medicine; Ritonavir; Testosterone (patch); Hormone therapy; Human immunodeficiency virus (HIV); Internal medicine; Cohort; Antiretroviral therapy; Gynecology; Viral load; Immunology; Breast cancer","score_opus":0.0447373969898414,"score_gpt":0.34226328225077934,"score_spread":0.29752588526093793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379875283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570113,0.00045726585,0.00004609502,0.00024561762,0.000013389672,0.00003993763,0.0015699788,0.000004482062,0.0019221002],"genre_scores_gemma":[0.99751425,0.00069000066,0.00012205536,0.0002432023,0.000011355494,0.000018127488,0.00078332744,0.0000053308695,0.0006123801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994987,0.000029448127,0.000024988654,0.00008921692,0.00016727696,0.00019025411],"domain_scores_gemma":[0.9991732,0.00003556666,0.00020796254,0.00003211985,0.00027537742,0.0002757677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036462204,0.0003655536,0.00033548186,0.0013830095,0.003564065,0.00086458353,0.0007394042,0.00035023838,0.0022139035],"category_scores_gemma":[0.0010726287,0.0003470469,0.00045123041,0.0028164606,0.0006191257,0.00034266926,0.0006381922,0.0007735954,0.0001981279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056981735,0.000026151285,0.9958513,0.000017363272,0.000016789896,0.00031179833,0.00080760656,0.000019882593,0.00019096058,0.00004967334,0.00042957938,0.002221845],"study_design_scores_gemma":[0.000009091328,0.0000564266,0.99295545,0.00004241569,0.000028368017,0.00096412405,0.0044495845,0.00013184977,0.000057185844,0.000028464738,0.0012612541,0.000015702564],"about_ca_topic_score_codex":0.9686374,"about_ca_topic_score_gemma":0.9794703,"teacher_disagreement_score":0.031362593,"about_ca_system_score_codex":0.007993408,"about_ca_system_score_gemma":0.012356905,"threshold_uncertainty_score":0.06309456},"labels":[],"label_agreement":null},{"id":"W4391965063","doi":"10.1177/13596535241233128","title":"Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada","year":2024,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Emtricitabine; Efavirenz; Medicine; Lamivudine; Abacavir; Context (archaeology); Incidence (geometry); Darunavir; Atazanavir; Adverse effect; Internal medicine; Pre-exposure prophylaxis; Human immunodeficiency virus (HIV); Virology; Viral load; Hepatitis B virus; Men who have sex with men; Syphilis; Antiretroviral therapy","score_opus":0.009831239983374972,"score_gpt":0.24051907442377488,"score_spread":0.2306878344403999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391965063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97708344,0.0044044773,0.00017830725,0.000835503,0.000025605392,0.00023459918,0.01025525,0.000032699238,0.006950109],"genre_scores_gemma":[0.99201035,0.0032688167,0.00021174469,0.0004264404,0.000010582783,0.000047258345,0.0021888788,0.000007697684,0.0018283867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850684,0.0001214313,0.00017872769,0.00018262301,0.0006322038,0.0003780823],"domain_scores_gemma":[0.99606043,0.00031529754,0.0011575882,0.00007645118,0.0015121095,0.00087805785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082866993,0.00029744447,0.0003738227,0.0013741873,0.0018176057,0.0012907161,0.0010245704,0.00046161513,0.0037655248],"category_scores_gemma":[0.0026186074,0.0003444223,0.0005004966,0.0035793586,0.00068251137,0.00029403396,0.00070593046,0.0009112526,0.00033022638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013014505,0.000047400066,0.9787153,0.00016839258,0.0000591712,0.0003516466,0.0007231536,0.00019976567,0.00015949918,0.00007081379,0.0027240019,0.016650666],"study_design_scores_gemma":[0.000010614647,0.000038277776,0.99662113,0.00014313971,0.00002852724,0.0002534345,0.0012431208,0.00019988927,0.00007202275,0.000017580065,0.0013591186,0.000013093833],"about_ca_topic_score_codex":0.98945135,"about_ca_topic_score_gemma":0.9927279,"teacher_disagreement_score":0.024012862,"about_ca_system_score_codex":0.024012862,"about_ca_system_score_gemma":0.026119268,"threshold_uncertainty_score":0.17422634},"labels":[],"label_agreement":null},{"id":"W4417144318","doi":"10.1177/13596535251405300","title":"Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection","year":2025,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Oseltamivir; Exacerbation; Neuraminidase inhibitor; Viral load; Influenza A virus; Titer; Combination therapy; Zanamivir; In vivo","score_opus":0.03990285508201662,"score_gpt":0.32060629329390244,"score_spread":0.2807034382118858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417144318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956915,0.0019289972,0.0009935282,0.00011795654,0.00007357805,0.00015173505,0.00025853276,0.000045434816,0.0007387352],"genre_scores_gemma":[0.9927468,0.0024404183,0.0025988317,0.00009158597,0.000032746302,0.00021975802,0.00039980834,0.0000120825425,0.001458039],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997446,0.000054667908,0.000018598756,0.000047667196,0.00007313986,0.00006133093],"domain_scores_gemma":[0.9998839,0.00001230931,0.00002413169,0.000008469422,0.000013934262,0.000057321537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003425185,0.00063020503,0.0009177222,0.00041382172,0.00016404915,0.00034520368,0.00050069275,0.00046150666,0.00073499506],"category_scores_gemma":[0.00013278528,0.00020760659,0.00042678643,0.00019592805,0.00029901223,0.0003461503,0.00019378345,0.0010939743,0.00016323947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025304907,0.0014241382,0.00034246972,0.00019791925,0.00005760707,0.00006343453,0.000031187992,0.00045809054,0.9885999,0.000074621144,0.00008852653,0.0061316206],"study_design_scores_gemma":[0.00085753266,0.06563878,0.0066437386,0.000045535373,0.00036958017,0.00028435222,0.00010821186,0.0030296978,0.9178334,0.00009586016,0.0050608474,0.000032510652],"about_ca_topic_score_codex":0.0006353995,"about_ca_topic_score_gemma":0.0010440253,"teacher_disagreement_score":0.0009177222,"about_ca_system_score_codex":0.00025011713,"about_ca_system_score_gemma":0.00031463619,"threshold_uncertainty_score":0.0024587512},"labels":[],"label_agreement":null},{"id":"W5201643","doi":"10.1177/135965350601100601","title":"Protease Inhibitor Effects on Triglyceride Synthesis and Adipokine Secretion in Human Omental and Subcutaneous Adipose Tissue","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; McGill University Health Centre","funders":"","keywords":"Internal medicine; Endocrinology; Adiponectin; Adipose tissue; Triglyceride; Adipokine; Leptin; Lipodystrophy; Chemistry; Insulin resistance; Adipocyte; Insulin; Medicine; Cholesterol; Obesity; Immunology","score_opus":0.009731149783210574,"score_gpt":0.2822791907776764,"score_spread":0.27254804099446583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W5201643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899227,0.007838786,0.00081090187,0.000042311924,0.00002283469,0.000026978452,0.0003587637,0.00003260846,0.0009440922],"genre_scores_gemma":[0.9927105,0.00368806,0.0018021747,0.000043399534,0.000017120863,0.000043161173,0.00076729694,0.000010666016,0.00091759133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998185,0.000064171334,0.000025389538,0.000028555536,0.00003341233,0.000029977906],"domain_scores_gemma":[0.99988294,0.00004742755,0.00002948688,0.000016052974,0.000011607069,0.000012606794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002028252,0.00032281267,0.0003025537,0.00014390801,0.00007503467,0.00031991376,0.0001364673,0.00014717823,0.0012866944],"category_scores_gemma":[0.0002847394,0.000101699545,0.00026811013,0.00017947423,0.0001607894,0.00013734456,0.00010671586,0.00038055205,0.0003174077],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044565685,0.0001777898,0.0010637338,0.00015546594,0.000044042634,0.00011905128,0.000035821333,0.00020413856,0.9842188,0.000052052623,0.000066694585,0.009405888],"study_design_scores_gemma":[0.00055521,0.009581529,0.030274078,0.000025794936,0.00012313179,0.0010146841,0.00007242176,0.0020136929,0.95378375,0.00003989871,0.0025027113,0.000013120861],"about_ca_topic_score_codex":0.0004921036,"about_ca_topic_score_gemma":0.00045792665,"teacher_disagreement_score":0.0012866944,"about_ca_system_score_codex":0.00014549418,"about_ca_system_score_gemma":0.00013910742,"threshold_uncertainty_score":0.004304409},"labels":[],"label_agreement":null},{"id":"W64237836","doi":"10.1177/135965350901400512","title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Alberta; Centre hospitalier universitaire de Québec","funders":"","keywords":"Valganciclovir; Ganciclovir; Human cytomegalovirus; Viral load; Virology; Cytomegalovirus; Betaherpesvirinae; Biology; Internal medicine; Drug resistance; Gastroenterology; Medicine; Immunology; Herpesviridae; Virus; Viral disease; Genetics","score_opus":0.03267598557897407,"score_gpt":0.31964853404408783,"score_spread":0.2869725484651138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W64237836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989254,0.00079641223,0.000055388242,0.00003231649,0.0000056798913,0.000017109784,0.0000216705,0.0000026708565,0.00014340569],"genre_scores_gemma":[0.9996126,0.00016584045,0.000057704958,0.00003694544,0.000016416092,0.000013046116,0.00005536317,9.133415e-7,0.00004112731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954224,0.00019584346,0.000039319442,0.0000675294,0.00007056769,0.00008450543],"domain_scores_gemma":[0.998489,0.00066391286,0.0004867418,0.000047392292,0.00003628457,0.00027664925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009808681,0.00023637188,0.00056212314,0.00018665899,0.00023525312,0.0005852175,0.0002195061,0.00045537818,0.00090650446],"category_scores_gemma":[0.0021803011,0.00013838097,0.0004993225,0.00018597503,0.00029997676,0.00026685212,0.00022417237,0.00056048605,0.00010019902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061096862,0.0013562954,0.87070924,0.00023900458,0.0004705828,0.00095038547,0.00019780097,0.00070031727,0.010477721,0.00007136008,0.0004054964,0.05332488],"study_design_scores_gemma":[0.005843606,0.0682265,0.9096462,0.00012555545,0.0007867336,0.0052971668,0.0002431434,0.0030376047,0.005414928,0.00019527586,0.0011551614,0.00002823235],"about_ca_topic_score_codex":0.00018219871,"about_ca_topic_score_gemma":0.00018292913,"teacher_disagreement_score":0.0009808681,"about_ca_system_score_codex":0.00027146892,"about_ca_system_score_gemma":0.00028123954,"threshold_uncertainty_score":0.0051873922},"labels":[],"label_agreement":null},{"id":"W69587150","doi":"10.1177/135965350400900503","title":"Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Interquartile range; Internal medicine; Odds ratio; Reverse-transcriptase inhibitor; Population; Regimen; Confidence interval; Logistic regression; Viral load; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.04014910648780618,"score_gpt":0.3641119251427931,"score_spread":0.32396281865498694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W69587150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99936754,0.0003444217,0.000014013186,0.000097534125,0.0000032033624,0.000004672414,0.000041940668,0.0000010807282,0.00012554399],"genre_scores_gemma":[0.9996426,0.0001117282,0.000031788826,0.000021871114,0.000009702324,0.000003622798,0.00006563566,7.444917e-7,0.00011227957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851304,0.0006440612,0.00008200159,0.00014037498,0.00026803438,0.00035238775],"domain_scores_gemma":[0.9921279,0.0019834193,0.0036830197,0.00018734121,0.00048838754,0.0015298928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016642468,0.00024377124,0.00032179558,0.00040413308,0.0005010582,0.00071050954,0.0005287731,0.00052427663,0.0019116137],"category_scores_gemma":[0.007975497,0.00017810939,0.00050809304,0.0005181412,0.00039180284,0.0004001479,0.0005874184,0.0007569048,0.00011286183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005669363,0.00015612946,0.9954015,0.000015107014,0.00013608145,0.000084698106,0.000075443284,0.00005520201,0.00005371662,0.000009476846,0.000060349445,0.0033852812],"study_design_scores_gemma":[0.000007955819,0.00015459771,0.999424,0.00001208585,0.000040509738,0.00009074145,0.00008063018,0.0001269419,0.000017468057,0.000005597495,0.000037934897,0.000001616577],"about_ca_topic_score_codex":0.0261912,"about_ca_topic_score_gemma":0.03736818,"teacher_disagreement_score":0.0261912,"about_ca_system_score_codex":0.0008427207,"about_ca_system_score_gemma":0.0012438069,"threshold_uncertainty_score":0.05207753},"labels":[],"label_agreement":null},{"id":"W76024419","doi":"10.1177/135965350701200114","title":"HIV-1 drug resistance surveillance using dried whole blood spots","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Public Health Agency of Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Drug resistance; Dried blood spot; Drug; Virology; Internal medicine; Pharmacology; Biology; Chemistry; Microbiology; Chromatography","score_opus":0.02623441622039107,"score_gpt":0.29876182322360295,"score_spread":0.2725274070032119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W76024419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804221,0.003517583,0.011796994,0.00012766787,0.000033734806,0.00020277553,0.0018279532,0.00020047047,0.0018706622],"genre_scores_gemma":[0.96017176,0.0019809983,0.0343518,0.00014912002,0.000044065968,0.00011426268,0.0018802573,0.000023450757,0.0012842948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939656,0.00016672458,0.000042899304,0.00017993766,0.00018478557,0.00002906851],"domain_scores_gemma":[0.99927074,0.00012899004,0.00033453802,0.00005512121,0.00017795568,0.00003267562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007833779,0.0003863681,0.00033523695,0.0010683398,0.00025778046,0.00047209123,0.0004159392,0.00035753427,0.00096306374],"category_scores_gemma":[0.0011080565,0.00017370755,0.00015622916,0.00065100665,0.00032751187,0.00025076634,0.00017893616,0.00015540441,0.0003657453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019175645,0.00021301751,0.522697,0.00073409016,0.00024876176,0.0004544839,0.00052995613,0.00093307905,0.36860135,0.00013060326,0.0011554582,0.10238472],"study_design_scores_gemma":[0.00009912169,0.0021032456,0.69367975,0.00017323667,0.00030117572,0.004444103,0.00059025554,0.004195376,0.28446296,0.00033727044,0.009564109,0.00004941305],"about_ca_topic_score_codex":0.0017368227,"about_ca_topic_score_gemma":0.0019081704,"teacher_disagreement_score":0.0017368227,"about_ca_system_score_codex":0.00022221477,"about_ca_system_score_gemma":0.00016809982,"threshold_uncertainty_score":0.0041429996},"labels":[],"label_agreement":null},{"id":"W77138857","doi":"10.1177/135965350801300603","title":"Inhibition of Human Metapneumovirus Replication by Small Interfering RNA","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Respiratory viral infections research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Human metapneumovirus; Metapneumovirus; Virology; Small interfering RNA; Biology; Replication (statistics); RNA; Medicine; Internal medicine; Genetics; Gene; Respiratory system; Respiratory tract infections","score_opus":0.11924954212736902,"score_gpt":0.37798063393009723,"score_spread":0.25873109180272824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W77138857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95672554,0.012203368,0.022257874,0.00018475743,0.00011625388,0.00033853142,0.0012751662,0.00040757185,0.0064909304],"genre_scores_gemma":[0.96895,0.004766326,0.021739133,0.00017394403,0.000033096894,0.00029916968,0.0016753897,0.000043463744,0.0023195546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998084,0.000035267112,0.000022845526,0.00004074792,0.0000624024,0.000030329955],"domain_scores_gemma":[0.9998946,0.000047890982,0.000020265945,0.000011069231,0.000017728844,0.000008378746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033177802,0.00056553463,0.0003065203,0.00025077857,0.00012173582,0.00029321987,0.0002406578,0.00027752962,0.0010857261],"category_scores_gemma":[0.00022658316,0.00012611847,0.0004502542,0.00012339269,0.00017150711,0.00010430201,0.00016459159,0.00038324884,0.00043542488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006737655,0.000031190113,0.00012879664,0.000098458426,0.000014780127,0.000029385215,0.000008572767,0.00024412075,0.9955617,0.000063992586,0.00007277678,0.003678758],"study_design_scores_gemma":[0.00001795402,0.00045566462,0.0009671568,0.000008534998,0.000028678982,0.000093771116,0.000005480484,0.0021293478,0.993515,0.000026536145,0.0027473818,0.000004544833],"about_ca_topic_score_codex":0.00030681468,"about_ca_topic_score_gemma":0.0005811955,"teacher_disagreement_score":0.0010857261,"about_ca_system_score_codex":0.0003318859,"about_ca_system_score_gemma":0.00021741606,"threshold_uncertainty_score":0.0036321282},"labels":[],"label_agreement":null},{"id":"W82537579","doi":"10.1177/135965350300800501","title":"Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Medicine; Antiretroviral therapy; Medical prescription; Medication adherence; Intensive care medicine; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Family medicine; Pharmacology","score_opus":0.04051657257031807,"score_gpt":0.35231153031812934,"score_spread":0.3117949577478113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W82537579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874085,0.0003884489,0.00003974944,0.000116602474,0.0000035253336,0.0000052119385,0.00010658381,0.0000022010977,0.00059681706],"genre_scores_gemma":[0.99963856,0.00009193427,0.000050857525,0.000027797367,0.0000075409716,0.0000016696307,0.00006638914,3.8731122e-7,0.00011489977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951303,0.00018345953,0.000037312253,0.00004441076,0.00014065727,0.00008117632],"domain_scores_gemma":[0.9964393,0.00080300815,0.002105715,0.000068850124,0.00022022502,0.00036286813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049140345,0.00011359386,0.00020890898,0.00025819958,0.00027278118,0.0005189936,0.00020526313,0.00048435296,0.0019025492],"category_scores_gemma":[0.0047100037,0.000122053025,0.00015805839,0.00059973705,0.00023174606,0.0002436913,0.00021666673,0.00035469173,0.00014663528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069039015,0.0000525808,0.9976248,0.000011375105,0.000025320594,0.0000393673,0.000065011955,0.000034469558,0.000052126303,0.000008794754,0.000088589535,0.0019284859],"study_design_scores_gemma":[0.0000037752204,0.00005587569,0.9994711,0.000006583442,0.000010499462,0.00016092468,0.000047618945,0.00013046004,0.000012853567,0.0000074175373,0.00009154428,0.0000012548409],"about_ca_topic_score_codex":0.017861616,"about_ca_topic_score_gemma":0.02954754,"teacher_disagreement_score":0.017861616,"about_ca_system_score_codex":0.00033237666,"about_ca_system_score_gemma":0.0005051146,"threshold_uncertainty_score":0.03551525},"labels":[],"label_agreement":null},{"id":"W90835625","doi":"10.1177/135965350300800504","title":"Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; AIDS Vancouver; University of British Columbia; Engineers Without Borders Canada","funders":"","keywords":"Antiretroviral therapy; Immunology; Medicine; Human immunodeficiency virus (HIV); Viral load; Lymphocyte; Coinfection; Virology; Lentivirus; Viral disease; Internal medicine","score_opus":0.014705210197817222,"score_gpt":0.2849259927228821,"score_spread":0.2702207825250649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W90835625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964768,0.0015809952,0.0009949331,0.00030199514,0.000016874661,0.000035033234,0.00016164234,0.00001271715,0.00041914202],"genre_scores_gemma":[0.99819946,0.0002533384,0.0012143624,0.00008022301,0.000032025633,0.000021143236,0.000099420715,0.0000025507734,0.0000974587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998784,0.000912981,0.00004732151,0.000068365065,0.00011728595,0.000070052134],"domain_scores_gemma":[0.9961999,0.0022922659,0.00087659684,0.000099340294,0.00019270754,0.00033917997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025381504,0.00040893073,0.00047571282,0.00061454927,0.00017724722,0.0007501309,0.00037887009,0.0003952463,0.000905271],"category_scores_gemma":[0.008577615,0.00018946812,0.00026391936,0.00046303947,0.0002648106,0.000390286,0.00037563784,0.0006186996,0.00016028715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009292296,0.00009767835,0.98506075,0.00005549422,0.00009909419,0.00009004732,0.00006187616,0.0007213241,0.00045193153,0.000040732568,0.0003120661,0.012079693],"study_design_scores_gemma":[0.00022501695,0.0023302063,0.96748984,0.00016123221,0.00030135416,0.0009823422,0.000645313,0.025376717,0.0009877522,0.00041127796,0.001057299,0.000031776948],"about_ca_topic_score_codex":0.0012552064,"about_ca_topic_score_gemma":0.003731903,"teacher_disagreement_score":0.0025381504,"about_ca_system_score_codex":0.00023062149,"about_ca_system_score_gemma":0.00057343213,"threshold_uncertainty_score":0.013423145},"labels":[],"label_agreement":null},{"id":"W914135345","doi":"10.1177/135965350200700308","title":"Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Clinical trial; Internal medicine; Adverse effect; Observational study; Confounding; Viral load; Randomized controlled trial; Psychosocial; Immunology; Human immunodeficiency virus (HIV); Psychiatry","score_opus":0.22693459846899092,"score_gpt":0.49470534481085976,"score_spread":0.2677707463418688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W914135345","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010166841,0.00061119895,0.0032945839,0.0003736932,0.00011752546,0.9603958,0.017450385,0.00021284887,0.0073770625],"genre_scores_gemma":[0.012475917,0.00035124575,0.008031061,0.00026550234,0.000051648818,0.97275484,0.0043286993,0.000048887294,0.0016921934],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.96368045,0.026547775,0.0047737947,0.0009437013,0.002201419,0.0018528079],"domain_scores_gemma":[0.9618565,0.013616549,0.006828676,0.00490981,0.009903789,0.002884635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.057349604,0.0022621073,0.0031436845,0.0020094574,0.0023655603,0.0023469622,0.0020571698,0.0036667055,0.041143794],"category_scores_gemma":[0.06109363,0.0015508758,0.0035385822,0.00360542,0.0010110653,0.0019458686,0.0020406973,0.0038451948,0.010285771],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7541499,0.012126654,0.026472928,0.021334678,0.0023200447,0.00035035601,0.0010779382,0.0027383654,0.0029538677,0.0043013785,0.07575012,0.09642378],"study_design_scores_gemma":[0.66791517,0.05242438,0.13930148,0.0069491,0.0027008685,0.0002924079,0.00044681082,0.0032224362,0.0031259442,0.0032923212,0.12012191,0.00020717888],"about_ca_topic_score_codex":0.0015790068,"about_ca_topic_score_gemma":0.0037428627,"teacher_disagreement_score":0.057349604,"about_ca_system_score_codex":0.0032589408,"about_ca_system_score_gemma":0.014456715,"threshold_uncertainty_score":0.30329734},"labels":[],"label_agreement":null},{"id":"W94004259","doi":"10.1177/135965350701200s04.1","title":"Influenza Virus Susceptibility and Resistance to Oseltamivir","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Manitoba","funders":"","keywords":"Oseltamivir; Neuraminidase; Neuraminidase inhibitor; Virology; Biology; Zanamivir; Virus; Infectivity; Influenza A virus; Resistance mutation; Microbiology; Drug resistance; Medicine; Genetics; Reverse transcriptase; Internal medicine; Gene; Polymerase chain reaction; Infectious disease (medical specialty)","score_opus":0.08393527582554833,"score_gpt":0.4072756966614836,"score_spread":0.3233404208359353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W94004259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979215,0.00073147967,0.00008770417,0.000033201875,0.0000043900623,0.000005503899,0.00011292218,0.000003301686,0.0011000013],"genre_scores_gemma":[0.99949384,0.000098161916,0.000032832933,0.000009260557,0.0000038758717,0.0000025317458,0.00006507092,0.0000010461455,0.0002931884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997191,0.00008201612,0.00003405488,0.00006814994,0.000055190398,0.00004143196],"domain_scores_gemma":[0.999318,0.00014221143,0.00028514894,0.00004171915,0.00006641862,0.00014642334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000333342,0.00014895774,0.00016599652,0.0006244554,0.00015900542,0.00027027552,0.00011156699,0.0003356511,0.0020682428],"category_scores_gemma":[0.0010924969,0.00010343102,0.00023292677,0.00029628346,0.00015699358,0.00022068062,0.00016704049,0.00033071567,0.00042831927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012489236,0.0001264176,0.9755241,0.000024115763,0.00008526786,0.00033896693,0.00020480617,0.00006432894,0.014779271,0.000083032806,0.0001255827,0.00739512],"study_design_scores_gemma":[0.000008426397,0.0005047227,0.99617636,0.000004591811,0.000018542274,0.001467687,0.0001006933,0.00015124334,0.0009962802,0.000058077687,0.00050840876,0.0000049202185],"about_ca_topic_score_codex":0.0006729057,"about_ca_topic_score_gemma":0.000416102,"teacher_disagreement_score":0.0020682428,"about_ca_system_score_codex":0.0001330956,"about_ca_system_score_gemma":0.0000740999,"threshold_uncertainty_score":0.006918967},"labels":[],"label_agreement":null},{"id":"W97603576","doi":"10.1177/135965350300800605","title":"Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance","year":2003,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Drug resistance; Biology; Resistance mutation; Nucleoside; Mutation; Nucleoside analogue; Antiretroviral therapy; Virology; Genetics; Medicine; Human immunodeficiency virus (HIV); Viral load; RNA; Gene","score_opus":0.0705908247958759,"score_gpt":0.38020921021209636,"score_spread":0.30961838541622044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W97603576","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000104694256,0.99777526,0.00013551491,0.00024526278,0.0003539873,0.000007851701,0.00000902128,0.000007651107,0.001360784],"genre_scores_gemma":[0.0004602095,0.9976307,0.00037491205,0.00026950028,0.00031512944,0.000009016447,0.00002287194,0.0000015455951,0.0009160689],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996463,0.00007869017,0.00005882885,0.000043136675,0.00015049231,0.000022463899],"domain_scores_gemma":[0.9995073,0.00021192968,0.00006180105,0.000012246001,0.00016383138,0.000042856867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072067557,0.0009806635,0.0016338978,0.0028455267,0.00035963889,0.0010828525,0.00089131563,0.0010983564,0.0054310346],"category_scores_gemma":[0.0010070701,0.00027512194,0.00045873795,0.003936108,0.00034874768,0.0016476342,0.0004887515,0.0011974393,0.0041079433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000643292,0.00008670735,0.00019333181,0.009174363,0.00005376752,0.00035251092,0.00006629077,0.00022296605,0.0012333016,0.0012187727,0.04283959,0.94449407],"study_design_scores_gemma":[0.00003406786,0.00012296009,0.0010930275,0.0044847345,0.00009204114,0.0029994217,0.00008405847,0.0000988127,0.00024858667,0.0013213077,0.98940593,0.000014948223],"about_ca_topic_score_codex":0.00095470937,"about_ca_topic_score_gemma":0.0021703546,"teacher_disagreement_score":0.0054310346,"about_ca_system_score_codex":0.00058887614,"about_ca_system_score_gemma":0.0011748021,"threshold_uncertainty_score":0.018168569},"labels":[],"label_agreement":null}]}